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Severe malarial anemia (SMA), caused by infections with Plasmodium falciparum, is one of the 
leading causes of childhood mortality in sub-Saharan Africa.  Although the molecular 
determinants of SMA are largely undefined, dysregulation in host-derived inflammatory 
mediators influences disease severity.  Macrophage migration inhibitory factor (MIF) is an 
important regulator of innate inflammatory responses that has recently been shown to suppress 
erythropoiesis and promote pathogenesis of SMA in murine models.  The role of MIF in 
childhood malarial pathogenesis was investigated by examining peripheral blood MIF production 
in children residing in a hyperendemic area of Gabon, and a holoendemic region of western 
Kenya.  The relationship between MIF concentrations and monocytic acquisition of  hemozoin, 
and the effects of MIF on erythropoiesis in vivo and in vitro were investigated.  In addition, the 
influence of genetic variation at MIF -173 (G/C) and -794 (CATT5-8) on MIF production and 
susceptibility to SMA and high-density parasitemia (HDP) was examined. Circulating MIF 
concentrations and peripheral blood mononuclear cells (PBMC) MIF production progressively 
declined with increasing anemia severity and increasing levels of hemozoin-containing 
monocytes.  However, circulating MIF concentrations were not significantly associated with 
reticulocyte production in children with acute malaria.  Additional experiments in malaria-naïve 
individuals demonstrated that hemozoin caused both increased and decreased MIF production in 
cultured PBMC based on genetic differences.  In addiiton, a novel in vitro model of 
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erythropoiesis was developed and used to demonstrate that treatment with exogenous MIF or 
blocking endogenous MIF did not signifcantly impact on the efficiency of erythropoiesis.  
Genetic analyses revealed that the MIF -173 CC genotype was associated with an increased risk 
of HDP compared to MIF -173 GG. In addition, individuals with the MIF -794CATT6/-173G 
haplotype were significantly protected from SMA while those with -794CATT7/8/-173C 
haplotypes were at an increased risk of developing SMA. Taken together, our findings 
demonstrate that SMA is associated with decreased MIF production and that individuals with 
high MIF-producing genetic variants are less susceptible to severe malaria. The public health 
significance of this study is that investigations presented here increase our understanding of 
protective inflammatory responses to childhood malaria, which is critical in the formulation of an 
effective malarial vaccine.   
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 1.0  CHAPTER ONE: INTRODUCTION 
Malaria continues to be a major global health concern, with an estimated 3.2 billion people 
across over 100 countries at risk of the disease (WHO 2005).  There are 350-500 clinical cases of 
malaria annually, resulting in about 2 million deaths around the world (WHO 2005). The 
majority of malaria morbidity occurs in Africa (~60%), which also accounts for 89% of the 
global malaria-related mortality (WHO 2003). In sub-Saharan Africa, malaria is one of the 
leading causes of childhood morbidity and mortality, being responsible for 25-35% of outpatient 
visits, 20-45% of hospital admissions, and up to 35% of inpatient deaths (WHO 2005).  In 
addition to directly causing 18% of all-cause mortality in children under five years old, malaria 
indirectly contributes to mortality through maternal anemia in pregnancy, low birth weights, pre-
term deliveries, and increased susceptibility and severity of other infections, such as bacteremia 
and human immunodeficiency virus (HIV) (Molineaux 1997; WHO 2005).  
 
1.1 MALARIA PARASITE 
Malaria is caused by infections of a protozoan parasite of the genus Plasmodium.  Four species 
of the genus infect humans, namely, P. vivax, P. ovale, P. malariae and P. falciparum.  The vast 
majority of malaria morbidity worldwide, and greater than 90% of malaria-related mortality in 
 sub-Saharan Africa result from P. falciparum infections (WHO 2005).  P. falciparum has a 
complex life cycle, requiring an invertebrate host, a female Anopheles mosquito, in addition to 
the human host for complete replication. The parasite’s life cycle includes a cycle of asexual 
division in the human liver, another cycle of pigment-producing asexual division in red blood 
cells (RBCs), and a sporogenic development in the mosquito.  The cycle begins with the bite by 
an infected mosquito inoculating the parasites in the form of sporozoites into the bloodstream of 
the human host (Figure 1).  After circulating in the bloodstream for not more than 1 hour, the 
sporozoites enter hepatocytes, where the parasites grow, multiply and develop directly into pre-
erythrocytic (PE) schizonts.  These schizonts take 5-7 days to mature, culminating in the rupture 
of the hepatocyte and release of merozoites into bloodstream to invade RBCs. Successful entry 
of the parasites into RBCs starts the erythrocytic cycle, which takes 36-48 hours to complete.  
Within the RBC, the merozoite develops into a trophozoite in a vacuole formed by the internal 
membrane of the host red cell.  The trophozoite feeds on hemoglobin (Hb) by ingesting small 
amounts of red cell cytoplasm, which leads to accumulation of malaria pigment, hemozoin (Hz), 
as an end product of Hb breakdown.  Fully matured trophozoites divide to form schizonts 
containing 8-32 merozoites, which rupture to release the merozoites, hemozoin and toxins into 
the blood stream.  The initiation of the systemic immune response, and the appearance of clinical 
symptoms such as fever, coincide with schizont rupture (Kwiatkowski et al. 1989; Kwiatkowski 
and Perlman 1999).  Merozoites that escape the host’s immune system re-invade new RBCs to 
begin another replication cycle. Occasionally, some trophozoites develop into male and female 
gametocytes which can be taken up by the mosquito in its blood meal.  Gametocytes differentiate 
into gametes in the midgut of the mosquito, and fertilization takes place to form a zygote. The 
zygote then develops into a motile ookinete, which penetrates the gut epithelium and matures to 
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 form the oocyst containing large numbers of sporozoites.  Mature sporozoites leave the oocytes 
and some find their way into the salivary gland of the mosquito, ready to be transmitted when the 
insect takes its next blood meal.  
 
Sporozoites
Merozoites
Schizont
Trophozoite
Erythrocyte
GametocytesInfected 
hepatocytes
Mosquito
Human
Hemozoin
 
 
Figure 1: P. falciparum life cycle in humans.    
Sporozoites injected into the blood stream during a bite by an infected mosquito find their way to the liver, where 
they infect hepatocytes.  The parasites then mature into pre-erythrocytic schizonts which burst to release merozoites 
into the blood stream.  These merozoites quickly invade erythrocytes, forming trophozoites which feed on host cell 
hemoglobin and grow rapidly.  Matured trophozoites divide into many daughter merozoites while developing into a 
schizont which also contains hemozoin as a by-product of hemoglobin degradation.  Rupture of mature schizonts 
releases hemozoin, and many merozoites to re-invade new erythrocytes and repeat the replicative cycle.  
Occasionally, some parasites develop into male and female gametocytes which can be taken up by the mosquito in a 
subsequent blood meal. 
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 1.2 CLINICAL MANIFESTATIONS OF MALARIA 
The clinical features of P. falciparum infection cover a wide spectrum from asymptomatic to 
fulminant disease leading to death.  The vast majority of cases present as a relatively mild, non-
specific febrile illness, which resolves rapidly if treated appropriately, however, some children 
develop severe, life-threatening complications.  The classical severe malarial presentations 
responsible for most of the malaria-associated mortality in children are severe anemia (Hb levels 
<5.0 g/dL), and cerebral malaria characterized by neurological symptoms, including deep coma 
(WHO 2000).  Other important features of severe malaria include hyperparasitemia, metabolic 
acidosis, respiratory distress, and hypoglycemia (WHO 2000). Clinical presentations of pediatric 
severe malaria vary markedly across regions with differing transmission intensities, with CM 
primarily occurring in lower transmission regions and SMA being most prevalent in 
holoendemic areas (Snow et al. 1997). Additional determinants of the clinical pattern of malaria 
include age, immune status, genetic factors, and parasite species, however, the relative 
contributions of individual factors in disease pathogenesis remains unknown. 
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 1.3 PATHOGENESIS OF SEVERE MALARIAL ANEMIA (SMA) 
The pathogenesis of SMA is multifactorial and not well understood. Some of the earliest studies 
of SMA identified three categories of patients: children with acute infection associated with RBC 
hemolysis, and who had the most marked anemia during the period after treatment; a second 
group of children appeared to have a more chronic form of P. falciparum infection, were 
profoundly anemic at presentation, showed gross dyserythropoietic changes in their bone 
marrows, and had a full reticulocyte response and rise in Hb after treatment; and a third group of 
children whose hematological abnormalities were intermediate to those of the acute and chronic 
groups (Abdalla et al. 1980).  Although the relative contributions of each of the potential 
mechanisms that promote anemia are not clear, three processes are involved in the development 
of SMA: direct and indirect destruction of parasitized red blood cells (pRBCs); increased 
clearance of uninfected erythrocytes; and suppression of erythropoiesis (Wickramasinghe and 
Abdalla 2000).  Destruction of red cells seems to occur both intravascularly via immune-
mediated mechanisms and parasite replication, and by sequestration of parasitized cells in the 
spleen and other parts of the microcirculation resulting from parasite adherence, increased 
rigidity and reduced deformability (Weatherall and Abdalla 1982).  The significance of the loss 
of uninfected RBCs in promoting SMA is demonstrated by studies showing that severe anemia is 
common even in individuals in which less than 1% of their erythrocytes are infected 
(Looareesuwan et al. 1987).  Although the mechanism(s) by which unparasitized RBCs are 
destroyed is not clear, RBC survival studies demonstrate that both endogenous RBCs and 
transfused normal erythrocytes have shortened survival during human P. falciparum malaria 
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 (Looareesuwan et al. 1987), suggesting that the existing inflammatory milieu may be detrimental 
to RBC survival.  Development of SMA in children is also enhanced by a defective 
erythropoietic response, resulting in an inadequate production of reticulocytes to replace lost 
RBCs.  Defective reticulocyte production during malaria is caused by depression of 
erythropoiesis, inhibition of reticulolyte release, and/or dyserythropoiesis (Rencricca et al.  1974) 
(Woodruff et al. 1979; Abdalla et al. 1980). Findings by Kurtzhals et al. suggested that P. 
falciparum infection caused a rapidly reversible suppression of the bone marrow response to 
erythropoietin (Kurtzhals et al. 1997).  In addition, children with SMA show marked 
dyserythropoietic changes, including multinuclear erythroblasts, karyorrhexis, incomplete and 
unequal amitotic nuclear divisions, and cytoplasmic bridging (Abdalla et al. 1980).  Although the 
molecular mechanisms that interfere with the erythropoietic process during malaria is not clear, 
deposition of Hz and over-production of pro-inflammatory mediators seem to contribute to 
suppression of erythropoiesis (Wickramasinghe and Abdalla 2000; Clark and Cowden 2003; 
McDevitt et al. 2004; Casals-Pascual et al. 2006).  
 
1.4 ROLE OF HEMOZOIN IN MALARIAL PATHOGENESIS 
During the erythrocytic stage of development, the malaria parasite forms a food vacuole in which 
host cell Hb is degraded into heme and globin.  The globin component is further digested into 
amino acids for the parasite’s metabolic needs; however, heme is toxic to the parasite and is thus 
aggregated into the insoluble dark-brown crystal, Hz (Figure 2).  The immune response to blood 
stage malaria is induced by the repeated exposure to large quantities of parasite 
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 products/antigens as matured parasites (schizonts) rupture and release young merozoites, Hz, and 
soluble antigens including glycosyl phosphatidyl inositols (GPIs).  Whilst most soluble parasite 
antigens released during schizont rupture circulate for only a limited time, Hz persists for several 
days even after parasite clearance (Metzger et al. 1995; Day et al. 1996).  Both circulating and 
resident phagocytes acquire Hz through phagocytosis of pRBCs or free Hz crystals released after 
schizont rupture ((Schwarzer et al. 1992), Figure 2).  Extensive deposition of Hz has been 
observed in the livers and bone marrows of children with SMA, and associated with 
ultrastructural abnormalities in these tissues, suggesting a role in disease pathogenesis (Abdalla 
1990; Wickramasinghe and Abdalla 2000; Giribaldi et al. 2004). Furthermore, several studies 
have demonstrated that acquisition of malarial pigment by circulating monocytes and neutrophils 
is significantly associated with disease severity (Nguyen et al. 1995; Luty et al. 2000; Lyke et al. 
2003; Casals-Pascual et al. 2006).  In addition, previous investigations from our laboratory, as 
well as those of others, show that ingestion of Hz by monocytes may enhance malarial 
pathogenesis by causing dysregulation in production of cytokine, chemokines, and effector 
molecules, including tumor necrosis factor (TNF)-α, interleukin (IL)-12, IL-10, macrophage 
inflammatory protein (MIP)-1α, MIP-1β, nitric oxide (NO), and prostaglandin (PG)-E2 
(Pichyangkul et al. 1994; Sherry et al. 1995; Perkins et al. 2003; Keller et al. 2004a; Keller et al. 
2004b; Ochiel et al. 2005; Keller et al. 2006a; Keller et al. 2006b).  In addition, acquisition of 
Hz by macrophages impairs their ability to repeat phagocytosis, and inhibits antigen presentation 
by down-regulating major histocompatibility (MHC)-II molecule expression (Schwarzer et al. 
1992; Arese and Schwarzer 1997) .  
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Figure 2: Hemozoin formation and acquisition by monocytes. 
Cleavage of host hemoglobin by the malaria parasite yields heme which is detoxified by crystallization into 
hemozoin, and globin which is digested into amino acids by parasitic proteases (A).  Hz accumulates within the 
parasitized RBCs (pRBCs) and can be seen as a dark-brown pigment in the matured schizont (B).  Monocytes 
acquire Hz through phagocytosis of pRBCs or free Hz released during schizonts rupture (C). 
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 1.5 ROLE OF THE INNATE IMMUNE RESPONSE IN MALARIAL 
PATHOGENESIS 
An integral part of a protective immune response to malarial infection is induction of interferon 
(IFN)-γ by IL-12; IFN-γ mediates control of parasitemia by activating monocytes/macrophages 
to undertake phagocytosis and secrete anti-plasmodial mediators including TNF-α and NO 
(Gyan et al. 1994; Stevenson and Riley 2004).  This mechanism is supported by our previous 
studies, as well as those of others, showing that increased production of IL-12 and IFN-γ is 
associated with protection from childhood malaria (Luty et al. 1999; Luty et al. 2000; Perkins et 
al. 2000; John et al. 2004; Moormann et al. 2006).  In addition, production of TNF-α may 
contribute to the protective immune response to malaria by inducing fever that is detrimental to 
parasite development, and/or by stimulating effector cells (Kwiatkowski and Perlman 1999).  
The host response to malaria also includes the production of increased numbers of peripheral 
blood monocytes and tissue macrophages in the spleen and the liver (Arese et al. 1991).  This is 
believed to be a result of activation and mobilization of blood monocytes, and suggests that the 
macrophage is a major immunologic effector cell in malaria.  Mononuclear phagocytes are able 
to recognize and ingest pRBCs, and have the potential to dispose of up to 40-80% of the total red 
cell mass over the course of a few days (Arese et al. 1991).  In addition to increased 
phagocytosis, macrophages and neutrophils produce toxic oxygen radicals, which participate in 
parasite killing (Dockrell and Playfair 1983).    
 Despite the important role in parasite clearance, immune activation and production of 
pro-inflammatory cytokines could contribute to SMA pathogenesis by inhibiting erythropoiesis 
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 and reducing RBC survival (Clark and Chaudhri 1988; Angulo and Fresno 2002; Clark and 
Cowden 2003; McDevitt et al. 2004).  For example, various studies have shown that over-
production of TNF-α, is associated with severe forms of malaria including SMA (Grau et al. 
1989; Kwiatkowski et al. 1990; Kurtzhals et al. 1998; Akanmori et al. 2000; Luty et al. 2000; 
Perkins et al. 2000), suggesting an important role for this mediator in disease pathogenesis.  
Furthermore, production of reactive oxygen and nitrogen species may also contribute to SMA by 
causing increased destruction of uninfected RBCs and suppressing erythropoiesis (Clark et al. 
1981; Shami and Weinberg 1996; Anstey et al. 1999; Keller et al. 2004b).  In addition, IL-1β 
and IL-6 are elevated during P. falciparum infection, correlate with malaria disease severity, and 
are associated with enhanced anemia (Kern et al. 1989; Day et al. 1999; Vogetseder et al. 2004; 
Dinarello 2005; Ganz 2006; Prakash et al. 2006).  Therefore, adequate induction of anti-
inflammatory cytokines, such as IL-4, IL-10, and transforming growth factor (TGF)-β is required 
to counter-balance the pro-inflammatory response, and prevent the prolonged production of 
potentially harmful mediators (Ho et al. 1995; Ho et al. 1998; Omer and Riley 1998; Winkler et 
al. 1998; Omer et al. 2000; Stevenson and Riley 2004).  Our previous studies, and those of 
others, demonstrate that the clinical course of severe malaria is influenced by the relative 
imbalance between TNF-α and IL-10 levels (Kurtzhals et al. 1998; Othoro et al. 1999; 
Akanmori et al. 2000; Perkins et al. 2000; Awandare et al. 2006a). 
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 1.6 MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF): BIOLOGICAL 
FEATURES 
Macrophage migration inhibitory factor (MIF) is a 12.5 kDa protein of 114 amino acid residues 
(Donn and Ray 2004).  Structural studies by X-ray crystallography show that MIF exists as a 
homotrimer (Sugimoto et al. 1996; Sun et al. 1996), however, bioactive monomeric and dimeric 
forms of MIF have been observed by other studies (Mischke et al. 1998).  MIF was one of the 
first proteins described to have cytokine activity when it was originally identified for its role in 
delayed-type hypersensitivity, where it inhibited the random migration of macrophages (Bloom 
and Bennett 1966; David 1966).  Although initially classified as a T cell-derived cytokine, recent 
studies have re-discovered MIF as a pleiotropic cytokine released by several other cell types, 
including monocytes/macrophages (Calandra et al. 1994), endothelial cells (Nishihira et al. 
1998), and cells of the anterior pituitary gland (Bernhagen et al. 1993).  Unlike most cytokines 
which are tightly regulated and induced only by stimulation, MIF is constitutively expressed at 
high levels and stored in vesicles, and therefore, can be rapidly released without de novo 
synthesis (Bernhagen et al. 1993; Bernhagen et al. 1998). MIF is also induced by various pro-
inflammatory stimuli, including bacterial endo- and exotoxins such as lipopolysaccharide (LPS), 
and cytokines such as IFN-γ and TNF-α  (Calandra et al. 1994).  Once released, MIF exerts 
potent pro-inflammatory properties by over-riding the immunosuppressive effects of 
glucocorticoids (Calandra et al. 1995; Calandra and Bucala 1995; Calandra et al. 2000), and 
inducing production of TNF-α, NO, and IL-12 ((Calandra and Bucala 1995; Juttner et al. 1998), 
Figure 3).  Studies in murine models of infection have demonstrated a central role for MIF in 
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 regulating protective innate immunity to the bacterial pathogens such as Salmonella enterica 
serovar Typhimurium (Koebernick et al. 2002), and parasites including Leishmania major 
(Juttner et al. 1998), and Trypanosoma cruzi (Reyes et al. 2006), by activating macrophages for 
phagocytosis and cytokine production.  Conversely, MIF exacerbates the pathogenesis of 
bacterial sepsis by promoting over-production of TNF-α, IL-6 and IL-1 (Calandra et al. 2000) 
(Calandra et al. 2003), demonstrating that MIF can elicit both protective and pathogenic immune 
responses to different infectious diseases. 
MIF protein lacks a signal sequence, and as such, its mechanism of secretion is unclear. 
However, recent evidence suggests that synthesized MIF does not go to the endoplasmic 
reticulum, instead it is secreted via a non-classical export pathway involving an ATP binding 
cassette transporter ((Flieger et al. 2003), Figure 3).   There is also ambiguity about the signal 
transduction pathways by which MIF exerts its biological activities, since MIF has no known 
receptors.  The best known putative MIF receptor thus far is CD74, a type II transmembrane 
protein, that binds MIF with high affinity and appears to play a role in mediating MIF-induced 
activation of the extracellular signal-regulated kinase (ERK)-1/ERK-2 pathway ((Leng et al. 
2003), Figure 3).   A receptor-independent endocytic pathway for MIF signal transduction has 
also been proposed, following evidence showing co-localization of MIF with the JUN-activation 
domain-binding protein 1 (JAB1) in the cytoplasm. The interaction between MIF and JAB1 is 
believed to mediate biological activities such as cell growth, transformation and apoptosis 
((Kleemann et al. 2000), Figure 3).  
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Figure 3: Biological activities of MIF.   
MIF production is induced by pro-inflammatory stimuli, including lipopolysaccharide (LPS) and IFN-γ. MIF lacks a 
signal sequence and is believed to be released via a non-classical pathway that involves an ATP-binding cassette 
(ABC) transporter.  b) Although a classical MIF receptor is yet to be identified, binding of MIF to the 
transmembrane protein CD74 is involved in the activation of the ERK 1/2 pathway that induces COX-2. However, 
the identities of intracellular adapter proteins involved in transduction of these signals are yet to be determined.  
COX-2 increases production of PGE2 which mediates MIF-induced suppression of apoptosis by inhibiting p53. MIF 
also inhibits apoptosis by reducing oxidative burst by an unknown mechanism.  c)  There is also evidence suggesting 
for a receptor-independent MIF uptake into the cytoplasm, where it binds with JAB1 to initiate a cascade of events 
that inhibit cell-cycle arrest and induce increased cell proliferation. d) A unique property of MIF is its ability to 
reverse glucocortocoid inhibition of NF-kB, thus allowing induction of several pro-inflammatory cytokines 
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 including, IL-1, IL-6, IL-8, Il-12, and TNF-α.  Production of TNF-α further augments the pro-inflammatory 
response by activating NF-κB to induce more mediators including MIF. e) Other biological activities of MIF include 
induction of inducible NO synthase (iNOS), upregulation of TLR4, and promotion of phagocytosis. 
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 1.7 MIF GENETICS 
The MIF gene is located on chromosome 22 of the human genome (Donn and Ray 2004).  It is a 
relatively small gene of <1 kb, made up of 205-, 173-, and 183-bp exons separated by 189- and 
95-bp introns ((Paralkar and Wistow 1994), Figure 4).  This gene is flanked by 250 bp of 3’ 
untranslated region and a 1 kb sequence at the 5’ end (Paralkar and Wistow 1994). The MIF 
promoter lacks a TATA-box, and has one known transcription start site located 97 bp upstream 
from the initiator methionine (Donn and Ray 2004).    Recently, a MIF homologue was identified 
in Plasmodium spp., including P. falciparum with about 39% sequence homology with human 
MIF (Augustijn et al. 2007; Cordery et al. 2007).  In addition, the MIF gene is highly conserved 
across species, including rats, mice, chickens, parasites, and fishes (Calandra and Roger 2003), 
suggesting that MIF plays important biological roles across different phylogenies.  Five 
polymorphisms of the MIF gene have been identified to date, including a tetranucleotide short 
tandem repeat polymorphism (STRP) at -794 (CATT5-8), and four single nucleotide 
polymorphisms (SNPs) at positions -173 (G/C), +24 (A/T), +254 (T/C) and +656 (C/G) (Donn et 
al. 2001; Baugh et al. 2002; Donn et al. 2002; Renner et al. 2005), Figure 4). The +24 SNP is 
very rare, and has not been well-studied, while the +254 and +656 polymorphisms are positioned 
in introns and thus not likely to have functional consequences.   However, considerable interest 
has been generated by the polymorphisms in the promoter, since these appear to functionally 
influence MIF gene expression.  The C allele at -173 creates a potential AP-4 binding site, and is 
generally associated with higher MIF production and increased susceptibility to inflammatory 
diseases such as arthritis and atopy (Donn et al. 2001; Donn et al. 2002; Barton et al. 2003; 
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 Radstake et al. 2005; Renner et al. 2005).  Similarly, longer CATT repeats at -794 correlate with 
increased MIF production and higher risk for various types of arthritis including rheumatoid 
arthritis and juvenile idiopathic arthritis (Baugh et al. 2002; Barton et al. 2003; Radstake et al. 
2005).  In addition, haplotypes of the two promoter polymorphisms are also associated with MIF 
production levels, and are better predictors of diseases susceptibility than either polymorphism 
alone (Donn et al. 2002; Barton et al. 2003; Donn et al. 2004; Hizawa et al. 2004).  
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Figure 4: MIF gene.   
The human MIF gene consists of three exons of 107 bp, 172 bp, and 66 bp, separated by two introns of 188 bp and 
94 bp.  A single transcription start site, located 97 bp from the methionine codon (ATG), is known.  There is ~ 1kb 
of 5’ flanking sequence, containing potential binding sites to several transcription factors including  cAMP response 
element binding protein (CREB), specificity protein 1 (SP1), activator protein 1 (AP1), GATA, E-twenty-six  (ETS), 
and nuclear factor  (NF)-κB.  Variation at five sites in the MIF gene has been reported: a tetranucleotide short 
tandem repeat polymorphism at -794 (CATT5-8), and single nucleotide polymorphisms (SNPs) at -173 (G/C), +25 
(A/T), +254 (T/C), and +656 (C/G).   
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 1.8 ROLE OF MIF IN MALARIAL PATHOGENESIS 
Despite the re-emergence of MIF as a central regulator of innate immunity (Calandra and Roger 
2003), the role of MIF in malarial pathogenesis remains largely unexplored.  Investigations in 
children with cerebral malaria (CM) showed that MIF levels were expressed at very low levels in 
blood vessel walls within the brain (Clark et al. 2003), and highly expressed in blood vessel 
walls of peripheral tissue in children with fatal falciparum malaria or sepsis (Clark et al. 2003; 
Clark and Cowden 2003).   Additional studies in women with malaria during pregnancy revealed 
that MIF production was increased in intervillous plasma and in cultured intervillous blood 
mononuclear cells, but not in peripheral plasma (Chaisavaneeyakorn et al. 2002; Chaiyaroj et al. 
2004; Chaisavaneeyakorn et al. 2005).  The best evidence for a role for MIF in malarial 
pathogenesis has come from studies in murine models, where MIF levels were elevated in both 
peripheral blood and bone marrows of mice with P. Chabaudi infections (Martiney et al. 2000; 
McDevitt et al. 2006).  These investigations also demonstrated that MIF was involved in 
suppression of erythropoiesis, and circulating levels of MIF correlated with severity of malarial 
anemia (Martiney et al. 2000; McDevitt et al. 2006).  Interestingly, recent studies have 
characterized MIF homologs from Plasmodial parasites including P. falciparum (Augustijn et al. 
2007; Cordery et al. 2007), providing additional evidence for a possible role for MIF in disease 
pathogenesis.  However, studies examining the relationship of MIF production with the 
pathogenesis of SMA in children that will validate the findings from murine malaria have not 
been reported.  In addition, although there is considerable evidence indicating that variation in 
immune response genes influences the pathogenesis of severe malaria, the role of genetic 
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 polymorphisms in the MIF promoter in conditioning susceptibility to SMA is unknown.  A 
recent study in a small cohort of Zambian children (n=40) revealed that carriers of >5 CATT 
repeat alleles at -794 had a higher risk of developing high-density parasitemia (HDP) relative to 
those with the 5-repeat allele (Zhong et al. 2005), demonstrating a potentially important role for 
MIF polymorphisms in malarial pathogenesis.   
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 2.0  CHAPTER TWO: SPECIFIC AIMS 
Infections of children with P. falciparum lead to increased destruction of RBCs which is 
complicated by suppression of erythropoiesis and the development of SMA if the infection is not 
quickly resolved. Although the host-specific factors that regulate these processes are only 
partially understood, it is clear that the nature and magnitude of innate immune mediator 
production (McDevitt et al. 2004) and genetic variation in host immune response genes 
(Kwiatkowski 2005) are important determinants of the development and outcomes of severe 
malaria.   Recent studies illustrate that MIF plays a pivotal role in regulating innate immune 
responses to invading pathogens (reviewed in (Calandra and Roger 2003)).  For example, MIF 
has potent pro-inflammatory properties that protect against Salmonella typhimurium (Koebernick 
et al. 2002) and Leishmania major (Juttner et al. 1998; Xu et al. 1998; Satoskar et al. 2001).  On 
the other hand, over-production of MIF is associated with enhanced pathogenesis of bacterial 
sepsis (Bernhagen et al. 1993; Bozza et al. 1999; Calandra et al. 2000), demonstrating that MIF 
could play both protective and pathogenic roles in different infections. An important property of 
MIF is its ability to override the immunosuppressive effects of glucocorticoids (Calandra et al. 
1995), thus allowing the increased production of proinflammatory cytokines, such as IFN-γ and 
IL-12 (Koebernick et al. 2002). In addition, MIF has potent anti-apoptotic properties (Hudson et 
al. 1999; Mitchell et al. 2002; Fingerle-Rowson et al. 2003) and supports proliferation of 
embryonic cells (Petrenko et al. 2003). Genetic variation in the MIF promoter influences MIF 
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 production and susceptibility to several inflammatory diseases in Cuacasians (Donn et al. 2001; 
Baugh et al. 2002; Donn et al. 2002; Barton et al. 2003; Renner et al. 2005), and is associated 
with HDP in Zambian children with malaria (Zhong et al. 2005).  The role of genetic variation in 
the MIF promoter in influencing MIF production and conditioning susceptibility to SMA has not 
been reported.  
Protective immunity to malaria requires an early induction of IFN-γ and IL-12 which 
drive a robust type 1 immune response for control of parasitemia (Crutcher et al. 1995; 
Stevenson et al. 1995; Angulo and Fresno 2002).  Therefore, we propose that elevated MIF 
production during acute malaria protects against SMA by promoting a rapid and potent innate 
immune response that could result in more efficient control over the initial phases of parasitemia.  
In addition, since phagocytosis of Hz by monocytes and neutrophils is associated with severe 
malaria (Nguyen et al. 1995; Luty et al. 2000; Lyke et al. 2003; Casals-Pascual et al. 2006) and 
dysregulation in cytokine production (Pichyangkul et al. 1994; Sherry et al. 1995; Perkins et al. 
2003; Keller et al. 2004a; Keller et al. 2004b; Ochiel et al. 2005; Keller et al. 2006a; Keller et al. 
2006b), we postulate that increased deposition of Hz in phagocytes will enhance SMA 
pathogenesis by suppressing MIF production.  Furthermore, since MIF supports cell 
proliferation, adequate MIF levels will be required for survival and efficient proliferation of 
erythroid progenitors to replace lost RBCs and prevent anemia during P. falciparum infection.  
In addition, we postulate that MIF promoter variants determine MIF production at baseline and 
in response to malaria infection, thereby influencing susceptibility to SMA.  
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 2.1 SPECIFIC AIM 1  
To determine the relationship of peripheral blood MIF production with circulating levels of 
MIF-associated inflammatory mediators, and to investigate the role of MIF in the 
development of severe anemia in children with acute P. falciparum infection. 
Hypothesis 1: Peripheral blood MIF production correlates with induction of pro-inflammatory 
mediators including IFN-γ, IL-12, TNF-α, and NO in children with acute malaria. 
Hypothesis 2: Elevated basal MIF production is protective against the development of severe 
malaria during subsequent P. falciparum infections  
 
Circulating MIF protein and PBMC MIF transcripts levels were determined in children 
with acute malaria and healthy controls using ELISA and real time RT-PCR respectively.  In 
addition, circulating levels of the pro-inflammatory mediators IFN-γ, IL-12, TNF-α, PGE2, and 
NO, and the anti-inflammatory cytokines IL-10 and TGF-β1 were examined.  Multivariate linear 
regression analyses were performed to determine the relationship between MIF and the other 
mediators.  Furthermore, using longitudinal data available for the cohort, MIF levels in healthy 
children with a history of mild malaria were compared to those with a history of severe malaria 
to investigate the role of basal MIF production and disease susceptibility.  
Additional studies were conducted to investigate the following hypotheses:   
Hypothesis 3: Peripheral blood MIF production is associated with anemia severity in 
children with acute P. falciparum malaria 
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 Hypothesis 4: Phagocyte acquisition of malarial pigment (hemozoin) leads to 
suppression of MIF production during acute malaria 
 
Children were recruited from Siaya District in western Kenya, where P. falciparum 
transmission is holoendemic, and the primary clinical manifestations of severe malaria are severe 
anemia and HDP (McElroy et al. 2000; Ong'echa et al. 2006).   Peripheral blood was obtained 
from children with differing severities of malarial anemia or uncomplicated malaria, and healthy 
aparasitemic controls and used to examine circulating MIF levels, production of MIF in cultured 
PBMC, and PBMC MIF transcript levels. In addition, a complete hematological evaluation of 
study participants was conducted, including full blood counts, reticulocyte counts, parasitemia 
and Hb determination, and quantification of pigment-containing monocytes (PCM) and pigment-
containing neutrophils (PCN).  The relationship between MIF production and anemia severity 
was examined by comparing MIF levels across groups, and also through a multivariate 
regression model with Hb as the dependent variable, and controlling for the confounding effects 
of age, gender, and parasitemia.  Furthermore, given the in vivo role of Hz in cytokine 
dysregulation (Luty et al. 2000; Perkins et al. 2003; Keller et al. 2006b) and pathogenesis of 
SMA (Wickramasinghe and Abdalla 2000; Casals-Pascual et al. 2006), the relationship of PCN 
and PCM with anemia severity and MIF production was examined.  Additional experiments 
investigated the effects of purified P. falciparum Hz (pfHz) on MIF production in cultured 
malaria-naïve PBMC and purified monocytes. 
 
  22
 2.2 SPECIFIC AIM 2 
To investigate the role of MIF in proliferation and differentiation of erythroid progenitor 
cells. 
Hypothesis 1: Endogenous MIF production is required to promote efficient proliferation of 
erythroid progenitors.  
Hypothesis 2: MIF-regulated inflammatory mediators TNF-α and NO are more detrimental to 
erythroid progenitor survival and differentiation than MIF. 
 
Given the difficulties in obtaining sufficient quantities of erythroid progenitors from bone 
marrows of severely anemic children and the lack of a reliable ex vivo or in vitro model for 
examining erythroid development, one of the aims of this study was to development a simple and 
reliable model to study erythropoiesis in vitro. Based on recently demonstrated methods for 
cultivating CD34+ hematopoietic stem cells in liquid culture and inducing them towards 
erythroid differentiation (Freyssinier et al. 1999; Neildez-Nguyen et al. 2002), an in vitro model 
of erythropoiesis was developed and used to evaluate the effects of MIF and MIF-regulated 
mediators, NO and TNF-α, on erythropoiesis.  For these investigations, peripheral blood CD34+ 
stem cells were induced to develop into RBCs in liquid culture by stimulation with 
erythropoietin (Epo) in the presence of anti-MIF blocking antibodies, recombinant human (rh) 
MIF, rhTNF-α or NO donor-compounds.  Erythroid cell proliferation was measured by a 
methylthiazoletetrazolium (MTT)-based assay, apoptosis by detection of nucleosomes using 
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 ELISA, and maturation of erythroid cells by assessing surface expression of CD34, CD45, CD71 
and glycophorin-A (GPA) using flow cytometry.   
 
2.3 SPECIFIC AIM 3   
To examine the influence of genetic variation at positions -173(G/C) and -794 (CATT5-8) of 
the MIF promoter on MIF production and susceptibility to SMA in children. 
Hypothesis 1:  MIF -173 and -794 variants that are associated with decreased MIF production 
also condition increased susceptibility to SMA 
Hypothesis 2: Haplotypes of the MIF -173 and -794 polymorphisms are stronger predictors of 
SMA susceptibility and MIF production levels than either polymorphism alone  
 
To test these hypotheses, DNA samples obtained from the Kenyan children enrolled for 
Specific Aim 1 were analyzed for MIF -173 and -794 genotypes.  The -173 SNP was examined in 
a high-throughput manner using allelic discrimination by real time RT-PCR, and results were 
validated by testing 10% of the samples using conventional restriction fragment length 
polymorphism (RFLP)-PCR. The -794 STRP was analyzed by PCR using florescent-labeled 
primers and products were resolved by capillary electrophoresis.  The relationships of MIF -173 
and -794 genotypes and haplotypes with SMA were examined using multivariate logistic 
regression models that controlled for the confounding effects of age, gender, sickle cell trait and 
HIV-1 status. In addition, data obtained in Specific Aim1 on circulating MIF levels and PBMC 
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 MIF production were analyzed according to genotypic and haplotypic groups in parasitemic and 
aparasitemic groups to determine the functional association between genotypic variants and MIF 
production.   
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 3.0  CHAPTER THREE: RESULTS, SPECIFIC AIM 1 
3.1 HYPOSTHESIS 1: PRESENTATION OF MANUSCRIPT ENTITLED: 
DECREASED CIRCULATING MACROPHAGE MIGRATION INHIBITORY FACTOR 
(MIF) PROTEIN AND BLOOD MONONUCLEAR CELL MIF TRANSCRIPTS IN 
CHILDREN WITH PLASMODIUM FALCIPARUM MALARIA 
Hypothesis 1: Peripheral blood MIF production correlates with induction of pro-inflammatory 
mediators including IFN-γ, IL-12, TNF-α, and NO in children with acute malaria. 
To address this hypothesis, circulating levels of MIF, IFN-γ, TNF-α, IL-12, IL-10, TGF-
β1, and PGE2, PBMC nitric oxide synthase (NOS) activity, and PBMC MIF transcripts levels 
were examined in a group of Gabonese children presenting with acute malaria and healthy age-
matched aparasitemic children.  The relationship of MIF levels with malaria disease and 
production of other inflammatory mediators was investigated.  The results of these investigations 
are presented in the following manuscript published in the journal Clinical Immunology (Clin. 
Immunol. 2006, 119: 219-225; reproduced with permission from Elsevier Limited). 
 
Gordon A Awandare1, James B. Hittner2, Peter G. Kremsner3,4 , Daniel O. Ochiel1, Christopher 
C. Keller1, J. Brice Weinberg5, Ian A. Clark6, and Douglas J. Perkins1. 
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 3.1.2 Abstract 
Plasmodium falciparum malaria remains one of the most frequently lethal diseases affecting 
children in sub-Saharan Africa, yet the immune mediators that regulate pathogenesis are only 
partially defined.  Since macrophage migration inhibitory factor (MIF) is important for 
regulating innate immunity in bacterial and parasitic infections, circulating MIF and peripheral 
blood mononuclear cell (PBMC) MIF transcripts were investigated in children with acute 
falciparum malaria.  Peripheral blood levels of MIF-regulatory cytokines and effector molecules, 
including interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-12, IL-10, 
transforming growth factor (TGF)-β1, bicyclo-prostaglandin (PG) E2, and nitric oxide synthase 
activity were also determined.  Circulating MIF and PBMC MIF mRNA were significantly lower 
in children with acute malaria relative to healthy, malaria-exposed children.  Peripheral blood 
MIF levels showed no association with either parasitemia or hemoglobin concentrations. 
Circulating MIF was, however, significantly associated with IL-12 and TGF-β1.  Multiple 
regression analyses revealed that IFN-γ was the most significant predictor of peripheral blood 
MIF concentrations.  These findings suggest that reduced MIF production may promote 
enhanced disease severity in children with falciparum malaria.      
 
Running title:  Low peripheral blood MIF in children with malaria 
Keywords:  Macrophage migration inhibitory factor (MIF); Plasmodium falciparum; malaria; 
anemia; immunity; cytokines. 
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 3.1.3 Introduction 
Malaria is a major global health problem with 300 to 500 million clinical cases each year 
resulting in more than 2 million deaths (WHO 2000), with the majority of malaria-associated 
mortality occurring in African children less than 5 years of age (Guilbert 2003).  Although four 
species of the malaria parasite infect humans, malaria-related mortality is primarily due to 
Plasmodium falciparum (WHO 2000).  The clinical presentation of falciparum malaria in 
children varies from asymptomatic infection to severe life-threatening complications such as one 
or more of the following: hyperparasitemia, hypoglycemia, cerebral malaria, severe anemia, 
respiratory distress, hyperlactatemia or others (WHO 2000).  Although the factors that determine 
disease severity during acute malaria are not clearly defined, host genetic factors, age of first 
exposure, and rate of exposure (endemicity) are all important for conditioning the acquisition of 
naturally acquired immunity.   
One cytokine that is largely unexplored in human malaria is macrophage migration 
inhibitory factor (MIF).  Recent studies illustrate that MIF is a critical regulatory factor of the 
innate immune response in that MIF can promote both protective immunity and enhanced 
pathogenesis in bacterial and parasitic infections (Bernhagen et al. 1993; Calandra et al. 1998; 
Juttner et al. 1998; Xu et al. 1998; Bozza et al. 1999; Calandra et al. 2000; Satoskar et al. 2001; 
Koebernick et al. 2002; Rodriguez-Sosa et al. 2003).  Although MIF was initially identified for 
its role in delayed-type hypersensitivity and thought to be primarily T-cell-derived (Bloom and 
Bennett 1966; David 1966), additional research has shown that MIF is a pro-inflammatory 
mediator released by the anterior pituitary gland in response to endotoxins (Bernhagen et al. 
1993), and by cells of the monocyte/macrophage lineage in response to bacterial toxins and pro-
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 inflammatory cytokines, such as interferon (IFN)-γ and tumor necrosis factor (TNF)-α (Calandra 
et al. 1994).   Consistent with the fact that pro-inflammatory-derived cytokines induce MIF 
expression, anti-inflammatory cytokines, such as IL-10 down-regulate MIF (Wu et al. 1993). 
Previous studies in a murine model of malaria showed that infection with P. chabaudi 
increased MIF in circulation, which was associated with enhanced anemia (Martiney et al. 2000), 
suggesting that increased MIF production may be an important factor for promoting malarial 
anemia (MA) (Martiney et al. 2000).  Recent investigations in children with cerebral malaria 
(CM) showed that MIF levels were expressed at very low levels in blood vessel walls within the 
brain (Clark et al. 2003), and highly expressed in blood vessel walls of peripheral tissue in 
children with fatal falciparum malaria or sepsis (Clark et al. 2003; Clark and Cowden 2003).   
Additional studies in women with malaria during pregnancy revealed that MIF production was 
increased in intervillous plasma and in cultured intervillous blood mononuclear cells, but not in 
peripheral plasma (Chaisavaneeyakorn et al. 2002; Chaiyaroj et al. 2004; Chaisavaneeyakorn et 
al. 2005).  While these earlier studies in rodent and human malaria suggest that MIF may be 
pathogenic by promoting an excessive pro-inflammatory response, adequate MIF levels may also 
be necessary to allow a potent inflammatory response that could provide protection against 
severe disease by ensuring rapid and efficient parasite clearance.  
To our knowledge, the role of MIF in regulating the immunological response to acute 
non-cerebral falciparum malaria in children has not previously been examined.  In the current 
study, peripheral blood levels of MIF and peripheral blood mononuclear cell (PBMC) MIF 
transcripts were determined in children with acute P. falciparum malaria in which the primary 
manifestation of acute malaria was hyperparasitemia and anemia.  In addition, the association 
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 between MIF and other immune mediators, such as IFN-γ, TNF-α, IL-12, IL-10, TGF-β, 
bicyclo-PGE2 and NO was investigated.    
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 3.1.4 Materials and methods 
3.1.4.1 Study participants. 
Children (ages 2-8 years) were selected from a longitudinal prospective study at the Albert 
Schweitzer Hospital in Lambarènè, Gabon (equatorial West Africa), an area of hyperendemic 
malaria transmission where hyperparasitemia and anemia are the predominant complications of 
acute malaria (Kun et al. 1998; Kun et al. 1998; Perkins et al. 1999).  Upon enrollment in the 
study, finger-prick blood (<100 μL) was obtained to determine parasitemia and anemia status.  
Peripheral blood smears were prepared and stained with Giemsa reagent and examined under oil 
immersion for malaria parasites.  Asexual malaria parasites were counted using the Lambarènè 
method (Planche et al. 2001).  Determinations of Hb levels were performed on finger-prick 
blood using a HemoCue system (HemoCue AB, Angelholm, Sweden).  Children presenting with 
acute P. falciparum malaria (Mal, n=23) were treated promptly with the appropriate antimalarials 
and supportive therapy.  None of the children in the current study had cerebral malaria.  Children 
diagnosed with any diseases other than malaria were excluded from the study.  Healthy 
aparasitemic controls (AC, n=25) were children in the convalescent phase of malaria and were 
currently free of malaria parasites and any other detectable disease for one or more months.  
Participation in the study was completely voluntary and written informed consent was 
obtained from the parent/guardian of the pediatric participants.  The study received approval 
from the ethics committee of the International Foundation of the Albert Schweitzer Hospital, 
Duke University Medical Center Investigational Review Board, and the University of Pittsburgh 
Institutional Review Board.    
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 3.1.4.2 Sample collection.    
Before delivery of anti-malarials and/or any other treatment interventions, venous blood was 
drawn into heparinized tubes (2-3mL), centrifuged and the plasma removed and stored frozen at 
-70oC until analysis.  PBMCs were isolated using Ficoll-Hypaque as described previously and 
stored frozen at -70oC until the time of use (Weinberg et al. 1981). 
3.1.4.3 Nitric oxide synthase (NOS) enzyme activity.   
Cell lysates were prepared from frozen PBMCs and NOS enzyme activity was determined by 
measuring the conversion of L-[14C]arginine to L-[14C]citrulline (Weinberg et al. 1994).  
Samples were assayed in triplicate and the average NOS enzyme activity was expressed as 
picomoles of citrulline/mg of protein.  This method of assaying NO production was selected 
since circulating markers of NO production, such as nitrate, can be influenced by dietary intake 
of nitrates.    
3.1.4.4 Cytokine and Prostaglandin measurements.   
Cytokine levels in plasma were determined using quantitative sandwich ELISA.  To eliminate 
variation between assays, all samples were assayed at the same time for each of the cytokines 
and effector molecules.  MIF was measured using a matched antibody pair from R & D systems 
(cat no. MAB289 and BAF289), according to the manufacturer’s recommendations.   Similarly, 
concentrations of IFN-γ, TNF-α, TGF-β1, and IL-10 were determined using commercially 
available reagents (R & D systems, Minneapolis).  For IL-12 measurements, a monoclonal 
antibody specific for the active heterodimer of IL-12 was used.  To exclude TGF-β1 released 
from platelets, a separate aliquot of platelet-poor plasma was generated by centrifugation at 
10,000g for 15 minutes.  The resulting plasma samples were activated by incubation with 2.5 N 
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 acetic acid/10N urea for 10 minutes, followed by neutralization with 2.7 N NaOH/1 M HEPES, 
before determination of TGF-β1.  All samples were assayed in duplicate and the sensitivities of 
detection were as follows: MIF >62.5 pg/mL; IFN-γ >3.0pg/mL; TNF-α >4.4 pg/mL; IL-12 >5.0 
pg/mL; IL-10 >3.0 pg/mL; and TGF-β1 >7.0 pg/mL).  PGE2 and the intermediary metabolite 
were converted to the stable form, bicyclo-PGE2, and measured using a commercially available 
EIA (Cayman Chemical, San Diego), according to our previously described methods (Perkins et 
al. 2001). 
3.1.4.5 MIF mRNA analyses.   
Total RNA was extracted from PBMCs using the GITC method as described previously 
(Chomczynski and Sacchi 1987).  The RNA yield was assessed by spectrophometry and 1μg of 
total RNA transcribed into cDNA using MuLV reverse transcriptase (Applied Biosystems, Foster 
City, CA).  A MIF specific fluorogenic PCR primer/probe set (assay ID Hs00236988_g1, 
Applied Biosystems, Foster City, CA) was used for real time PCR run on the ABI Prism 7700 
sequence detection system (Applied Biosystems, Foster City, CA).  Each sample was run in 
duplicate.  The housekeeping gene, β-actin (assay ID NM_001101, Applied Biosystems, Foster 
City, CA), was amplified from each sample to normalize template concentrations.  Comparisons 
between samples were made using differences in critical threshold values (∆CT = critical 
threshold cycle of MIF – critical threshold cycle for β-actin).    MIF mRNA levels in PBMCs of 
children were expressed as fold change relative to β-actin mRNA (2-∆CT).   
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 3.1.4.6 Statistical analyses.   
Non-parametric data are presented as box plots showing medians and interquartile range, while 
normalized data are presented as bar graphs showing means and standard errors of means (SEM).  
Age, Hb concentration, body temperature and plasma levels of cytokines and effector molecules 
between groups were compared using Mann-Whitney U-tests.  MIF transcript levels between 
groups of children were normalized against β-actin levels and compared by Student’s t test.  
Linear associations between MIF and cytokines and effector molecules were examined via 
Pearson correlations and multiple regression analysis.  Statistical significance for all tests was set 
at P<0.05. 
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 3.1.5 Results 
3.1.5.1 Patient Characteristics.   
Children with acute P. falciparum malaria (Mal, n=23) were recruited from the Albert 
Schweitzer Hospital in Lambarènè, Gabon.  Aparasitemic, age-matched controls (AC, n=25) 
were recruited from a longitudinal cohort study which allowed for a known history of falciparum 
malaria in children from the same geographic location.  The clinical, parasitological, and 
laboratory characteristics of the AC and Mal groups are summarized in Table 1.  There were no 
significant differences in age (mos) between the two groups (P=0.2).  Hb concentrations (g/dL) 
were significantly higher in the control group (P<0.01), while body temperature (◦C) was 
significantly higher in children with acute malaria (P<0.05).     
3.1.5.2 Plasma MIF in children with acute malaria.   
To investigate the role of MIF in the pathogenesis of childhood MA, plasma MIF levels were 
determined in children with acute P. falciparum malaria and age-matched aparasitemic controls.  
Since erythrocytes contain large quantities of MIF (Mizue et al. 2000), plasma samples were 
used instead of serum to avoid the possible influence of MIF released from lysis of erythrocytes 
that can result during the clotting process.  Compared to aparasitemic controls, children with 
acute malaria had significantly lower plasma MIF concentrations (P<0.05, Figure 5A).  The 
mean (range) of MIF levels were 1224 (190-3893) for children with acute malaria versus 1627 
(710-3829) for aparasitemic controls. 
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 3.1.5.3 MIF mRNA in PBMCs during acute malaria.   
Determining the cellular source responsible for altered MIF levels in circulation can be complex 
because MIF is produced from a number of different sources including cells of the endocrine 
system and several immune cells  (Bernhagen et al. 1993; Calandra et al. 1994; Calandra and 
Roger 2003).  Since we have previously shown that reductions of circulating cytokines and 
effector molecules is due to altered PBMC transcriptional regulation in children with acute 
malaria (Perkins et al. 2001; Ochiel et al. 2005), PBMC MIF transcripts were examined by real 
time RT-PCR.  There was a positive, but non-statistically significant association between 
circulating MIF protein and PBMC transcript levels (r=0.26, P=0.156). MIF transcripts were 
significantly lower in children with acute malaria compared to aparasitemic controls (P<0.05, 
Figure 5B), suggesting that reductions in circulating MIF may be, at least in part, related to 
reduced MIF mRNA expression in PBMC.    
3.1.5.4 Production of MIF-associated cytokines and mediators in children with acute malaria.     
To examine the association between altered MIF and other important immunological mediators 
during acute falciparum malaria, levels of IFN-γ, TNF-α, IL-12, TGF-β1, IL-10, bicyclo-PGE2, 
and NOS enzyme activity were determined.  Circulating levels of inflammatory mediators in 
aparasitemic children and children with acute malaria are shown in Table 2.  Children with acute 
malaria had significantly higher levels of IFN-γ (P<0.01), TNF-α (P<0.005), IL-10 (P<0.0001), 
and NOS enzyme activity (P<0.005).  In contrast, bicyclo-PGE2 and TGF-β1 were significantly 
reduced in children with acute malaria (P<0.01 and P<0.001, respectively), while IL-12 was 
non-significantly reduced in children with malaria (P=0.5).  Portions of the cytokine and effector 
molecule data were previously reported as part of our studies examining acute falciparum 
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 malaria in Gabonese children (Perkins et al. 1999; Luty et al. 2000; Perkins et al. 2000; Perkins 
et al. 2001; Keller et al. 2004b).   
3.1.5.5 Associations between cytokines and effector molecules and MIF in children with acute 
malaria.   
To examine the strength and direction of linear association between plasma MIF and the various 
cytokines and effector molecules, Pearson correlations and a multiple regression analysis were 
conducted.  For these analyses, MIF was logarithmically transformed, and several of the 
cytokines were either logarithmically or square-root transformed, to reduce positive skewness 
and increase normality.  There was a significant positive correlation between MIF and both IL-
12 (r=0.22, P<0.05) and TGF-β1 (r=0.27, P<0.01).  When the study participants were stratified 
into two groups according to the case definitions (i.e., AC and Mal), the association between IL-
12 and MIF remained significant for children with acute malaria (r=0.37, P<0.05), but was non-
significant for the aparasitemic controls (r=0.21, P=0.2, Figure 6A).  The association between 
TGF-β1 and MIF was also reduced to non-significance when the two groups were examined 
separately (r=0.19, P=0.2, for Mal; r=0.30, P=0.08, for AC; Figure 6B).   
In the multivariate analysis, both aparasitemic controls and children with acute malaria 
were included in the model.  For these analyses, MIF served as the criterion variable; the 
predictors were age, parasitemia, cytokines (i.e., IFN-γ, TNF-α, IL-12, IL-10, and TGF-β), and 
effector molecules (i.e., bicyclo-PGE2 and NOS enzyme activity), and the covariate consisted of 
group status (Mal versus AC).  The regression was hierarchical with group status entered first in 
the model and all of the predictors entered in the second step.  The multivariate model revealed 
that IFN-γ was the most significant predictor of MIF, with a standardized partial regression 
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 coefficient (β-weight) of 0.31 (P=0.05).  Moreover, the positive association was independent of 
disease severity since group status was controlled for in the model, illustrating that IFN-γ is an 
important cytokine for regulating peripheral blood MIF levels in both aparasitemic, malaria-
exposed children and children with acute malaria.    
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 3.1.6 Discussion 
To our knowledge, this is the first published report on MIF production and regulation in children 
with non-cerebral malaria.  Consistent with present results showing that circulating MIF levels 
are decreased in children with malaria, previous studies illustrated that plasma MIF protein was 
decreased (although not statistically significant) in women with P. falciparum malaria during 
pregnancy (Chaisavaneeyakorn et al. 2002; Chaiyaroj et al. 2004).  However, it is interesting to 
note that intervillous plasma levels in these same women were increased during acute malaria 
(Chaisavaneeyakorn et al. 2002; Chaiyaroj et al. 2004).   Plasma MIF levels reported here (≈ 1-4 
ng/mL) for aparasitemic controls are slightly lower than those reported elsewhere in adult 
Caucasians (Calandra et al. 2000), but are within the range of levels in peripheral plasma of 
malaria-exposed African women (Chaisavaneeyakorn et al. 2002; Chaiyaroj et al. 2004).  Post-
mortem histochemistry studies in Malawian children with CM illustrated that MIF protein 
expression is largely absent within cerebral structures, but highly expressed in chest wall blood 
vessels (Clark et al. 2003).  Since MIF has recently been shown to be regulated differently in 
individual compartments of malaria-infected placentas (Chaisavaneeyakorn et al. 2002; 
Chaiyaroj et al. 2004; Chaisavaneeyakorn et al. 2005), it is feasible that peripheral blood MIF 
regulation may differ from that in central and peripheral tissues, thus accounting for the 
differences in MIF responses observed here versus those in placental malaria and CM.   
Findings presented here illustrate that MIF transcript levels in ex vivo PBMCs are 
decreased in acute malaria relative to aparasitemic controls, and that reduced MIF gene 
expression corresponds with decreased plasma MIF concentrations.  These results suggest that 
PBMC may be an important source of circulating MIF during acute malaria.  Decreased MIF 
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 transcription in PBMC from children with acute malaria could be due to parasite-derived 
products such as hemozoin, and/or parasite-induced changes in host immune mediators, such as 
cytokines and effector molecules.  In the current study, MIF was not significantly associated with 
parasitemia (data not shown), suggesting that an altered inflammatory milieu rather than 
parasitemia per se may account for suppression of MIF in acute disease.        
Infection of mice with P. chabaudi resulted in increased serum MIF levels that were 
associated with enhanced levels of anemia  (Martiney et al. 2000).  Results presented here show 
that MIF levels declined in children with malarial anemia compared to healthy, malaria-exposed 
children.  However, MIF levels were not significantly associated with Hb concentrations (data 
not presented).  Since glucocorticoids regulate MIF production differently in the hypothalamo-
pituitary-adrenal axis of humans versus rodents (Isidori et al. 2002), it remains to be determined 
if murine and human regulation of MIF production differ during a malaria infection.   
A number of studies have identified IL-12 as a central factor for promoting a protective 
immune response in animal models of malaria (reviewed in (Crutcher et al. 1995)).  In addition, 
we have shown that low IL-12 levels are associated with increased disease severity in children 
with malaria (Luty et al. 2000; Perkins et al. 2000).  The association between MIF and IL-12 
levels reported here suggests a potentially significant biologic relationship in which reduced MIF 
levels combined with low IL-12 could enhance malaria disease severity.  Previous studies have 
shown that induction of other proinflammatory mediators (TNF-α, NO and PGE2) are related to 
MIF production (Calandra et al. 1994; Juttner et al. 1998; Koebernick et al. 2002; Mitchell et al. 
2002).  In the present studies, we found no evidence to suggest that MIF may be responsible for 
increased TNF-α and NO production during acute malaria, as MIF levels were decreased in 
children with malaria in the presence of increased TNF-α and NO. On the contrary, increased 
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 NO production could be contributing to suppression of MIF, since NO has potent 
immunosuppressive properties.  Furthermore, although both MIF and PGE2 were decreased in 
children with acute malaria, the correlation between MIF and PGE2 was not significant.  Earlier 
studies in Gabonese children demonstrated that potent IFN-γ responses in PBMC stimulated with 
malarial antigens were associated with protection against severe malaria (Luty et al. 1999).  
Therefore, the finding that IFN-γ had the greatest predictive value on circulating MIF levels 
raises the possibility that IFN-γ be an important factor for regulating MIF production during 
acute malaria.  This potentially important relationship requires additional studies for this 
postulate to be confirmed.      
Increased levels of IL-10 suppress MIF transcription in both human and murine 
monocytes/macrophages (Wu et al. 1993).  In this study, circulating IL-10 was highly elevated in 
children with acute malaria. Although elevated IL-10 may contribute to decreased MIF protein 
and transcripts, the statistically non-significant correlation between MIF and IL-10 levels does 
not support the notion that over-production of IL-10 is responsible for down-regulation of MIF 
gene expression.     
Experiments in murine models of malaria illustrate that TGF-β is an important molecule 
for regulating disease severity (Omer and Riley 1998; Tsutsui and Kamiyama 1999).  We have 
further shown that reduced levels of TGF-β1 are associated with enhanced disease severity in 
children with acute malaria (Luty et al. 2000; Perkins et al. 2000).  Thus, it is possible that 
concomitantly reduced MIF, IL-12 and TGF-β1 levels in children with acute malaria may 
promote an ineffective immune response that culminates in enhanced pathogenesis.  It is 
important to note that interrelationships between MIF and other immune mediators described in 
this study are not conclusive evidence of cross-regulation among these mediators during acute 
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 malaria.  Therefore, additional mechanism-based studies aimed at defining the role of MIF in 
regulating cytokine responses during malaria may offer important insight into the role of innate 
immunity in determining malaria disease outcomes.   
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  Table 1: Clinical, parasitological, and laboratory characteristics of study participants. 
 
Characteristic Aparasitemic controls Acute malaria 
Number of children, n 25 23 
Age, years 4.6 (0.6) 4.9 (0.3) 
Hyperparasitemia*   
     ≥ 200,000 parasites/μL 0 10 
Severe anemia*   
     Hemoglobin ≤6.0 g/dL 0 2 
     PCV ≤ 20% 0 7 
Parasitemia   
     Parasites/μL 0 160246 (30432)
     Geometric mean 0 90591.5 
Hemoglobin, g/dL 11.6 (0.5) 9.0 (0.4) 
Platelet count, X 106/L ND 170.0 (18.0) 
Glucose, mg/dL ND 85.0 (4.3) 
Body temperature, oC 37.1 (0.2) 38.8 (0.2) 
 
Data are presented as mean (SEM) or geometric mean for parasitemia. 
* indicates number of children in each category.    
ND, not determined. 
Differences between the two groups were statistically significant for hemoglobin (P<0.01) and 
body temperature (P<0.05), but not age (P=0.2) (Mann-Whitney U-test).   
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 Table 2: Levels of cytokines and effector molecules in children with acute malaria compared 
to aparasitemic controls. 
 
 
Cytokines and Effector 
Molecules 
Aparasitemic controls Acute malaria p-value 
MIF (pg/mL) 1493 (936-2428) 913 (710-2252) < 0.05 
IL-12 (pg/mL) 40 (29-77) 61 (2-82)  = 0.5 
IFN-γ (pg/mL) 20 (0-27) 36 (16-59) < 0.01 
TNF-α (pg/mL) 64 (30-118) 152 (89-279) < 0.005 
NOS (pmol/mg protein) 232 (159-372) 522 (328-611) < 0.005 
Bicyclo-PGE2 (pg/mL) 29 (21-38) 19 (9-26) < 0.01 
IL-10 (pg/mL) 0 (0-18) 152 (99-268) < 0.0001 
TGF-β1 (ng/mL) 16 (11-20) 8 (6-11) < 0. 001 
Data are presented as median (interquartile range).   
Levels of cytokines and effector molecules between the two groups were compared using Mann-
Whitney U-test, and p < 0.05 was considered statistically significant.  
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Figure 5: Circulating MIF protein and PBMC MIF transcripts in children with acute P. 
falciparum malaria. 
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 Figure 5: Circulating MIF protein and PBMC MIF transcripts in children with acute P. 
falciparum malaria.  (A) Plasma levels of MIF in children with acute malaria (Mal, n=23) and aparasitemic 
controls (AC, n=25) were measured by ELISA.  Data are presented as box plots where the box represents the 
interquartile range, the line through the box is the median, whiskers indicate the 10th and 90th percentiles and 
individual symbols are outliers.  Differences in MIF levels between the groups were statistically significant (P<0.05, 
Mann-Whitney U-test).  (B) MIF-specific mRNA levels in PBMC of children with Mal (n=19) and AC (n=20) were 
determined by real time RT-PCR and normalized against β-actin mRNA levels.  Bars represent mean + SEM of MIF 
mRNA expressed relative to β-actin transcripts for the two groups.  Differences in MIF transcript levels were 
statistically significant (P<0.05, Student’s t-test). 
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Figure 6:  Association of plasma MIF with IL-12 and TGF-β in children with acute malaria 
and aparasitemic controls.   
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 Figure 6:  Association of plasma MIF with IL-12 and TGF-β in children with acute malaria 
and aparasitemic controls.  Plasma levels of MIF, IL-12 and TGF-β1 were determined by ELISA.  MIF 
concentrations were log-transformed for normality. (A) Correlation of plasma MIF with IL-12 for children with 
acute malaria (Mal, n=21) and aparasitemic controls (AC, n=24).   Pearson correlation: r=0.374, P<0.05 for Mal; 
r=0.214, P=0.2 for AC; r=0.216, P<0.05 for combined sample).  (B)  Correlation of plasma MIF with TGF-β1 for 
Mal (n=19) and AC (n=22).  Pearson correlation: r=0.193, P=0.214 for Mal; r=0.303, P=0.08 for AC; r=0.271, 
P<0.01 for combined sample).    
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 3.2 HYPOTHESIS 2, PRESENTATION OF MANUSCRIPT ENTITLED: HIGHER 
PRODUCTION OF PERIPHERAL BLOOD MACROPHAGE MIGRATION INHIBITORY 
FACTOR IN HEALTHY CHILDREN WITH A HISTORY OF MILD MALARIA RELATIVE 
TO CHILDREN WITH A HISTORY OF SEVERE MALARIA. 
Hypothesis 2: Elevated basal MIF production is protective against the development of severe 
malaria during subsequent P. falciparum infections.  
 
This hypothesis was addressed by examining plasma MIF levels and PBMC MIF 
transcripts in healthy aparasitemic Gabonese children enrolled in a longitudinal prospective 
study. The relationship between MIF production and severe malaria susceptibility was 
investigated by comparing children with different malaria disease histories: prior episodes of 
mild malaria and prior episodes of severe malaria.  The results of these investigations are 
presented in the following manuscript published in the American Journal of Tropical Medicine 
and Hygiene (Am J Trop Med Hyg 2007, 76(6): 1033-1036; reproduced with permission form 
Am J Trop Med Hyg). 
 
Gordon A Awandare1, Peter G. Kremsner2, James B. Hittner3, Christopher C. Keller4, Ian A. 
Clark5, J. Brice Weinberg6, and Douglas J. Perkins1. 
 
1Department of Infectious Diseases and Microbiology, Graduate School of Public Health, 
University of Pittsburgh, Pittsburgh, PA; 2Medical Research Unit, Albert Schweitzer Hospital, 
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 Lambarènè, Gabon, and Department of Parasitology, Institute for Tropical Medicine, University 
of Tübingen, Germany; 3Department of Psychology, College of Charleston, Charleston, SC, 
USA. 4Lake Erie College of Osteopathic Medicine, Erie, PA; 5Department of Medicine, VA and 
Duke University Medical Centers, Durham, NC; 6School of Biochemistry and Molecular 
Biology, Australian National University, Canberra, ACT 0200, Australia. 
 
Running title:  Elevated MIF in healthy children with prior mild malaria 
Keywords:  Macrophage migration inhibitory factor (MIF), Plasmodium falciparum, severe 
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 3.2.1 Footnote page 
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 3.2.2 Abstract 
Plasmodium falciparum malaria is one of the leading causes of childhood morbidity and 
mortality in sub-Saharan Africa. The host immune response to P. falciparum is a critical 
determinant of malarial pathogenesis and disease outcomes. Macrophage migration inhibitory 
factor (MIF) is a central regulator of innate immune responses to bacterial and parasitic 
infections. Our recent investigations demonstrated that peripheral blood MIF production was 
suppressed in children with severe malaria. Since examination of MIF production in children 
with active disease does not account for the inherent ability of the host to generate MIF, basal 
circulating MIF and peripheral blood mononuclear cell (PBMC) MIF transcript levels were 
determined in healthy children with a history of either mild or severe malaria. Children with 
prior mild malaria had higher plasma MIF levels and PBMC MIF transcripts than children with 
an identical number of previous episodes of severe malaria.  Results presented here suggest that 
elevated basal MIF production may be important in generating immune responses that protect 
against the development of severe malaria.    
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 3.2.3 Introduction, study participants, methods, results, and discussion. 
Greater than one million people in sub-Saharan Africa die each year from Plasmodium 
falciparum malaria, with the majority of the deaths occurring in children less than 5 years of age 
(Guilbert 2003).  The clinical manifestations of pediatric falciparum malaria vary from 
asymptomatic infection to severe life-threatening complications, such as hyperparasitemia, 
hypoglycemia, cerebral malaria, severe anemia, respiratory distress, and hyperlactatemia (WHO 
2000; Taylor et al. 2006).  A number of important factors appear to influence disease severity 
including host genetic variation, age of first exposure, and rate of exposure (endemicity) (Snow 
et al. 1997; Kwiatkowski 2005).  In addition, it is well established that the host immune response 
to P. falciparum is an important determinant of the development and outcomes of childhood 
malaria (Clark and Cowden 2003; Clark et al. 2004).     
As part of our ongoing studies examining the role of the host immune response in 
conditioning the outcomes of pediatric malaria, we have been investigating the role of 
macrophage migration inhibitory factor (MIF) in the pathogenesis of malaria.(Awandare et al. 
2006b; Awandare et al. 2006c; Awandare et al. 2007b)   Many studies have identified MIF as a 
central regulator of innate and adaptive immune responses that could mediate both protection 
and enhanced pathogenesis of bacterial and parasitic infections (Bernhagen et al. 1993; Bacher et 
al. 1996; Calandra et al. 1998; Juttner et al. 1998; Calandra et al. 2000; Koebernick et al. 2002; 
Calandra and Roger 2003; Reyes et al. 2006).  Although previous studies in placental malaria 
and in murine models of malaria have suggested a pathogenic role for MIF in malaria (Martiney 
et al. 2000; Chaisavaneeyakorn et al. 2002; Chaiyaroj et al. 2004; McDevitt et al. 2006), our 
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 recent studies demonstrate that increased circulating MIF production is associated with 
protection from severe childhood malaria (Awandare et al. 2006a; Awandare et al. 2007b).   
To further clarify the role of MIF in malarial immunity, we examined MIF protein levels 
in circulation and MIF mRNA levels in peripheral blood mononuclear cells (PBMCs) from a 
group of healthy children (ages 2-8 years; mean age=6.3 years) enrolled in a longitudinal 
prospective study previously conducted at the Albert Schweitzer Hospital in Lambarènè, Gabon, 
a hyperendemic P. falciparum transmission area. In this region, hyperparasitemia and severe 
anemia are the predominant complications of severe malaria (Kun et al. 1998; Kun et al. 1998; 
Perkins et al. 1999).  Study participants selected for investigation were in the convalescent phase 
of malaria and were free of malaria parasites and any other detectable diseases for four or more 
months based on bi-monthly malaria parasitemia determinations and clinical evaluations.  A 
more detailed description of this study cohort is provided in our previous publication (Perkins et 
al. 1999).  Based on their previous malaria disease history, children were divided into two 
groups: prior mild malaria (PMM, n=15; 8 males and 7 females; mean age of 6 years 3 months) 
or prior severe malaria (PSM, n=10; 6 males and 4 females; mean age of 6 years 4 months).  
Definitions of malaria disease severity during the acute illness were based on World Health 
Organization criteria (WHO 2000), with severe malaria defined as >200,000 parasites/μL and/or 
hemoglobin (Hb) ≤5.0g/dL and mild malaria defined as <100,000 parasites/μL, Hb >5.0g/dL, 
and without any signs or symptoms of severe malaria.  None of the study participants had a prior 
episode of cerebral malaria.  Children in the PMM and PSM groups were matched so that the 
mean number of previous malaria episodes was identical in the two groups.  Moreover, children 
selected for the PMM group had no prior history of severe malaria, while those in the PSM group 
had no prior history of mild malaria.  Participation in the study was completely voluntary and 
  57
 written informed consent was obtained from the parents/guardians of the pediatric participants. 
The study was approved by the ethics committee of the International Foundation of the Albert 
Schweitzer Hospital, Duke University Medical Center Investigational Review Board, and the 
University of Pittsburgh Investigational Review Board.  Venous blood (<5 mL) was collected 
into EDTA-containing vials, plasma was separated, and PBMC isolated according to our 
previous methods (Weinberg et al. 1981).  At the time of sampling, a physical and clinical 
evaluation was performed to verify that the children were healthy and a thick blood smear was 
prepared to confirm that the study participants were free of malaria parasites.  Plasma MIF 
concentrations were measured using commercially available ELISA (R&D systems, 
Minneapolis, MN). MIF transcripts were determined in ex vivo PBMC by Taqman® real time 
RT-PCR (Applied Biosystems, Foster City, CA) and normalized to β-actin according to our 
previous methods (Awandare et al. 2006b). 
Healthy children were selected for investigation since differences in MIF production 
during an active infection may reflect the overall response to the pathogen, while baseline 
measurements in disease-free children in the convalescent phase of disease likely reflects either 
inherent genetic differences and/or adaptation to prior malaria episodes.   As shown in Figure 
7A, children with PMM [median (interquartile range), 1704 (1161-2497)] had significantly 
higher circulating MIF levels than children with PSM [1007 (887-1230), (P<0.005)].  In 
addition, MIF transcripts measured in ex vivo PBMC demonstrated that children with PMM had 
2.4-fold higher MIF mRNA levels than children with PSM (P=0.2, Figure 7B).  
Unlike most cytokines, MIF is constitutively produced in significant quantities, and is 
further augmented by inflammatory stimuli (Bernhagen et al. 1998).  Therefore, baseline MIF 
production may be important for determining the nature and magnitude of the host immune 
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 response to an invading pathogen such as Plasmodium.  Since samples examined in this study 
were taken from healthy children that had fully resolved their malarial infection, the observed 
levels of circulating MIF and PBMC MIF transcripts represent basal MIF production.  Results 
presented here show that children with prior episodes of mild malaria produce significantly 
higher baseline levels of MIF than children that previously experienced severe disease. Given the 
pivotal role of MIF in mediating innate immunity and regulation of pro-inflammatory cytokine 
production (Juttner et al. 1998; Koebernick et al. 2002; Calandra and Roger 2003; Reyes et al. 
2006), we propose that elevated baseline MIF levels may protect against the development of 
severe malaria by promoting a rapid and potent innate immune response that could result in more 
efficient control over the initial phases of parasitemia. For example, adequate MIF production is 
required for induction of interleukin-12, tumor necrosis factor-α and nitric oxide (NO) (Juttner et 
al. 1998; Koebernick et al. 2002; Reyes et al. 2006), all of which are important mediators of the 
innate immune response to malaria (Crutcher et al. 1995; Luty et al. 2000; Perkins et al. 2000; 
Chang and Stevenson 2004).  In addition, since MIF is important in adaptive immunity through 
promotion of T and B cell activation and proliferation, and antibody production (Bacher et al. 
1996) adequate MIF concentrations may be required for an efficient antigen-specific immune 
response to malaria.  Conversely, elevated MIF in children with PMM may be related to the 
phenomenon of malarial tolerance (Clark and Cowden 2003; Clark et al. 2004) in which elevated 
MIF levels may provide negative-feedback mechanisms that help control over-expression of pro-
inflammatory cytokines that could cause enhanced pathology.  Our previous studies in the same 
cohort of healthy, malaria-exposed children illustrated that NO production was significantly 
higher in the PMM group (Perkins et al. 1999).  This previous finding, along with results 
presented here are consistent with our hypothesis that elevated levels of regulatory inflammatory 
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 mediators in children with prior malaria exposure may condition tolerance to malaria and reduce 
susceptibility to severe disease (Clark and Cowden 2003; Clark et al. 2004).  Alternatively, 
differences in host genetics may explain our current findings.  Two polymorphisms in the MIF 
promoter (MIF -173 G/C and MIF -794 CAAT5-8) have been associated with functional changes 
in MIF production in a number of inflammatory diseases (Donn et al. 2001; Baugh et al. 2002; 
Donn et al. 2002; Donn et al. 2004).  In addition, we recently demonstrated a significant 
association between circulating MIF levels and MIF -173 G/C variability in Kenyan children 
(Awandare et al. 2006c).  Although polymorphic variability was not determined here, we are 
currently investigating the impact of MIF promoter polymorphisms on baseline and malaria-
induced MIF production in pediatric populations.  
 
We thank the following staff members of Albert Schweitzer Hospital in Lambaréné 
Gabon for technical assistance to the study: Dr. Anita van den Biggerlaar, Judith Jans, Dr. Hanna 
Knoop, Dr. Doris Luckner, Barbara Moritz, Anselme Ndzengue, Marcel Nkeyi, Dr. Daniela 
Schmid, and Dr. Milena Sovric.  The study was conducted at the University of Pittsburgh, and 
supported in part by the National Institutes of Health Grant (AI-51305-01 DJP) and (AI-41764 
JBW), the VA Research Service (JBW) and Fogarty International Training Grant (5D43-
TW00588-4 DJP). 
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Figure 7: Circulating MIF and PBMC MIF mRNA in healthy children with prior mild 
malaria or prior severe malaria. 
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 Figure 7: Circulating MIF and PBMC MIF mRNA in healthy children with prior mild 
malaria or prior severe malaria.  Children were stratified into prior mild malaria (PMM, n=15) and prior 
severe malaria (PSM, n=10) based on their history of malaria disease severity.  (A) Plasma levels of MIF are 
presented as box plots where the box represents the interquartile range, the line through the box is the median, 
whiskers indicate the 10th and 90th percentiles and individual symbols are outliers.  *Differences in MIF levels in 
PMM compared to PSM were statistically significant (P<0.005, Mann-Whitney U-test).  (B)  Bars represent mean + 
SEM of MIF mRNA relative to β-actin mRNA for the two groups.  MIF mRNA levels in PSM (n=12) compared to 
PMM (n=8) were not statistically significant (P=0.2, Student’s t-test).  There was insufficient RNA obtained from 
PBMC of 5 children and as such, their samples failed to amplify during the RT-PCR.   
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 3.3 HYPOTHESIS 3 AND 4, PRESENTATION OF MANUSCRIPT ENTITLED: 
ROLE OF MONOCYTE-ACQUIRED HEMOZOIN IN SUPPRESSION OF MACROPHAGE 
MIGRATION INHIBITORY FACTOR IN CHILDREN WITH SEVERE MALARIAL 
ANEMIA. 
Hypothesis 3: Peripheral blood MIF production is associated with anemia severity in children 
with acute P. falciparum malaria 
Hypothesis 4: Phagocyte acquisition of malarial pigment (hemozoin) leads to suppression of 
MIF production during acute malaria 
 
The studies conducted in the Gabonese cohort were limited by the small sample size, which did 
not allow categorization of children according to disease severity.  Therefore, to address 
hypotheses 3, peripheral blood MIF production was examined in a large cohort of Kenyan 
children presenting at a rural hospital with varying severities of malarial anemia and parasitemia. 
This study was conducted as part of a larger ongoing study examining the molecular, 
immunological and genetic basis of SMA at the Siaya district hospital in western Kenya, where 
P. falciparum transmission is holoendemic, and SMA and HDP are the primary clinical 
manifestations of severe malaria (McElroy et al. 2000; Ong'echa et al. 2006).  Additional studies 
addressing hypothesis 4 investigated the relationship between levels of pigment-containing 
monocytes and neutrophils, MIF production and SMA pathogenesis.  Data resulting from these 
studies are presented in the following manuscript published in the journal Infection and Immunity 
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 (Infect Immun 2007, 75: 201-210; reproduced with permission from the American Society for 
Microbiology). 
Gordon A. Awandare1, 2, 3, Yamo Ouma2, Collins Ouma2, Tom Were2, Richard Otieno2, 
Christopher C. Keller4, Gregory C. Davenport1, James   B. Hittner5, John Vulule6, Robert 
Ferrell7, John M. Ong’echa2, Douglas J. Perkins1, 2 
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3Department of Biochemistry, University of Ghana, Legon, Accra, Ghana. 
4Lake Erie College of Osteopathic Medicine, Erie, PA 
5Department of Psychology, College of Charleston, Charleston, SC. 
6Center for Vector Biology and Control Research, Kenya Medical Research Institute, Kisumu, 
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 3.3.2 Abstract 
Severe malarial anemia (SMA), caused by Plasmodium falciparum infections, is one of the 
leading causes of childhood mortality in sub-Saharan Africa.  Although the molecular 
determinants of SMA are largely undefined, dysregulation in host-derived inflammatory 
mediators influences disease severity.  Macrophage migration inhibitory factor (MIF) is an 
important regulator of innate inflammatory responses that has recently been shown to suppress 
erythropoiesis and promote pathogenesis of SMA in murine models.  To examine the role of MIF 
in the development of childhood SMA, peripheral blood MIF production was examined in 
Kenyan children (aged <3 years, n=357) with P. falciparum malarial anemia.  All children in the 
study were free from bacteremia and HIV-1.  Since deposition of malarial pigment (hemozoin) 
contributes to suppression of erythropoiesis, the relationship between MIF concentrations and 
monocytic acquisition of Hz was also examined in vivo and in vitro. Circulating MIF 
concentrations declined with increasing severity of anemia and significantly correlated with 
peripheral blood leukocyte MIF transcripts.  MIF concentrations in peripheral blood were not 
significantly associated with the reticulocyte production.  Multivariate regression analyses, 
controlling for age, gender and parasitemia, further revealed that elevated levels of pigment-
containing monocytes (PCM) was associated with SMA and decreased MIF production.   In 
addition, PCM levels were a better predictor of hemoglobin and MIF concentrations than parasite 
density.  Additional experiments in malaria-naïve individuals demonstrated that hemozoin 
caused both increased and decreased MIF production in cultured peripheral blood mononuclear 
cells (PBMC) in a donor-specific manner, independent of apoptosis.  However, PBMC MIF 
production in children with acute malaria progressively declined with increasing anemia severity.  
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 Results presented here demonstrate that acquisition of hemozoin by monocytes is associated with 
suppression of peripheral blood MIF production and enhanced severity of anemia in childhood 
malaria.    
 
 
Key words:  Plasmodium falciparum, malaria, anemia, MIF, malarial pigment (hemozoin)                                   
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 3.3.3 Introduction 
Annually, there are 350-500 million clinical cases of malaria that result in over one million 
deaths (WHO 2005).  The majority of malaria-related mortality are due to infections with 
Plasmodium falciparum and occur in immune-naïve infants and young children in sub-Saharan 
Africa, accounting for 18% of all deaths before five years of age (WHO 2005).  Severe malarial 
anemia (SMA) accounts for the greatest proportion of malaria related morbidity and mortality 
worldwide (Breman et al. 2001).  In holoendemic P. falciparum transmission areas, SMA is the 
commonest clinical presentation of severe malaria in children less than three years of age, with 
cerebral malaria (CM) occurring only in rare cases (McElroy et al. 2000; Ong'echa et al. 2006).  
Markedly reduced hemoglobin (Hb) concentrations in children with SMA result from 
overlapping, but distinct processes including direct and indirect destruction of parasitized red 
blood cells (pRBCs), increased clearance of uninfected erythrocytes, and suppression of 
erythropoiesis (Weatherall and Abdalla 1982; Abdalla 1990; Wickramasinghe and Abdalla 
2000).  Our recent studies in western Kenya, as well as those of others, illustrate that children 
with SMA (Hb<6.0g/dL) have lower peripheral parasite densities than parasitemic children 
without anemia (Hb ≥11.0 g/dL) (McElroy et al. 2000; Ong'echa et al. 2006), suggesting that 
acute hemolysis of RBCs is not likely responsible for the low Hb levels observed in children 
with SMA in this holoendemic region.  It is well-documented that children with SMA have a 
number of bone marrow abnormalities including dyserythropoiesis, ineffective erythropoiesis, 
and reduced proliferation of erythroid colonies (Srichaikul et al. 1969; Weatherall and Abdalla 
1982; Abdalla 1990; Wickramasinghe and Abdalla 2000).  These findings, along with studies 
showing that the reticulocyte response is reduced relative to the degree of anemia in children 
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 with malarial anemia, even in the presence of elevated levels of erythropoietin (Burchard et al. 
1995; Kurtzhals et al. 1997; Nussenblatt et al. 2001), suggest that suppression of erythropoiesis 
may play a central role in the development of SMA.          
 Although the molecular mechanisms that regulate suppression of erythropoiesis are only 
partially defined, over-production of pro-inflammatory mediators is thought to play a prominent 
role in conditioning the severity of childhood malarial anemia (Clark et al. 1981; Kurtzhals et al. 
1998; Othoro et al. 1999; Luty et al. 2000; Perkins et al. 2000; McDevitt et al. 2004).  Recent 
investigations by our laboratory (Keller et al. 2004b; Ochiel et al. 2005; Awandare et al. 2006b; 
Were 2006) and others (Martiney et al. 2000; McDevitt et al. 2006) have focused on defining the 
role of pro-inflammatory mediators such as macrophage migration inhibitory factor (MIF) in the 
immunopathogenesis of malarial anemia, since MIF plays a pivotal role in regulating the innate 
immune response to invading pathogens (Calandra and Roger 2003).  MIF is a pleiotropic 
cytokine released by several cell types including, monocytes/macrophages (Calandra et al. 
1994), T cells (David 1966; Bacher et al. 1996), and cells of the anterior pituitary gland 
(Bernhagen et al. 1993).  Although MIF has potent pro-inflammatory properties that protect 
against Salmonella typhimurium (Koebernick et al. 2002), Leishmania major (Juttner et al. 1998; 
Xu et al. 1998; Satoskar et al. 2001) and Trypanosoma cruzi (Reyes et al. 2006), elevated levels 
of circulating MIF are also associated with enhanced pathogenesis of bacterial sepsis (Bernhagen 
et al. 1993; Bozza et al. 1999; Calandra et al. 2000), suggesting that increased MIF production 
can elicit both protective and pathogenic responses in different infectious diseases.   
Previous investigations have observed elevated levels of MIF protein in blood vessel 
walls of Malawian children with cerebral malaria (Clark et al. 2003; Clark and Cowden 2003), 
and intervillous blood mononuclear cells from women with placental malaria 
  69
 (Chaisavaneeyakorn et al. 2002; Chaiyaroj et al. 2004).  Studies in murine models of malaria 
show that elevated plasma MIF concentrations are associated with suppression of erythropoiesis 
and enhanced severity of anemia (Martiney et al. 2000; McDevitt et al. 2006).  However, our 
recent investigations, which were the first to report circulating MIF levels in children with 
malaria, demonstrated that peripheral blood MIF concentrations and peripheral blood 
mononuclear cell (PBMC) MIF mRNA expression were reduced in Gabonese children with 
mild-to-moderate forms of malarial anemia and hyperparasitemia (Awandare et al. 2006b).  In 
contrast, subsequent studies have shown that plasma MIF levels are elevated in Zambian children 
with malarial anemia (McDevitt et al. 2006).   
Although the host-parasite interactions that mediate MIF production are largely 
undefined, studies from our laboratory (Perkins et al. 2003; Keller et al. 2004a; Keller et al. 
2004b), and others (Pichyangkul et al. 1994; Sherry et al. 1995; Arese and Schwarzer 1997; 
McDevitt et al. 2006) show that ingestion of malarial pigment, hemozoin (Hz) by phagocytic 
cells causes dysregulation in cytokine production.  Hz is a coordinated aggregation polymer of 
heme generated by Plasmodia during digestion of host Hb (Goldie et al. 1990).  During a malaria 
infection, Hz is acquired by leukocytes through direct phagocytosis of pRBCs and free Hz 
released upon pRBCs rupture (Schwarzer et al. 1992).  Recent studies have demonstrated that Hz 
contributes to the pathogenesis of SMA by suppressing erythropoiesis both directly and in 
synergy with pro-inflammatory cytokines such as TNF-α(Casals-Pascual et al. 2006).  In 
addition, acquisition of Hz by murine macrophages and human monocytes is associated with 
enhanced MIF production (Martiney et al. 2000; McDevitt et al. 2006).   
To investigate the role of MIF in the immunopathogenesis of malarial anemia, peripheral 
blood MIF concentrations and leukocyte MIF transcript levels were measured in infants and 
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 young children residing in a holoendemic P. falciparum transmission area where severe anemia 
is the primary clinical manifestation of severe malaria.  In addition, to examine host-parasite 
interactions that may be important for regulating MIF production, the relationship between 
circulating MIF levels and monocytic acquisition of Hz was determined.  The direct effect of Hz 
on MIF production was also investigated in cultured PBMC from malaria-naïve individuals.   In 
vivo and in vitro results presented here demonstrate that MIF is suppressed in children with SMA 
and that monocyte-acquired pfHz plays an important role in promoting SMA and decreasing MIF 
production.            
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 3.3.4 Study participants, materials, and methods 
3.3.4.1 Study site.  
Children (n=357, age 3-31 mos) were recruited at the pediatric ward of the Siaya District 
Hospital (SDH), Nyanza Province, western Kenya.  In this region, malaria is holoendemic with 
entomological inoculation rates of up to 300 per annum (Beier et al. 1994).  Approximately 1/3 
of all pediatric admissions to SDH are due to SMA, which accounts for ~50% of all pediatric 
deaths at hospital (Lackritz et al. 1992).  A detailed description of the study site and cohort is 
provided in our recent report (McElroy et al. 2000; Ong'echa et al. 2006). 
3.3.4.2 Study participants.   
A questionnaire and medical informatics system were used to recruit children at their first 
hospital contact for the treatment of malaria.  After obtaining informed written consent from the 
parents/guardians of children presenting at SDH with the signs and symptoms of malaria, 
heel/finger-prick blood (<100 μL) was used to determine parasitemia and Hb concentrations.  
Children with P. falciparum parasitemia (any density) were categorized according to the 
following criteria: uncomplicated malaria (UM, Hb≥11.0 g/dL, n=26); mild malarial anemia 
(MlMA, 8.0≤Hb<11.0 g/dL, n=75), moderate malarial anemia (MdMA, 6.0≤Hb<8.0 g/dL, 
n=98); and SMA (Hb<6.0 g/dL, n=119).  Case definitions of anemia were based on previous 
studies in western Kenya examining >10,000 longitudinal Hb measurements in an age- and 
geographically-matched population (McElroy et al. 2000).  Healthy, aparasitemic children (AC, 
Hb≥11.0 g/dL, n=39) presenting at SDH for routine immunizations were recruited as controls.  
In addition, only those children that were afebrile for ≥2 weeks were included in the AC group.  
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 None of the children in the current study had any signs/symptoms of CM.  Since HIV-1 and 
bacteremia are common co-pathogens that influence anemia status in children with malaria 
(Akpede and Sykes 1993; Berkley et al. 1999; Graham et al. 2000; Otieno et al. 2006), and could 
influence MIF production, all study participants were screened for HIV-1 and/or bacteremia and 
those children found to have co-pathogens were excluded from all analyses.  Pre- and post-test 
HIV counseling was provided to parents/guardians of all children enrolled.  The study was 
approved by the Ethics Committees of the Kenya Ministry of Health and the University of 
Pittsburgh Institutional Review Board.   
3.3.4.3 Sample collection.   
Prior to administration of antimalarials and/or any other treatment interventions, venous blood 
(<3 mL: a volume determined to be safe based on size, weight, and anemia status) was collected, 
and plasma isolated according to our previous methods (McElroy et al. 2000; Ong'echa et al. 
2006). Leukocytes were obtained from the buffy coat by lysing RBCs followed by storage in 
RNAlater® (Ambion) at -20oC until use.   
3.3.4.4 Laboratory evaluation.   
Giemsa-stained blood smears were used to determine parasitemia and pigment-containing 
monocytes and neutrophils.  The number of RBCs infected with asexual P. falciparum parasites 
were determined per 300 leukocytes, and peripheral parasite density/μL of blood was calculated 
using the WBC count/μL obtained on a Coulter® AcT diff2™ (Beckman Coulter Corp.).  A total 
of 30 monocytes and 100 neutrophils were examined per thin smear, and the number of pigment-
containing monocytes (PCM) or pigment-containing neutrophils (PCN) was expressed as a 
percentage of the total number of monocytes and neutrophils, respectively (Nguyen et al. 1995; 
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 Lyke et al. 2003).  The number of PCM/μL of blood was calculated by multiplying the percent 
of PCM by the absolute number of monocytes/μL obtained from the Coulter® AcT diff2™.  
Reticulocyte counts (percent) were determined using new methylene-blue-stained slides, and the 
absolute reticulocyte number (ARN) was calculated by multiplying the reticulocyte percent/100 
by total RBC counts.  HIV-1 status was determined per our previously described HIV-1 serology 
and PCR methods (Otieno et al. 2006), while bacteremia was determined using the WampoleTM 
ISOLATORTM 1.5 mL microbial system (Inverness Medical).   
3.3.4.5 Determination of plasma MIF and leukocyte MIF transcript levels.   
To avoid the possible influence of MIF released from lysis of erythrocytes (Mizue et al. 2000) 
during blood clotting, circulating MIF levels were determined in plasma rather than serum 
samples.  In addition, visibly hemolyzed samples were excluded from measurements. Plasma and 
culture supernatant MIF concentrations were determined by ELISA with a matched anti-MIF 
antibody pair (R&D systems).  All samples were assayed at 1:5 and 1:10 dilutions in duplicate, 
and according to manufacturer’s recommendations.  The limit of detection was >31.25 pg/mL.  
For determination of MIF transcript levels, total RNA was extracted from leukocyte pellets using 
the guanidinium isothiocyanate (GITC) method as described previously (Chomczynski and 
Sacchi 1987).  Fluorogenic primer/probe sets specific for MIF and the housekeeping gene, β-
actin (assay IDs Hs00236988_g1 and 4326315E respectively, Applied Biosystems) were used for 
real time RT-PCR on an ABI Prism® 7700 sequence detection system (Applied Biosystems).  
MIF mRNA levels were normalized by expressing transcripts as fold-change relative to β-actin 
mRNA (2-∆CT, where ∆CT=critical threshold cycle of MIF – critical threshold cycle for β-actin), 
as described previously (Awandare et al. 2006b). 
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 3.3.4.6 PBMC cultures.   
Venous blood was obtained from healthy, malaria-naïve US donors (n=15) and children with 
acute malaria (n=94).  PBMC were isolated using Ficoll-Hypaque according to previous methods 
(Weinberg et al. 1981).   To ensure complete removal of RBCs, PBMC were treated with RBC 
lysis buffer (BioWhittaker) for five minutes and then washed prior to culture.  P. falciparum-
derived Hz (pfHz) was isolated from laboratory-cultivated P. falciparum (PfD6) and synthetic 
Hz (sHz) was prepared from hemin chloride (Sigma) as described previously (Keller et al. 
2004b).   Endotoxin levels in all pfHz and sHz preparations were determined to be <0.125 U/mL 
(i.e., <0.025 ng/mL; Limulus amebocyte lysate test, BioWhittaker).  PBMC were plated at 1×106 
cells/mL in Dulbecco’s modified Eagles medium (DMEM) containing HEPES buffer (25mM), 
penicillin (100 U/mL)/streptomycin (100 μg/mL) and 10% heat inactivated human serum from a 
non-malarious region.  Experiments conducted in children with acute malaria were cultured in 
media alone, while PBMC from US donors were stimulated with media alone (unstimulated 
control), physiological concentrations of pfHz (10 μg/mL) (Keller et al. 2004b), sHz (10 μg/mL), 
or lipopolysaccharide (LPS, 100 ng/mL; Alexis Corp.) and interferon (IFN)-γ (200 U/mL; 
Biosource).  
3.3.4.7 Cell viability and apoptosis assays.   
Viability of cultured PBMC was determined using a methylthiazoletetrazolium (MTT)-based 
assay according to manufacturer’s recommendations (Sigma).  Cellular apoptosis was assessed 
by quantifying the concentrations of nucleosomes in cell lysates (early-stage apoptosis) and 
culture supernatants (late-stage apoptosis) using a cell death detection ELISA (Roche 
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 Diagnostics) according to manufacturer’s recommendations, with nucleosome concentrations in 
treated cells expressed as a percentage relative to untreated cells (control).      
3.3.4.8 Statistical analyses.   
Kruskal-Wallis tests were used to compare variables across three or more groups, and where 
significant differences were observed, Mann-Whitney U tests were conducted for pairwise 
comparisons.  Statistical associations between variables were examined using Pearson’s 
correlation tests, and multivariate linear and logistic regression analyses, controlling for age and 
gender. Prior to performing Pearson’s correlational analyses, the distributional characteristics of 
all variables were examined for departures from normality using the Kolmogorov-Smirnov test. 
Those variables with significant skewness were transformed toward normality.  P-values less 
than 0.05 were considered statistically significant for all analyses. 
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 3.3.5 Results 
3.3.5.1 Clinical, parasitological, and hematological characteristics of study participants.   
To examine the role of MIF in the immunopathogenesis of malarial anemia, children (n=357) 
were stratified into clinical anemia categories.  The clinical, parasitological, and hematological 
characteristics of the study participants upon admission are summarized in Table 3.  Across-
group comparisons showed significant differences in age (P=0.005) and axillary temperature 
(P<0.001).  Children in the UM group were significantly older relative to all other groups 
(P<0.01 for all comparisons).  Axillary temperature was elevated in all categories of children 
with acute malaria relative to the AC group (P<0.001 for all groups).  Mean peripheral 
parasitemia (P=0.117), geometric mean parasitemia, and the proportions of children with HDP 
(≥10,000 parasites/μL; P=0.656) were not significantly different among children with acute 
malaria (Table 3).  Since anemia severity was the basis for classification, Hb and RBC numbers 
decreased across the groups (P<0.001 for both comparisons).  In contrast, the ARN increased 
with increasing severity of anemia (P<0.001).  Taken together, these data illustrate that the 
severity of anemia in this holoendemic P. falciparum transmission region is not significantly 
associated with peripheral parasite density.      
3.3.5.2 Circulating MIF levels progressively decline with increasing severity of malarial 
anemia.   
Our previous investigations showed that peripheral blood MIF concentrations were suppressed in 
a small cohort of children with acute malaria (Awandare et al. 2006b) .  In contrast, additional 
studies (also limited by sample size) illustrated that plasma MIF concentrations were elevated in 
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 children with acute malaria (McDevitt et al. 2006).  To more fully investigate the role of MIF in 
the immunopathogenesis of childhood malaria, children were stratified according to malarial 
anemia status and circulating MIF levels were examined in the following groups: UM (n=23), 
MlMA (n=71), MdMA (n=94) and SMA (n=109); and healthy, aparasitemic controls (AC, 
n=39).  As shown in Figure 8A, MIF concentrations progressively declined in parasitemic 
children with increasing severity of anemia.  Children with SMA [median (interquartile range) 
3422 (1566-4993) pg/mL)] had lower plasma MIF levels than the AC [4383 (2807-6376) pg/mL, 
P<0.05], UM [5225 (3615-9071) pg/mL, P<0.001], and MlMA [4611 (3270-6665) pg/mL, 
P<0.001] groups (Figure 8A).  In addition, there was a significant positive correlation between 
circulating MIF levels and Hb concentrations (r=0.23, P<0.001) and a significant inverse 
correlation between plasma MIF levels and parasitemia (r=-0.16, P<0.05) among children with 
malaria (Figures 8B and C).  However, there was a non-significant correlation between 
circulating MIF concentrations and the absolute reticulocyte number (r=0.10, P=0.10, Figure 
8D).  Multiple regression analysis, controlling for age and gender, further revealed that MIF was 
a significant positive predictor of Hb concentration (standardized partial regression coefficient, 
β-weight=0.153, P<0.005) and a negative predictor of parasitemia (β-weight=-0.096, P=0.067).  
These results demonstrate that SMA is characterized by reduced peripheral blood MIF 
concentrations and that pRBCs and/or a parasitic product(s) either directly or indirectly promote 
suppression of MIF concentrations.     
3.3.5.3 Peripheral blood leukocyte MIF transcripts as a source of circulating MIF. 
Although MIF is produced by a number of different cell types (Bernhagen et al. 1993; Calandra 
et al. 1994; Calandra and Roger 2003), our recent investigations in Gabonese children with 
malaria demonstrated that suppression of plasma MIF concentrations was associated with 
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 decreased PBMC MIF transcripts (Awandare et al. 2006b).  Based on the number of different 
experimental measures performed with limited blood sample volumes from children with 
malarial anemia, we opted to measure MIF transcripts in peripheral blood leukocytes (PBL) from 
a subset of children in which matched samples were available.  These experiments revealed that 
MIF transcripts closely paralleled circulating MIF concentrations (r=0.68, P=0.01; Figure 9), 
suggesting that MIF gene expression in PBL may be an important source of circulating MIF 
levels.     
3.3.5.4 MIF production from cultured PBMC progressively declines with increasing anemia 
severity.   
To further investigate MIF production in children with malarial anemia, PBMC MIF production 
was measured under baseline conditions in cultured cells isolated from children with varying 
degrees of malarial anemia and healthy controls: AC (n=24), UM (n=15), MlMA (n=37), MdMA 
(n=13), and SMA (n=5).  MIF concentrations in culture supernatants taken after 48 hrs were 
significantly increased in children with UM [median (interquartile range) 2218 (1418-3989) 
pg/mL)] relative to the AC group [1034 (615-1902) pg/mL, P<0.005, Figure 10).  However, MIF 
production progressively declined with increasing anemia severity, with the SMA group [511 
(264-2312) pg/mL)] having lower culture supernatant MIF levels than the UM (P<0.05), MlMA 
[1609 (940-2439) pg/mL, P=0.08], and MdMA [842 (495-3737) pg/mL, P=0.43] groups (Figure 
10).  There was no significant difference in PBMC MIF production in any of the malarial anemia 
groups relative to AC (SMA, P=0.51; MdMA, P=0.87 and MlMA, P=0.06).  Taken together, 
these in vitro experiments demonstrate that reduced MIF production from PBMC contributes to 
decreased circulating MIF levels in children with malarial anemia. Furthermore, increased MIF 
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 production in children with a good clinical outcome, i.e., the UM group, suggests that an 
adequate MIF response may provide protection against severe malaria. 
3.3.5.5 In vivo acquisition of pfHz by monocytes is associated with enhanced SMA.  
Recent studies in individuals with malaria suggest that phagocytosis of pfHz by monocytes and 
neutrophils is an important predictor of clinical severity (Nguyen et al. 1995; Amodu et al. 1998; 
Lyke et al. 2003; Casals-Pascual et al. 2006).  Additional studies have demonstrated that sHz 
enhanced MIF production in mouse peritoneal macrophages and human mononuclear cells 
(McDevitt et al. 2006).  To further examine the role of naturally acquired pfHz in conditioning 
disease outcomes in children with malarial anemia, the relationship between intracellular 
malarial pigment and malaria disease severity was determined.  Percentages of PCM ranged from 
0-90% (mean=10%), while the percentages of PCN ranged from 0-9% (mean=0.3%), with PCM 
present in 47% (144/306) and PCN present in 12% (37/306) of the study participants, 
respectively.  Based on the higher abundance of PCM relative to PCN, we examined the impact 
of PCM on clinical outcomes.  The proportion of pigment-containing monocytes (%PCM) and 
PCM/μL progressively increased across the acute malaria groups (p<0.001 for both comparisons, 
see Table 3).  In a multiple regression model controlling for age, gender, and parasitemia, PCM 
emerged as a strong predictor of Hb concentrations (β-weight=-0.434, P<0.001).   
To further investigate the role of PCM in conditioning the outcomes of acute malaria, 
children were stratified into three groups according to the distribution of PCM: no PCM (0% 
PCM), low PCM (PCM≤10%), and high PCM (PCM>10%).  These analyses revealed that age 
was not significantly different across the groups (P=0.645).  Moreover, although parasitemia 
increased with elevated PCM across the three groups (P=0.034, Table 4), parasitemia and the 
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 percentage of HDP did not significantly differ between the high and low PCM groups (P=0.181 
and P=0.086, respectively, Table 4).  Conversely, Hb concentrations decreased with increasing 
pfHz deposition (P<0.001, across groups), with the high PCM group having the highest 
percentage of SMA cases (Table 4).  Multiple logistic regression analyses controlling for age, 
gender, and parasitemia demonstrated that the risk of SMA was increased for the low PCM 
(OR=3.4; 95% CI, 1.8-6.6, P<0.0001) and high PCM (OR=7.5; 95% CI, 4.1-14.0, P<0.0001) 
groups relative to the no PCM group (Table 4).  There was also an increased risk of SMA in the 
high PCM group compared to the low PCM group (OR=2.1; 95% CI, 1.1-4.3, P<0.05).  Thus, 
consistent with the demonstrated role of Hz in suppression of erythropoiesis during malarial 
anemia (Casals-Pascual et al. 2006), these results show that deposition of pfHz in circulating 
monocytes is associated with an increased prevalence of SMA.    
3.3.5.6 In vivo acquisition of pfHz by monocytes is associated with suppression of MIF.   
Since PCM was strongly correlated with SMA, and MIF concentrations declined with increasing 
severity of anemia, the relationship between PCM and MIF was examined.  The high PCM group 
had lower MIF levels [median (interquartile range), 3115 (1525-4879) pg/mL] than the no PCM 
[4417 (3112-6266) pg/mL; P<0.005] and low PCM groups [4584 (1525-4879) pg/mL; P<0.05, 
Figure 11A].  Furthermore, circulating MIF concentrations were significantly inversely 
correlated with PCM levels (r=-0.23, P<0.001; Figure 11B).  Multiple linear regression analyses 
controlling for age and gender further revealed that PCM (β-weight=-0.238, P<0.001) was a 
stronger predictor of MIF than parasitemia (β-weight=-0.087, P=0.024), suggesting that 
monocytic acquisition of pfHz may contribute to suppression of MIF concentrations.     
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 3.3.5.7 pfHz and sHz decrease MIF production in cultured PBMC independent of apoptosis.    
Since the in vivo results suggested that PCM may be an important factor for suppressing MIF 
production, the direct effect of malarial pigment on MIF production was examined in PBMC 
from healthy, malaria-naïve U.S donors.  Cultures were stimulated with concentrations of pfHz 
or sHz comparable to those in children with severe malaria (i.e., 10 μg/mL) (Keller et al. 2004b), 
and LPS and IFN-γ (L/I) as a positive control.  Treatment of PBMC with pfHz or sHz resulted in 
a significant increase in MIF production in 3/15 donors (P<0.05 for all comparisons; Group 1, 
Figure 12A), while MIF production was significantly decreased in 11/15 donors (P<0.05 for all 
comparisons; Group 2, Figure 12A).  In addition, there was no significant change in MIF 
production in pfHz- or sHz-stimulated PBMC from one donor (data not shown).  Stimulation of 
PBMC with L/I increased MIF production in 9/15 donors (P<0.05 for all comparisons, Figure 
12A), while MIF production was not significantly altered in PBMC of 6/15 donors (data not 
shown).   
Since pfHz or sHz could alter MIF by influencing PBMC viability, cellular metabolism 
was investigated with the MTT assay.  Relative to control conditions, stimulation with pfHz or 
sHz had no significant effect on cellular viability at 48 hrs (P=0.601 and P=0.522, respectively), 
while L/I reduced viability by 28% (P<0.05; Figure 12B).  Examination of cellular apoptosis by 
measuring nucleosome release (DNA fragmentation) revealed that both early- and late-stage 
apoptosis were unaffected by sHz treatment (P=0.247, and P=0.928, respectively).  However, 
stimulation with L/I increased both early and late apoptosis (P<0.001 for both comparisons, 
Figure 12C) which may explain the lack of significantly enhanced MIF production in some of 
the donors.  Taken together, these results show that malarial pigment decreases MIF production 
from PBMC, independent of altered cell viability or apoptosis.  
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 3.3.6 Discussion 
A number of studies in murine models of malaria suggest that there is a circulating host-derived 
inflammatory mediator(s) that inhibits the erythropoietic response (Silverman et al. 1987; Miller 
et al. 1989; Yap and Stevenson 1991), and recent evidence has identified MIF as that potential 
immune mediator that suppresses erythropoiesis during malaria (Martiney et al. 2000; McDevitt 
et al. 2006).  However, the role of MIF in regulating anemia in childhood malaria remains 
unclear because of contradictory findings in small cohorts of children (Awandare et al. 2006b; 
McDevitt et al. 2006).  While our previous study demonstrated suppression of circulating MIF 
and ex vivo PBMC MIF transcripts in Gabonese children with acute malaria versus healthy, 
aparasitemic controls (Awandare et al. 2006b), subsequent investigations illustrated that plasma 
MIF levels were elevated in Zambian children with malarial anemia relative to healthy controls 
(McDevitt et al. 2006).   
To further investigate the role of MIF in the immunopathogenesis of malarial anemia, the 
relationship between MIF production and anemia was investigated in a large cohort of clinically 
well-characterized children that were stratified according to the severity of malarial anemia.  
These studies confirmed our previous finding in Gabon (Awandare et al. 2006b) and extended 
this observation by demonstrating that circulating MIF levels and MIF production from PBMC 
isolated from children with acute malaria progressively declined with increasing severity of 
malarial anemia.  Results presented here also illustrated that there was a significant positive 
correlation between circulating MIF levels and Hb concentrations.  Moreover, the large sample 
size in the current study allowed us to confirm the significant positive association between MIF 
and Hb by conducting multivariate regression analyses that controlled for important confounders 
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 such as age.  Our previous studies in this cohort of children demonstrated that the reticulocyte 
response was inappropriate for the level of anemia, and that children with malarial anemia had 
suppression of erythropoiesis (Were 2006).  Correlation analyses examining the relationship 
between MIF and erythropoiesis revealed that MIF was not significantly associated with the 
absolute reticulocyte number, suggesting that circulating MIF may not be responsible for 
suppression of erythropoiesis.   
The basis of different MIF production patterns in Zambian children (McDevitt et al. 
2006) versus those in Gabon (Awandare et al. 2006b) and in Kenyan children presented here 
remains to be defined.  However, our studies in western Kenya and those of others (Akpede and 
Sykes 1993; Berkley et al. 1999; Graham et al. 2000; Otieno et al. 2006) have shown that 
children presenting with malarial anemia often have co-infections with bacteremia and HIV-1 
which could potentially alter MIF production.  Although children with co-infections were 
excluded from our analyses, it is not certain if such co-infected children were excluded from 
other studies.  In addition, since RBCs contain substantial quantities of MIF (Mizue et al. 2000), 
the use of plasma from hemolyzed blood could yield falsely elevated MIF concentrations.  For 
analysis of circulating MIF in the current study, all plasma samples were examined by an 
individual who was blinded to the clinical categories of study participants, and those samples 
with evidence of hemolysis were excluded from measurement.  Furthermore, it is well 
documented that malaria transmission intensity conditions the host immune response and age-
specific pathophysiological manifestations of P. falciparum (Marsh and Snow 1997; Snow et al. 
1997).  The relatively older children examined in Zambia (mean age: 25.5 mos.), where P. 
falciparum endemicity is lower, therefore, may have different immunopathogenic mechanisms 
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 responsible for the promotion of malarial anemia than the younger children examined here in 
western Kenya (see Table 1) residing in a holoendemic transmission area. 
Recent investigations illustrated that MIF suppresses erythropoietin-dependent colony 
formation in cultured erythroid progenitor cells and Hb synthesis in murine and human cell lines 
(McDevitt et al. 2006).  Additional studies showed that elevated MIF concentrations are present 
in bone marrow lysates of P. chabaudi-infected mice (Martiney et al. 2000).  However, 
measurement of MIF concentrations in the bone marrow of children with SMA will be important 
for understanding the role of MIF in human malaria since contrasting roles of MIF in murine 
studies (Martiney et al. 2000; McDevitt et al. 2006) versus those in human is not unprecedented.  
For example, previous investigations revealed that MIF production in response to glucocorticoids 
differs in murine and human systems (Isidori et al. 2002; Alourfi et al. 2005).  Furthermore, 
while anemia in murine models of malaria closely correlate with peripheral parasitemia and RBC 
hemolysis, data presented here illustrate that parasite density and anemia severity are unrelated in 
children with SMA.  It is also important to note that MIF production during malaria appears to be 
both tissue- and compartment-specific (Chaisavaneeyakorn et al. 2002; Clark et al. 2003; 
Chaisavaneeyakorn et al. 2005).  For example, previous studies in women with placental malaria 
showed increased MIF locally in intervillous blood in the presence of decreased peripheral blood 
MIF concentrations (Chaisavaneeyakorn et al. 2002).  Therefore, our findings do not exclude the 
possibility that MIF may be increased in the local milieu within the bone marrows of the children 
in our cohort despite the reduced concentrations of MIF in the peripheral circulation.  
Previous studies in malaria-endemic regions illustrate that phagocytosis of pfHz by 
monocytes and neutrophils is a better index of disease severity than peripheral parasitemia 
(Metzger et al. 1995; Nguyen et al. 1995; Amodu et al. 1998; Lyke et al. 2003; Casals-Pascual et 
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 al. 2006).    This may be related to the fact that concomitant peripheral parasitemia does not 
account for parasite sequestration within microvascular networks and/or the duration of 
infection.  In this study, there was a lower prevalence of PCM and PCN than previously observed 
by others (Metzger et al. 1995; Amodu et al. 1998; Lyke et al. 2003).  This may be because 
children in the present study were younger and, therefore, likely more immune-naïve to P. 
falciparum.  Importantly, the clearance kinetics of PCM and PCN differ considerably, with 
median PCM and PCN clearance times of approximately ten and four days, respectively (Day et 
al. 1996).  Increased abundance of PCM relative to PCN in the current cohort suggests that 
malarial anemia results from prolonged (chronic) malaria infections.  Although Hz has been 
shown to regulate MIF production in vitro (Awandare et al. 2006c; McDevitt et al. 2006), the 
relationship between MIF production and Hz levels in vivo has not previously been examined.  
Multivariate analyses controlling for age, gender, and parasitemia revealed a significant 
association between increased levels of PCM, SMA, and decreased circulating MIF levels, 
suggesting that acquisition of pfHz by monocytes may promote SMA and suppress peripheral 
MIF production.     
Based on the statistical relationship between elevated PCM and decreased MIF, malarial 
pigment was investigated as a parasitic source responsible for MIF suppression in children with 
SMA.  A series of experiments in cultured PBMC from malaria-naïve donors identified two main 
types of responders: those who increased MIF production and those who decreased MIF 
production in response to stimulation by physiological doses (Keller et al. 2004b) of pfHz or 
sHz.  Cell viability experiments further demonstrated that reductions in MIF production were not 
mediated by loss in cell viability or increased apoptosis.  Identical results observed with pfHz 
and sHz demonstrate that the core ferriprotoporphyrin-IX structure, rather than adherent host 
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 and/or parasitic proteins, lipids or nucleic acids is responsible for altering MIF production.  
Recent studies in cultured mononuclear cells from individuals with low (5-CATT/5-CATT) and 
high expression MIF-794 alleles (6-CATT/6-CATT and 6-CATT/7-CATT) show that MIF 
production in response to sHz stimulation was genotype-dependent (McDevitt et al. 2006).  
Although the genetic background of the donors examined in the present study were unknown, 
subsequent investigations in our laboratories have revealed that PBMC from individuals with the 
GG genotype at MIF -173 have increased MIF production, while GC individuals have decreased 
MIF production following stimulation with pfHz (Awandare et al. 2006c).  It is, therefore, not 
surprising that circulating MIF concentrations were generally inversely correlated with PCM 
levels in the study cohort, since the C allele is predominant in this cohort of children (Awandare 
et al. 2006c). The molecular mechanism(s) by which acquisition of malarial pigment decreases 
MIF production remains to be defined.  However, previous studies demonstrated that ingestion 
of Hz causes impairment of several cellular functions including cytokine secretion, phagocytosis, 
and antigen-presentation (Schwarzer et al. 1992; Schwarzer et al. 1998).  It remains to be 
determined if suppression of MIF in response to Hz occurs through a direct or indirect 
mechanism following phagocytosis of Hz.  Taken together, results presented here, which 
represent the most comprehensive examination to date on the role of MIF in promoting 
childhood malarial anemia, suggest that MIF may not be responsible for enhanced anemia in 
pediatric populations with acute falciparum malaria, and that monocytic ingestion of Hz is 
responsible, either directly or indirectly, for suppression of MIF.     
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 Table 3: Clinical, parasitological, and hematological characteristics of study participants. 
 
Characteristic AC UM MlMA MdMA SMA P-value 
Number, n 39 26 75 98 119  
Age, mos 9.1 (1.2) 14.0 (1.9) 12.2 (0.8) 11.5 (0.6) 10.2 (0.6) 0.005a
Axillary temperature, oC 36.8 (0.2) 37.6 (0.2) 37.6 (0.1) 37.7 (0.1) 37.6 (0.1) <0.001a
Parasites/μL 0 84118 (22734) 44168 (6092) 48697 (5925) 74490 (10443) 0.117a
Geomean parasites/μL 0 29689 21020 18623 31458  
HDP, n (%) 0 20 (77) 53 (71) 71 (72) 93 (78) 0.656b
Hemoglobin, g/dL 11.7 (0.1) 11.8 (0.2) 9.2 (0.1) 6.9 (0.1) 4.7 (0.1) <0.001a
Hematocrit, % 35.2 (0.3) 34.5 (1.1) 28.0 (0.4) 21.7 (0.2) 15.1 (0.3) <0.001a
RBC, x 106/μL 4.91 (0.08) 4.78 (0.13) 4.15 (0.07) 3.23 (0.06) 2.18 (0.05) <0.001a
ARN, x 103/μL 97.5 (18.7) 105.7 (16.5) 110.6 (8.7) 147.3 (11.6) 140.7 (10.4) <0.001a
PCM, % - 0.8 (0.8) 3.1 (1.0) 7.6 (1.4) 15.2 (1.6) <0.001a
PCM/μL - 0.01 (0.01) 0.04 (0.02) 0.09 (0.02) 0.23 (0.03) <0.001a
 
Data are presented as mean (SEM) except where otherwise indicated. Comparisons of parasitemia were among parasitemic groups 
only.  
aKruskal-Wallis test  
bChi-Square test 
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 AC, aparasitemic controls (P. falciparum negative, Hb≥11.0 g/dL); UM, uncomplicated malaria (Hb≥11.0 g/dL); MlMA, mild 
malarial anemia (8.0≤Hb<11.0 g/dL); MdMA, moderate malarial anemia (6.0≤Hb<8.0 g/dL); SMA, severe malarial anemia (Hb<6.0 
g/dL). HDP, high density parasitemia (≥10,000 parasites/μL); RBC, red blood cells; ARN, absolute reticulocyte number; PCM, 
pigment-containing monocytes. 
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 Table 4: Relationship between monocyte acquisition of hemozoin and disease severity in children with malaria. 
 
Characteristic Percent pigment-containing monocytes (PCM) 
 No PCM (0%) Low PCM (≤10%) High PCM (>10%) P-value 
Number, n (%) 162 (53) 62 (20) 82 (27)  
Age, mos 11.3 (0.5) 12.2 (0.9) 11.1 (0.8) 0.645a
Parasitemia, /μL 49371 (5088) 60141 (9906) 80447 (13266)b 0.034a
HDP, n (%) 113 (70) 50 (79) 67 (82) 0.086c
Hemoglobin, g/dL 7.8 (0.2) 6.5 (0.2) 5.7 (0.2)d < 0.001a
SMA, n (%) 34 (21) 28 (46) 53 (65)d < 0.001b
Odds of SMAe 1 3.4 (1.8-6.6) 7.5 (4.1-14.0)  
 
Data are presented as mean (SEM) unless otherwise indicated.   
aKruskal-Wallis test 
bSignificantly different from no PCM group, but not low PCM group 
cChi-Square test 
dSignificantly different from No PCM and low PCM groups. 
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eMultivariate logistic regression using No PCM group as reference and controlling for age, gender, and parasitemia; shown as odds 
ratio (95% confidence interval), P<0.0001 for both low and high PCM groups. 
HDP, high density parasitemia (≥10,000 parasites/µL); SMA, severe malarial anemia (Hb<6.0 g/dL). 
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Figure 8: Relationship of plasma MIF with anemia, parasite density and reticulocyte number. 
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Figure 8. Relationship of plasma MIF with anemia, parasite density and reticulocyte number. 
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 Figure 8. Relationship of plasma MIF with anemia, parasite density and reticulocyte number.  
Plasma levels of MIF in children with malaria and controls were determined by ELISA.  (A) Data are presented 
according to anemia categories: uncomplicated malaria (UM, Hb≥11.0 g/dL, n=23), mild malarial anemia (MlMA, 
8.0≤Hb<11.0 g/dL, n=71), moderate MA (MdMA, 6.0≤Hb<8.0 g/dL, n=94) and severe MA (SMA, Hb<6.0 g/dL, 
n=109).  Aparasitemic controls (AC, n=39) with Hb≥11.0 g/dL were used as a reference group.  Boxes represent the 
interquartile range, the line through the box is the median, whiskers show 10th and 90th percentiles, and symbols are 
outliers.  Median (interquartile range) levels of MIF were: AC, 4383 (2807-6376); UM, 5225 (3615-9071); MlMA, 
4611 (3270-6665); MdMA, 4197 (2862-5743); and SMA, 3422 (1566-4993).  *P<0.05, **P<0.001; Mann-Whitney 
U tests conducted after analysis of variance (Kruskal-Wallis test) revealed significant differences across groups. 
Linear relationships of plasma MIF levels with hemoglobin concentrations (B), parasite density (C), and absolute 
reticulocyte number (ARN) (D), in children with malaria (n=298) are shown as scatter plots. MIF concentrations and 
parasitemia were log-transformed while ARN was square root (sqrt)-transformed for normality, and statistical 
association was determined by Pearson’s correlation tests. 
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Figure 9: Correlation of peripheral blood leukocytes (PBL) MIF mRNA with circulating MIF.   
Levels of MIF mRNA in PBL (n=13) were determined by real time RT-PCR and expressed relative to endogenous 
β-actin mRNA levels.  The scatter plot shows the correlation of PBL MIF mRNA with circulating MIF levels in 
matched samples.  Statistical association was determined by Pearson’s rank correlation test.  
  96
  
 
Clinical Categories
AC UM MlMA MdMA SMA
PB
M
C
 M
IF
 p
ro
du
ct
io
n 
(p
g/
m
L)
0
1000
2000
3000
4000
5000
6000
7000
8000
**
*
 
Figure 10: MIF production from peripheral blood mononuclear cells (PBMC) of children 
with acute malaria.   
Peripheral blood mononuclear cells (PBMC) were isolated from children with acute malaria and healthy controls 
(AC) and cultured for 48 hrs: AC (n=24), UM (n=15), MlMA (n=37), MdMA (n=13), and SMA (n=5).  MIF 
concentrations in culture supernatants were determined by ELISA and presented as box plots in which the box 
represents the interquartile range, the line through the box is the median, whiskers show 10th and 90th percentiles, 
and symbols are outliers.  Median (interquartile range) levels of MIF were: AC, 1034 (615-1902); UM, 2218 (1418-
3989); MlMA, 1609 (940-2439); MdMA, 842 (495-3737); and SMA, 511 (264-2312) pg/mL).  *P<0.05, 
**P<0.005, Mann-Whitney U tests conducted after analysis of variance (Kruskal-Wallis test) revealed significant 
differences across groups. 
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Figure 11: Relationship between plasma MIF levels and pigment-containing monocytes.   
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 Figure 11.  Relationship between plasma MIF levels and pigment-containing monocytes.  
Giemsa-stained blood smears obtained from children with malaria were examined for the presence of pigment-
containing monocytes (PCM).  (A)  Plasma levels of MIF are presented according to percentage of total monocytes 
containing pigment: No PCM (no PCM observed, n=149), low PCM (≤10% PCM, n=60) and high PCM (>10% 
PCM, n=79).  Boxes represent the interquartile range, the line through the box is the median, whiskers show 10th and 
90th percentiles, and symbols are outliers. Median (interquartile range) levels of MIF were: No PCM, 4417 (3112-
6266); low PCM, 4584 (2019-6331); and high PCM, 4417 (3112-6266). *P<0.05, **P<0.005; Mann-Whitney U 
tests conducted after analysis of variance (Kruskal-Wallis test) revealed significant differences across groups. (B)  
Correlation between circulating MIF concentrations and PCM/μL of blood.  MIF levels were log-transformed while 
PCM/μL values were square-root-transformed for normality and Pearson’s correlation test was used to examine 
statistical association.   
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Figure 12: Effects of hemozoin on MIF production and apoptosis of cultured leukocytes.   
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Figure 12.  Effects of hemozoin on MIF production and apoptosis of cultured leukocytes.  
PBMC from malaria-naïve donors were cultured (1x106 cells/mL) in the presence of media alone (Con), 10 μg/mL 
hemozoin (pfHz), 10 μg/mL β-hematin (sHz), or a combination of 100 ng/mL lipopolysaccharide (L) and 200 U/mL 
IFN-γ (I). (A). Supernatants were harvested after 48 hrs of incubation and MIF concentrations determined by 
ELISA.  Data shown are for three donors representative of individuals for whom MIF increased (Group 1) and three 
donors representative of individuals for whom MIF decreased (Group 2) in response to stimulation with pfHz and 
sHz.  Differences in MIF levels between treated cells and control conditions were statistically significant (p<0.05 for 
all comparisons, Student’s t test). (B). Cell viability was assessed in PBMC of 3 donors after 48 hrs of culture using 
a methylthiazoletetrazolium (MTT) assay, and expressed as percent control. (C). PBMC apoptosis was determined 
by detecting nucleosomes in cell lysates and supernatants at 48 hrs using ELISA.  Data are presented as mean 
(SEM) of independent experiments. *P< 0.05 compared to Con; Student’s t test. 
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 4.0  CHAPTER FOUR: RESULTS, SPECIFIC AIM 2  
To investigate the role of MIF in proliferation and differentiation of erythroid progenitor 
cells. 
4.1 HYPOTHESES 1 AND 2, PRESENTATION OF MANUSCRIPT ENTITLED: AN 
INVESTIGATION OF THE ROLES OF MALARIA-ASSOCIATED INFLAMMATORY 
MEDIATORS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF), TUMOR 
NECROSIS FACTOR (TNF)-α, AND NITRIC OXIDE (NO) IN REGULATION OF 
ERYTHROPOIESIS USING A NOVEL IN VITRO MODEL. 
Hypothesis 1: Endogenous MIF production is required to promote efficient proliferation of 
erythroid progenitors.   
Hypothesis 2: MIF-regulated inflammatory mediators TNF-α and NO are more detrimental to 
erythroid progenitor survival and differentiation than MIF. 
 
To address hypotheses 1 and 2, an in vitro model of erythropoiesis was developed and used to 
investigate the roles of MIF and MIF-regulated inflammatory mediators TNF-α and NO in 
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 influencing erythroid cell development.  The following manuscript describes the erythropoiesis 
model and contrasts the roles of MIF, TNF-α, and NO in regulating erythropoiesis.   
 
Gordon A. Awandare, Daniel O. Ochiel, Paolo Piazza, Christopher C. Keller, Douglas J. Perkins 
 
University of Pittsburgh Graduate School of Public Health, Department of Infectious Diseases 
and Microbiology, Pittsburgh, PA.  
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A portion of this work was presented at the 54th Annual Meeting of the American Society of 
Tropical Medicine and Hygiene (December 11th-15th, 2005, Washington DC, USA).  The study 
was approved by the Ethics Committee of the University of Pittsburgh Institutional Review 
Board, and written, informed consent was obtained from all participants. 
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Phone (412)-624-5894  
Fax (412)-624-5364 
E-mail: djp@pitt.edu
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 4.1.2 Abstract 
One of the most lethal complications of Plasmodium falciparum malaria is severe malarial 
anemia (SMA), which appears related to malaria-induced suppression of erythropoiesis.  Studies 
required to identify the specific mechanisms and the molecular mediators involved in inhibiting 
red cell development have been hampered by difficulties in obtaining bone marrows of children, 
and the lack of reliable models for examining erythroid development.  Using different 
combinations of growth factors, we developed a two-step strategy for obtaining sufficient 
quantities of peripheral blood CD34+ stem cells in liquid culture, followed by induction of 
erythroid maturation in the presence of inflammatory mediators that have previously been 
implicated in malaria-induced suppression of erythropoiesis [i.e., macrophage migration 
inhibitory factor (MIF), tumor necrosis factor (TNF)-α, and nitric oxide (NO)].  In addition, 
since erythroid cells produce high levels of MIF endogenously, the effect of MIF-blocking 
antibodies on erythropoiesis was also examined. Addition of exogenous MIF and neutralization 
of endogenous MIF modestly increased proliferation of early erythroid progenitors, but had no 
noticeable effects on cellular apoptosis and maturation.  However, TNF-α and NO substantially 
suppressed erythroid cell proliferation which appeared to be partly due to increased cellular 
apoptosis.  In addition, NO significantly inhibited erythroid cell maturation as shown by 
decreased expression of the erythroid lineage marker, glycophorin A.  Taken together, these 
results demonstrate that TNF-α and NO are more detrimental to erythroid cell development than 
MIF, suggesting that these mediators may play a more important role in suppressing 
erythropoiesis during malaria.           
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 4.1.3 Introduction 
Although there is convincing evidence that suppression of erythropoiesis contributes to the 
development of SMA (Weatherall and Abdalla 1982; Abdalla 1990; Kurtzhals et al. 1997; 
Wickramasinghe and Abdalla 2000), the precise mechanisms and molecular mediators involved 
are unknown.  Some studies have reported inadequate production of erythropoietin (Epo) during 
malaria (Burgmann et al. 1996), however, deficient Epo production does not seem to be the 
major basis for inadequate erythropoiesis since appropriately increased levels of Epo in children 
with malarial anemia have also been reported (Burchard et al. 1995; Kurtzhals et al. 1997) 
(Nussenblatt et al. 2001). There is considerable evidence that dysregulation in innate immune 
responses favoring an over-production of pro-inflammatory mediators plays an important role in 
suppression of erythropoiesis during a malarial infection (Clark and Chaudhri 1988; Angulo and 
Fresno 2002; Clark and Cowden 2003; McDevitt et al. 2004).   
Recent studies have demonstrated that MIF inhibits development of both erythroid and 
myeloid progenitors in vitro, suggesting that MIF may be a critical factor in suppression of 
erythropoiesis during malaria (Martiney et al. 2000; McDevitt et al. 2006).  On the contrary, 
several other studies have described an important role for MIF in cell survival and proliferation, 
through activation of the MAP kinase signal cascade (Petrenko et al. 2003) and suppression of 
the pro-apoptotic factor p53 (Hudson et al. 1999; Mitchell et al. 1999; Fingerle-Rowson et al. 
2003).  In addition, MIF-knockout embryonic fibroblasts show impairment in both normal and 
stimuli-induced cell growth (Petrenko et al. 2003), in a manner analogous to the inefficient 
response of erythroid progenitors to increased erythropoietin in children with SMA (Burchard et 
al. 1995).  Furthermore, RBCs store substantial quantities of preformed MIF (Mizue et al. 2000), 
and recent studies in our laboratory revealed that committed erythroid progenitors produce high 
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 levels of MIF (Awandare, unpublished observations), suggesting that MIF could be required for 
erythroid cell development.  Therefore, to evaluate the role of MIF in erythroid development, the 
effects of endogenously produced MIF, as well as exogenously supplemented MIF on 
erythropoiesis was examined.   In addition, since there is over-production TNF-α and NO in 
children with malaria (Clark and Chaudhri 1988; Kwiatkowski et al. 1989; Kwiatkowski 1990; 
Anstey et al. 1999; Perkins et al. 2000; Keller et al. 2004b), the relative contributions of these 
inflammatory mediators in suppression of erythropoiesis will also be examined.  
Studies on the mechanisms and molecular mediators involved in suppression of the 
erythropoietic response during human malaria have been hampered by difficulties in obtaining 
sufficient quantities of erythroid progenitors from bone marrows of severely anemic children and 
the lack of a reliable ex vivo or in vitro model for examining erythroid development.  Recently, it 
has been shown that CD34+ hematopoietic stem cells can be cultivated in liquid culture and 
induced to differentiate into RBCs (Freyssinier et al. 1999; Neildez-Nguyen et al. 2002).  Based 
on these principles, an in vitro model of erythropoiesis was developed and used to evaluate the 
effects of exogenous MIF, MIF blocking antibodies, TNF-α, and NO on erythropoiesis.    
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 4.1.4 Materials and methods 
4.1.4.1 Isolation of CD34+ cells.   
PBMC were isolated using Ficoll-hypaque from donor leukopack samples (50mL) obtained from 
the University of Pittsburgh Medical Center (UPMC) blood bank.  PBMC were washed twice 
and resuspended in phosphate buffered saline (PBS) containing 0.5% bovine serum albumin 
(BSA) and 0.6% anticoagulant citrate dextrose formula A (ACD-A).  Hematopoietic progenitor 
cells (CD34+) were enriched by two cycles of positive selection using anti-CD34 microbeads 
and magnetic cell sorting on Midi-MACS columns (Direct CD34 Progenitor cell isolation kit, 
Miltenyi Biotec).  The number of viable CD34+ cells obtained was determined by trypan blue 
exclusion. 
4.1.4.2 Erythroid cell growth media.   
Culture media used in this study were based on previously described methods (Freyssinier et al. 
1999; Neildez-Nguyen et al. 2002) that have been modified for selectively optimizing erythroid 
development with negligible contamination from other cell lineages.  Basic culture medium was 
composed of Iscove’s Modified Dulbecco’s Medium (IMDM, Gibco, Invitrogen, Carlsbad, CA) 
containing 15% BIT (mixture of 5% BSA, 50 μg/mL bovine pancreatic insulin and 1 mg/mL 
human transferrin; Stem cell technology), 100 U/mL penicillin-streptomycin, and 2mM L-
glutamine.  Primary culture medium was prepared from the basic culture medium by adding a 
combination of cytokines: 10 ng/mL recombinant human (rh) IL-3, 10 ng/mL rh IL-6, and 100 
ng/mL rh stem cell factor (SCF) [R&D systems, Minneapolis, MN].  Secondary cultures were 
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 initiated by stimulation with rh erythropoietin (1 U/mL, R&D systems, Minneapolis, MN) to 
induce erythropoiesis.   
4.1.4.3 Primary cell culture.   
CD34+ cells were plated in a 24-well plate at 1 x 105 cells/well in PCM and incubated at 37 oC in 
a humidified atmosphere of 5% CO2 and 5% oxygen for 3 days.  At the end of the incubation 
period, cells were harvested, washed twice in IMDM and the number of viable cells determined 
using trypan blue exclusion. 
4.1.4.4 Secondary cell culture.    
To initiate erythropoiesis, cells obtained from the primary culture were re-plated at 15 X 103 
cells/well and stimulated with Epo alone (Epo Control), or in the presence of rh MIF (200 
ng/mL, 100 ng/mL), MIF blocking antibodies (100 μg/mL, 50 μg/mL), rh TNF-α (100 ng/mL, 
50 ng/mL, BD Pharmingen), and nitric oxide donors, DETANOATE (propylamine propylamine; 
100 μM, 50 μM) and PAPANOATE (diethylene triamine; 100 μM, 50 μM; Cayman Chemical), 
and were left to incubate as before for 11 additional days.  Additional cells were cultured in the 
absence of Epo (No Epo) to serve as a negative control for erythropoiesis.  In order to maintain 
optimal balance of nutrients, media were replenished every two days by replacing half of the 
culture medium with freshly prepared media. 
 Purified bioactive rMIF and mouse ascites fluid from which MIF blocking 
antibodies were isolated were kind gifts from Dr. Richard Bucala of Yale University, New 
Haven, CT.  Anti-MIF monoclonal antibodies (Clone NIH3D9) were isolated from ascites fluid 
by Protein-A affinity purification (Pierce, Rockford IL), followed by dialysis with the Slide-A-
Lyzer system (Pierce, Rockford, IL).  The purified antibodies were concentrated using the 
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 Amicon Ultra-15 centrifugal filter device (Millipore, Billerica, MA), and quantified using a 
Coomassie (Bradford) protein assay (Pierce, Rockford, IL) with bovine IgG as standard. 
4.1.4.5 Cell proliferation assays.   
Cell proliferation was assessed using a methylthiazoletetrazolium (MTT)-based assay (Sigma, St. 
Louis, MO).  The assay is based on the ability of viable cells to metabolize the tetrazolium salt to 
form an insoluble formazan dye which is then quantified by spectrophotometry.  Briefly, on the 
indicated days, cells were resuspended by gentle tituration and 200 μL of culture from each well 
was transferred to a corresponding well in a 96-well plate.  Twenty microliters of MTT 
(dissolved at 5 mg/mL in PBS) was added, and the plate was incubated under culture conditions 
for 4 hours.  After the supernatant was removed, the formazan produced was solubilized using 
isopropanol and absorbance was read at 570nm.  Relative cell proliferations across different 
conditions were determined by expressing absorbances as percentages relative to baseline (Epo 
Con).  
4.1.4.6 Apoptosis assays.   
Cellular apoptosis was assessed by quantifying the concentrations of nucleosomes in cell lysates 
(early-stage apoptosis) and culture supernatants (late-stage apoptosis) using a cell death detection 
ELISA according to manufacturer’s recommendations (Roche Diagnostics).  Briefly, cells were 
resuspended by gentle tituration and 100 mL of culture was transferred to a 96-well plate. The 
plate was centrifuged at 1000 rpm for 10 mins, and the supernatants harvested for nucleosome 
ELISA.  The cell pellet was gently washed in 100 mL of fresh PBS before lysis, followed by 
centrifugation and collection of lysate for nucleosome detection.  To account for differences in 
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 cell concentrations across conditions, nucleosome levels were normalized using the 
corresponding MTT assay data, and then expressed as fold-change relative to Epo Con.  
4.1.4.7 Immunophenotypying assays.   
Maturation of erythroid cells was monitored by determination of surface expression of stage-
specific markers CD34, CD45, CD71 and glycophorin A (GPA).  Cells were washed and 
resuspended in PBS containing 0.5% BSA and incubated with fluorescein isothiocyanate (FITC) 
- or phycoerythrin (PE)-conjugated antibodies at 4oC for 25 minutes.  After two washes, cells 
were resuspended in 300 μL of PBS (containing 0.5% BSA and 1% paraformaldehyde) for flow 
cytometric analysis. A DNA dye, 7-amino actinomycin D (7-AAD, BD Biosciences, Franklin 
Lakes, NJ), was added to the stained cells 10 mins before acquisition to differentiate between 
dead and live cells. 
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 4.1.5 Results 
4.1.5.1 An in vitro model for studying regulation of erythropoiesis.   
Based on recently demonstrated techniques for cultivating hematopoietic stem cells in liquid 
culture (Freyssinier et al. 1999; Neildez-Nguyen et al. 2002), we developed an in vitro model of 
erythropoiesis was developed using peripheral-blood mobilized CD34+ cells.  Since frequency of 
CD34+ cells in PBMC is ~ 0.05-0.2 %, a small quantity of CD34+ cells were first expanded 
without differentiation for three days using a carefully optimized cocktail of growth factors 
including IL-3, IL-6, and SCF (Freyssinier et al. 1999), and then induced towards erythroid 
lineage during an additional 11 days by stimulation with Epo (Figure 13).  Prior to Epo 
stimulation, cells were divided into different culture wells and treated with the potential 
inhibitors under investigation.  The efficiency and effectiveness of erythropoiesis was 
continuously monitored during 14 days of erythroid cell growth and development by examining 
cell proliferation and differentiation (maturation) (Figure 13).  Cell proliferation was measured 
using a biochemical method, which quantifies cellular metabolism, in place of the traditional 
methods such as microscopical enumeration of cells.  In addition, since there is differential 
expression of surface markers at key developmental stages of erythroid cell maturation (Figure 
14), cell differentiation during secondary culture was monitored using immunophenotypic 
analyses by multi-color flow cytometry.  CD34+ cells develop through the burst-forming units-
erythoid (BFU-E)  and colony-forming unit-erythroid (CFU-E) stages to more mature 
erythroblasts and reticulocytes by losing CD34 and CD45 expression, while gaining expression 
of CD71 (transferrin receptor) and glycophorin-A (GPA). GPA is an anchor protein expressed 
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 exclusively on the surface of mature erythroid lineage cells, and is thus a reliable marker of 
erythroid cell development (Xiao et al. 2002).   
Relative to unstimulated cells (No Epo), there was rapid proliferation of erythroid cells in 
response to Epo stimulation during 11 days of secondary culture (Figure 15A).  The 
immunophenotypic scheme for analyzing erythroid cell differentiation in response to Epo is 
illustrated in Figure 15B.  Immature CD34+ progenitors on day 3 express high levels CD45 and 
CD71, but are negative for GPA. By day 10 (7 days of Epo stimulation), expression of CD34 is 
completely lost and CD45 is down-regulated, with a majority of cells expressing GPA, 
demonstrating erythroid maturation (Figure 15B, and Table 5).  Of note, expression of other 
lineage markers, including CD3, CD14, and HLA-DR was very low or absent (Table 5, and data 
not shown), confirming that the vast majority of the cells were committed erythroid cells by day 
10.  On the contrary, cells cultured in the absence of Epo (No Epo) retained high expression of 
CD34 and CD45, expressed low levels of GPA, and also expressed HLA-DR (Table 5). 
4.1.5.2 Effects of MIF, TNF-α and NO on erythroid cell proliferation during erythropoiesis. 
Although previous studies demonstrated that MIF suppressed hematopoiesis, studies in our 
laboratory show that erythroid progenitors produced high levels of MIF during erythropoiesis 
(Figure 15C).  To examine the role of MIF in erythroid cell development, erythropoiesis was 
induced in the presence of either exogenous MIF (rMIF; 200 and 100 ng/mL), at doses that 
suppressed hematopoiesis in previous studies (McDevitt et al. 2006), or MIF blocking antibodies 
(anti-MIF; 100 and 50 μg/mL), at concentrations sufficient to completely block endogenous MIF 
(Calandra et al. 2000).  In addition, since there is over-production of TNF-α and NO in children 
with malaria, the effects of these other malaria-associated inflammatory mediators on 
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 suppression of erythropoiesis were also examined.  NO was provided in culture by two NO 
donors: one with a very short half-life (PAPANONOATE, 15 mins), and another with a longer 
half-life (DETANONOATE, 22 hrs).  Addition of rMIF at 200 and 100 ng/mL marginally 
increased erythroid cell proliferation on days 6 and 8 of culture (P<0.05 for all comparisons) 
relative to baseline levels, however, by day 14 cultures both doses of rMIF significantly 
decreased cellular proliferation (P<0.05, Figure 16A).   Interestingly, treatment with anti-MIF 
increased proliferation on days 6 and 8 (P<0.05 relative to baseline, and isotype control 
treatment), but this effect disappeared by day 10, with cell numbers being similar to baseline 
levels by day 14 (Figure 16B).  On the contrary, TNF-α (100 and 10 ng/mL) exerted a 
substantial and sustained, dose-dependent suppressive effect on erythroid cell proliferation 
throughout the culture period, and these effects where statistically significant on days 8, 10 and 
14 (P<0.05 for all comparisons, Figure 16C).  Treatment with both PAPANONOATE 
(PAPANO, 100 and 50 μM) and DETANONOATE (DETANO, 100 and 50 μM) elicited similar 
patterns of cell proliferation, characterized by a marked early, dose-dependent suppression on 
days 6 and 8 (P<0.05 for all comparisons, Figures 16D and 16E).  Although there was a trend 
towards recovery by days 10 and 14, cell proliferation in the presence of NO donors remained 
below baseline levels, maintaining statistically significant differences for DETANO (P<0.05 for 
all comparisons, Figure 16D), but not for PAPANO (P<0.10 for all comparisons, Figure 16E).  
These results demonstrate that TNF-α and NO are much more detrimental to erythroid cell 
development than MIF.  In addition, endogenously produced MIF does not appear to play a 
critical role in erythropoiesis. 
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 4.1.5.3 Effects of MIF, TNF-α and NO on erythroid cell survival during erythropoiesis.   
To investigate whether the effects of MIF, TNF-α, and NO on erythroid cell proliferation was 
associated with changes in cell survivability, cellular apoptosis was determined by measuring the 
release of nucleosomes. To ensure detection of total apoptosis, nucleosome concentrations were 
determined in both cell lysates (early-stage apoptosis), and culture supernatants (late-stage 
apoptosis) after 3 days of stimulation.  Although rMIF marginally increased apoptosis of 
erythroid cells, these effects were not statistically significant (P<0.10 for all comparisons, Figure 
17A). In addition, cellular apoptosis in the presence of anti-MIF was indistinguishable from 
levels observed at baseline and in IgG-treated cells (P>0.50 for all comparisons, Figure 17A).  
Similarly, TNF-α had no significant effects on erythroid cell apoptosis relative to baseline levels 
(P>0.05 for all comparisons, Figure 17B).  Late-stage apoptosis was increased in cells cultured 
in the presence of PAPANO, and this difference was statistically significant for the higher dose 
of PAPANO (P<0.05), but not for the lower dose (P=0.2, Figure 17C).  PAPANO had no 
significant effect on levels of early-stage apoptosis (P>0.5 for all comparisons, Figure 17C).  
There was a significant and dose-dependent increase in erythroid cell apoptosis in the presence 
of DETANO (P<0.05 for all comparisons), with the differences being more pronounced for late-
stage apoptosis (Figure 17C).   Taken together, these data demonstrate that, except for TNF-α, 
suppression of erythroid cell proliferation is generally associated with an increased level of 
apoptosis. 
  115
 4.1.5.4 Effects of MIF, TNF-α and NO on differentiation of erythroid progenitors in response 
to Epo stimulation.   
Suppression of erythropoiesis during malaria results from both ineffective reticulocyte 
production and dyserythropoiesis (Wickramasinghe and Abdalla 2000; Chang and Stevenson 
2004), suggesting that erythroid cell maturation may be impaired.  Therefore, the roles of MIF, 
TNF-α and NO in regulating erythroid cell differentiation in response to Epo stimulation was 
investigated by examining expression of CD34, CD45, CD71 and GPA (Table 5 and Figure 18).  
There were no significant differences in expression of maturation markers between cells treated 
with rMIF or anti-MIF and control conditions (Table 5, and Figures 18A and 18B). Treatment 
with a high dose of TNF-α seemed to slightly augment erythroid cell maturation as evidenced by 
an accelerated down-regulation of CD45 and a marginal increase in GPA expression; however, 
these differences were not statistically significant (P>0.5 for all comparisons; Table 5 and Figure 
18C).  Conversely, in the presence high doses (100 μM) of either NO donors, there was higher 
retention of CD45 and CD34, and less GPA expression relative to Epo Con (Table 5, Figure 18D 
and 18E), indicating an inhibition of erythroid cell maturation.  These effects of NO were dose-
dependent, and reached statistical significance for DETANO (P<0.05 for all comparisons) but 
not PAPANO (P>0.1 for all comparisons).  Thus, while MIF and TNF-α did not appear to 
influence erythroid cell differentiation, sustained NO stimulation markedly suppresses 
maturation of erythroid progenitors during erythropoiesis.  
 
  116
 4.1.6 Discussion 
Although previous studies have implicated MIF in the suppression of erythropoiesis during 
murine malaria (Martiney et al. 2000; McDevitt et al. 2006), results presented in Specific Aim 1 
demonstrate that peripheral blood MIF production is not significantly related to reticulocyte 
production in children with malarial anemia.  Therefore, it was of interest to further define the 
role of MIF in regulating erythropoiesis, and to examine the potential contribution of MIF 
relative to other malaria-associated inflammatory mediators in inhibiting erythroid cell 
development.  However, a major impediment to obtaining a complete understanding of the 
mechanisms contributing to suppression of erythropoiesis during malaria is the difficulty 
associated with obtaining bone marrow samples from severely anemic children, coupled with the 
lack of a reliable in vitro model for studying the regulation of erythropoiesis.  Studies presented 
here describe a novel in vitro erythropoiesis model using peripheral blood mobilized CD34+ 
hematopoietic stem cells cultivated in liquid culture. Our results show that a small number of 
CD34+ cells can be successfully amplified with growth factors to sufficient numbers for testing 
soluble mediators of inflammation that may alter erythropoiesis, avoiding the requirement for 
bone marrow cells. Furthermore, the use of molecular/biochemical methods for assessing cell 
proliferation and apoptosis, and flow cytometry for phenotypic characterization of erythroid 
cells, provides a more reliable and objective alternative to exclusive use of microscopic analysis.  
The method developed here showed reliability and reproducibility in comparing the effects of the 
potential inhibitors of erythroid development investigated. 
 Contrary to previous studies demonstrating that MIF inhibited the development of 
hematopoietic cells (Martiney et al. 2000; McDevitt et al. 2006), results presented here show a 
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 bi-phasic effect of MIF on erythropoiesis: slightly augmenting proliferation of early progenitors, 
and marginally suppressing growth of older cells.  In addition, since MIF is ubiquitous, we tested 
erythroid cell culture supernatants for MIF protein as part of our investigations.  These analyses 
showed, for the first time, that erythroid progenitors produced large quantities of MIF during 
erythropoiesis, raising the possibility of a positive role for MIF in erythropoiesis.  However, 
neutralization of endogenous MIF using anti-MIF blocking antibodies did not reveal any adverse 
effects on erythropoiesis; instead it slightly augmented early erythroid cell proliferation.  
Although the similar effects elicited by both rMIF and anti-MIF appear contradictory, these 
results are consistent with the fact that various studies have described both pro- and anti-
proliferative properties of MIF (Martiney et al. 2000; McDevitt et al. 2006; Hudson et al. 1999; 
Mitchell et al. 1999; Fingerle-Rowson et al. 2003; Petrenko et al. 2003), suggesting that MIF 
may be important in maintaining a balanced erythropoietic response.  
Since several inflammatory mediators are over-produced during malaria, it was of interest 
to investigate the potential roles of MIF-regulated mediators in contributing to suppression of 
erythropoiesis.  Of the comprehensive panel of mediators examined in Specific Aim 1, TNF-α 
and NO oxide were the most-upregulated pro-inflammatory mediators in children with acute 
malaria.  Since previous studies demonstrate that TNF-α and NO can suppress erythroid cell 
development in vivo and in vitro (Johnson et al. 1989; Rusten and Jacobsen 1995; Shami and 
Weinberg 1996; Anstey et al. 1999; Xiao et al. 2002), the effects of these mediators on 
erythropoiesis were examined along with MIF.   Unlike the modest effects observed for MIF, 
treatment with both TNF-α and NO substantially suppressed erythroid cell proliferation, with 
inhibition margins of up to 65% for TNF-α, and 90% for NO.  Furthermore, while MIF and 
TNF-α had no significant effects on erythroid cell differentiation, high levels of NO significantly 
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 inhibited maturation of erythroid cells, characterized by reduced GPA expression.   While the 
mechanisms by which TNF-α inhibited erythropoiesis in the model system are not clear, 
measurement of cellular apoptosis revealed that NO-induced suppression of erythropoiesis is, at 
least in part, due to induction of cell death.  Taken together, results presented here demonstrate 
that TNF-α and NO, rather than MIF, may be the major suppressors of erythropoiesis in children 
with malarial anemia. 
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 Table 5:  Phenotypic characterization of erythroid cell maturation status on day 10 
 
Conditions Mean (SEM) percent of total live cells expressing markers 
 GPA CD45 CD34 HLA-DR 
Epo Con 87 (4) 21 (2) 1 (0) 0 (0) 
rMIF (200 ng/mL) 91 (0) 30 (0) 0 (0) 0 (0) 
rMIF (100 ng/mL) 91 (0) 27 (0) 0 (0) 0 (0) 
IgG control (100 μg/mL) 92 (0) 28 (1) 0 (0) 0 (0) 
Anti-MIF (100 μg/mL) 91 (1) 27 (0) 0 (0) 0 (0) 
Anti-MIF (50 μg/mL) 91 (1) 29 (1) 0 (0) 0 (0) 
PAPANO (100 μM) 83 (6) 20 (4) 2 (1) 0 (0) 
PAPANO (50 μM) 81(6) 25 (3) 2 (0) 0 (0) 
DETANO (100 μM) 70 (4) 37 (2) 11 (1) 0 (0) 
DETANO (50 μM) 76 (4) 29 (2) 5 (1) 0 (0) 
TNF-α (100 ng/mL) 87 (6) 14 (5) 1 (0) 1 (0) 
TNF-α 10 (10 ng/mL) 87 (6) 16 (5) 1 (0) 1 (0) 
No Epo 16 (5) 92 (2) 44 (3) 44 (3) 
 
 
Data shown are proportions of gated live (7-AAD-) cells that were positive for the indicated 
surface markers, and are presented as mean (SEM) for 2 to 4 experiments. 
 
 
  120
 Day 0
Isolate CD34+ cells 
from donor PBMCs
Expand with rhIL-3, 
rhIL-6 & rhSCF
Differentiate to RBCs with Epo in the presence 
of: rMIF, anti-MIF, TNF-α, and NO.
Controls: media alone (Epo Con), No Epo
Immunophenotyping
MTT assay
Apoptosis assay
Immunophenotyping
MTT assay
Immunophenotyping
Primary culture Secondary culture (erythropoiesis)
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Day 3 Days 6 & 8 Day 10 Day 14
 
Figure 13: Experimental design for in vitro model of erythropoiesis.   
CD34+ hematopoietic stem cells were isolated from donor PBMC by labeling them with magnetic bead-conjugated 
anti-CD34 monoclonal antibodies followed by positive selection on a magnetic column. Purified CD34+ cells were 
expanded for 3 days in stem cell growth media containing IL-3, IL-6, and SCF.  After 3 days of primary culture, 
cells were induced toward erythroid lineage development by the addition of erythropoietin alone (Epo Con), or in 
the presence of rMIF, anti-MIF, TNF-α or NO.  During 11 days of erythropoiesis, cell proliferation (MTT assay), 
apoptosis, and maturation (immunophenotyping by flow cytometry) were measured at the indicated time points. 
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Figure 14: Phenotypic markers expressed at key developmental stages of erythroid lineage 
cells. 
In response to signals from erythropoietin (Epo), multipotent CD34+ stem cells commit to the erythroid lineage, 
forming burst-forming units (BFU-E).  BFU-Es develop into colony-forming units (CFU-E) with the appearance of 
surface markers including CD71 and CD36.  Under appropriate conditions, including sufficient Epo signals, CFU-Es 
mature into glycophorin A (GPA)-expressing erythroblasts, accompanied by loss of CD34 and down-regulation of 
CD45. Following active hemoglobin synthesis, erythroblasts develop into reticulocytes, which mature into 
erythrocytes accompanied by enucleation and loss of CD71 expression. Markers selected for immunophenotyping 
are indicated in bold font. 
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Figure 15: Proliferation, differentiation, and MIF production of erythroid progenitors. 
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Figure 15: Proliferation, differentiation, and MIF production of erythroid progenitors during 
erythropoiesis.  Peripheral blood-mobilized CD34+ stem cells were expanded in liquid culture for 3 days using a 
combination of growth factors (including IL-6, IL-3 and SCF), and then induced towards erythroid lineage by the 
addition of Epo for a further 11 days.  A) Cell proliferation in response to Epo (Epo Con) was measured by the MTT 
assay and expressed as fold-change relative to cells cultured without Epo (No Epo). Data show means (SEM) for 5 
independent experiments. *P<0.05 relative to day 3. B) Erythroid cell maturation during erythropoiesis was 
analyzed by immunophenotypic characterization.  Surface expression of CD34, CD71, CD45 and glycophorin A 
(GPA) was determined by staining with FITC- or PE-conjugated antibodies and analyzed by flow cytometry.  Data 
show expression of surface markers in gated live cells (7AAD-) before addition of Epo (Day 3) and 7 days after 
initiation of Epo stimulation (Day 10).  Percentages shown are the proportion of total events within the indicated 
region. C) Supernatants were harvested from erythroid cultures at the indicated time points and analyzed for MIF 
protein levels using ELISA.  Data show means (SEM) of two independent experiments set up in duplicate. *P<0.05 
relative to day 6. 
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Figure 16: Effects of rMIF, anti-MIF, TNF-α and NO on proliferation of erythroid cells 
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Figure 16: Effects of rMIF, anti-MIF, TNF-α and NO on proliferation of erythroid cells 
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Figure 16: Effects of rMIF, anti-MIF, TNF-α and NO on proliferation of erythroid cells.  
CD34+ stem cells were induced to undergo erythropoiesis by erythropoietin (Epo) stimulation alone (Epo Con), or 
in the presence of: A) rMIF (200 and 100 ng/mL), B) anti-MIF blocking antibodies (100 and 50 μg/mL), or IgG 
isotype control antibody (100 μg/mL); C) TNF-α (100 and 10 ng/mL), D) nitric oxide (NO) donor, 
PAPANONOATE (100 and 50 μM), and E) NO donor, DETANOATE (100 and 50 μM). As an additional control, 
some cells were cultured without Epo (No Epo). Cell proliferation was measured at the indicated days using a 
methylthiazoletetrazolium (MTT)-based assay. Data show cell proliferation of erythroid cells expressed relative to 
baseline conditions (Epo Con), and are presented as mean + SEM of 5 independent experiments. *Indicate time 
points at which treatments with both doses of the mediators had statistically significant effects relative to Epo Con 
(P<0.05, paired t test). 
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Figure 17: Effects of rMIF, anti-MIF, TNF-α and NO on survival of erythroid cells 
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Figure 17: Effects of rMIF, anti-MIF, TNF-α and NO on survival of erythroid cells.   
CD34+ stem cells were induced to undergo erythropoiesis by erythropoietin (Epo) stimulation alone (Epo Con), or 
in the presence of: A) rMIF (200 and 100 ng/mL), anti-MIF blocking antibodies (100 and 50 μg/mL), or IgG isotype 
control antibody (100 μg/mL); B) TNF-α (100 and 10 ng/mL), and C) nitric oxide (NO) donors, PAPANONOATE 
(100 and 50μM), and DETANOATE (100 and 50μM). As an additional control, some cells were cultured without 
Epo (No Epo). Cellular apoptosis was examined after 3 days of stimulation by measuring the release of nucleosomes 
in cell lysates (early-stage apoptosis), and supernatants (late-stage apoptosis) by ELISA. Nucleosome concentrations 
were expressed as fold-change relative to baseline conditions (Epo Con), and are presented as mean (SEM) of 3 
independent experiments. *Indicate treatments that had statistically significant effects relative to Epo Con (P<0.05, 
paired t test). 
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Figure 18: Effects of rMIF, anti-MIF, TNF-α and NO on erythroid cell maturation. 
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Figure 18: Effects of rMIF, anti-MIF, TNF-α and NO on survival of erythroid cells.   
CD34+ stem cells were induced toward erythroid differentiation by erythropoietin (Epo) stimulation alone (Epo 
Con), or in the presence of: A) rMIF (200 ng/mL), B) anti-MIF blocking antibodies (100 μg/mL), C) TNF-α (100 
ng/mL), D) nitric oxide (NO) donor, PAPANONOATE (100 μM), and E) NO donor, DETANOATE (100 μM). 
Erythroid cell maturation was analyzed by determining surface expression of the erythroid lineage-specific marker 
glycophorin-A (GPA). Histogram overlays show changes in GPA expression elicited by treatment with high doses 
of the respective mediators relative to baseline control conditions (Epo Con) on Day 10 of culture. Data are shown 
for gated live cells (7-AAD-), and cell counts are normalized for each histogram.  Data are representative of 2 to 4 
experiments. 
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 5.0  CHAPTER FIVE: RESULTS, SPECIFIC AIM 3 
To examine the influence of genetic variation at positions -173 (G/C) and -794 (CATT5-8) of 
the MIF promoter on MIF production and susceptibility to SMA in children. 
5.1 HYPOTHESIS 1, PRESENTATION OF MANUSCRIPT ENTITLED: A 
MACROPHAGE MIGRATION INHIBITORY FACTOR PROMOTER POLYMORPHISM IS 
ASSOCIATED WITH HIGH-DENSITY PARASITEMIA IN CHILDREN WITH MALARIA.  
Hypothesis 1: MIF -173 and -794 variants that are associated with decreased MIF production 
also condition increased susceptibility to SMA.   
 
To address one part of hypothesis 1, the MIF -173 polymorphism was analyzed in the cohort of 
Kenyan children enrolled for the investigations in Specific Aim 1. The role of variation at MIF -
173 in conditioning susceptibility to severe malaria (defined as HDP and/or SMA) in children 
residing in an area with holoendemic P. falciparum transmission was examined.   In addition, the 
functional significance of the MIF -173 SNP in influencing MIF production was investigated.  
The findings of these investigations are presented in the following manuscript published in the 
journal Genes and Immunity (Gene Immun 2006, 7(7):568-75; reproduced with permission from 
Nature Publishing Group). 
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 5.1.2 Abstract 
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that regulates innate and 
adaptive immune responses to bacterial and parasitic infections.  Functional promoter variants in 
the MIF gene influence susceptibility to inflammatory diseases in Caucasians.  Since the role of 
genetic variation in the MIF gene in conditioning malaria disease outcomes is largely 
unexplored, the relationship between a G to C transition at MIF -173 and susceptibility to high-
density parasitemia (HDP) and severe malarial anemia (SMA) was examined in Kenyan children 
(aged 3-36 mos; n=477) in a holoendemic Plasmodium falciparum transmission region.  In a 
multivariate model, controlling for age, gender, HIV-1 status, and sickle-cell trait, MIF -173CC 
was associated with an increased risk of HDP compared to MIF -173GG. No significant 
associations were found between MIF -173 genotypic variants and susceptibility to SMA.  
Additional studies demonstrated that homozygous G alleles were associated with lower basal 
circulating MIF levels relative to the GC group. However, stimulation of cultured peripheral 
blood mononuclear cells with malarial pigment (hemozoin) increased MIF production in the GG 
group and decreased MIF production in the GC group.  Thus, variability at MIF -173 is 
associated with functional changes in MIF production and susceptibility to HDP in children with 
malaria.  
 
Running title:  MIF -173 SNP associated with malaria parasitemia 
 
Key words:  Macrophage migration inhibitory factor (MIF), genetic polymorphism, parasitemia, 
severe malaria 
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 5.1.3 Introduction 
Malaria is one of the leading causes of childhood morbidity and mortality in sub-Saharan Africa, 
accounting for 25-35% of the outpatient visits, 20-45% of the hospital admissions, and up to 
35% of inpatient deaths (WHO 2005).  The vast majority of the global malaria cases occur in 
sub-Saharan Africa in which greater than 90% of the clinical cases are caused by Plasmodium 
falciparum infections (WHO 2005).  Clinical manifestations of P. falciparum malaria vary 
widely, and range from mild fevers to severe life-threatening complications including: 
hyperparasitemia, hypoglycemia, renal insufficiency, cerebral malaria (CM), severe malarial 
anemia (SMA), and respiratory distress (Marsh et al. 1995; Mockenhaupt et al. 2004; Dzeing-
Ella et al. 2005).   
Transmission intensity and the age at which malaria is acquired are important 
determinants of the clinical manifestations of the disease (Snow et al. 1997).  However, 
transmission intensity and age do not adequately explain variation in malaria disease severity 
among age-matched infants and young children (aged 0 to 3 yrs) with similar levels of parasite 
exposure and infection rates.  Diverse clinical outcomes under these circumstances appear to be 
conditioned by genetic variability since malaria has exerted significant selective pressure on the 
human genome, particularly in host-immune response genes that mediate susceptibility and 
clinical outcomes of the disease (Kwiatkowski 2005).   
Macrophage migration inhibitory factor (MIF) is a ubiquitous cytokine produced by T 
cells (David 1966; Bacher et al. 1996), monocytes/macrophages (Calandra et al. 1994), and the 
anterior pituitary gland (Bernhagen et al. 1993) in response to pro-inflammatory stimuli.  Unlike 
most cytokines, MIF is constitutively expressed at high levels and stored in preformed vesicles, 
and therefore, can be rapidly released without de novo gene expression (Bernhagen et al. 1993; 
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 Bernhagen et al. 1998).  MIF has potent pro-inflammatory properties and is an important 
mediator of both innate and adaptive immune responses to bacterial and parasitic infections 
(Bacher et al. 1996; Juttner et al. 1998; Bozza et al. 1999; Calandra et al. 2000; Koebernick et 
al. 2002; Calandra and Roger 2003).  Variation in the MIF gene has been shown to influence 
susceptibility to several inflammatory diseases in non-African populations, including rheumatoid 
arthritis, atopy, ulcerative colitis, and lung disease (Hizawa et al. 2004; Plant et al. 2005; Renner 
et al. 2005).  To date, five polymorphisms have been identified in the MIF gene, four single 
nucleotide polymorphisms (SNPs) at positions -173 (G/C), +24 (A/T), +254 (T/C) and +656 
(C/G), and a tetranucleotide repeat at -794 (CATT5-8) (Donn et al. 2001; Baugh et al. 2002; 
Donn et al. 2002).  However, only the MIF -173 and MIF -794 polymorphisms have been 
reported to affect both basal and stimuli-induced MIF production, and influence susceptibility to 
chronic inflammatory and infectious diseases in Caucasians (Donn et al. 2001; Baugh et al. 
2002; Donn et al. 2002; Barton et al. 2003; Donn et al. 2004; Radstake et al. 2005; Renner et al. 
2005).  In addition, high MIF-producing alleles of the -794 CATT repeat were associated with 
increased susceptibility to high-density parasitemia (HDP, ≥10 000 parasites/μL) in Zambian 
children with acute malaria (Zhong et al. 2005).  The role of polymorphic variability in MIF -173 
in influencing susceptibility to severe malaria, however, has not been elucidated.     
Although elevated MIF levels are associated with enhanced pathogenesis in murine 
models of malaria (Martiney et al. 2000; McDevitt et al. 2006), investigations in human malaria 
have yielded contrasting findings (Awandare et al. 2006b; McDevitt et al. 2006).  Previous 
investigations showed that MIF production was elevated in intervillous blood during placental 
malaria (Chaisavaneeyakorn et al. 2002; Chaiyaroj et al. 2004), thoracic blood vessels of 
Malawian children with CM (Clark et al. 2003), and in peripheral blood from Zambian children 
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 with acute malaria (McDevitt et al. 2006).  However, we have recently shown that circulating 
MIF concentrations and peripheral blood leukocyte (PBL) MIF transcripts are suppressed in 
Gabonese children with mild-to-moderate forms of malarial anemia and hyperparasitemia 
(Awandare et al. 2006b), and in Kenyan children with SMA (Awandare et al. 2007b).   
To further define the role of MIF in the immunopathogenesis of malaria, we investigated 
the impact of polymorphic variability at MIF -173 on susceptibility and clinical outcomes of 
severe malaria, and MIF production.  To accomplish these experimental objectives, we 
performed a cross-sectional, case-control study in a large population of infants and young 
children with acute malaria (cases) and healthy, aparasitemic individuals (controls).  Results 
presented here describe the relationship between MIF -173 variants and susceptibility to HDP 
(≥10 000 parasites/μL) and SMA (hemoglobin, Hb<6.0 g/dL).  In addition, we describe the 
functional association between MIF -173 genotypes and circulating MIF levels in children with 
and without malaria, and MIF production in cultured peripheral blood mononuclear cells 
(PBMC) stimulated with malarial pigment (hemozoin, pfHz).    
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 5.1.4 Study participants and methods 
5.1.4.1 Study site.  
Study participants (n=477) were recruited at the pediatric ward of the Siaya District Hospital 
(SDH), Nyanza Province, western Kenya.  P. falciparum transmission in this region is 
holoendemic with entomological inoculation rates of 100-300 infective bites per annum (Beier et 
al. 1994).  Common clinical presentations of severe P. falciparum malaria at SDH include HDP 
and SMA, with CM occurring only in rare cases (Lackritz et al. 1992; Ong'echa et al. 2006).  
This area provides a homogenous population for investigating genetic associations with disease 
susceptibility since >99% of the inhabitants belong to the Luo ethnic group (Ong'echa et al. 
2006). Additional detail on the study location and manifestations of malaria in the study cohort 
are presented in our recent publication (Ong'echa et al. 2006).   
5.1.4.2 Study participants.   
Study participants (aged 3-36 mos) were enrolled after obtaining written, informed consent from 
the parents/guardians.  The study was approved by the Ethics Committees of the Kenya Medical 
Research Institute and the University of Pittsburgh Institutional Review Board.  Malaria cases 
(n=363) were recruited from children presenting at SDH for their first hospital contact for the 
treatment of malaria.  Children attending SDH for routine childhood immunizations, free of 
malaria parasites, afebrile and without history of diarrhea for at least two weeks were enrolled as 
healthy, aparasitemic controls (AC, n=114).  All children were from the Luo ethnic group.  HDP 
was defined using 10 000 parasites/μL as cut-off as per previous studies from the same 
geographic location (Aidoo et al. 2002), and elsewhere (Zhong et al. 2005).   SMA was defined 
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 as Hb<6.0 g/dL with any parasite density based on previous investigations examining over 10 
000 repeated Hb measurements in an age- and geographically-matched cohort from the region of 
western Kenya where the present studies were conducted (McElroy et al. 2000). Only children 
infected with the P. falciparum species were included in this study; those with detectable P. 
ovale or P. malariae species were excluded from this study.  None of the study participants had 
CM.  Children with prior hospitalizations for any cause were excluded from the study.   
5.1.4.3 Laboratory evaluation.   
Giemsa-stained thin and thick blood smears were used for determination of parasitemia.  The 
number of asexual parasites per 300 leukocytes was obtained and parasites/μL calculated as 
described previously (Planche et al. 2001).  Hb concentrations were determined using a 
Hemocue® system (Hemocue AB, Angelholm, Sweden).  HIV-1 status was determined using 
two serological methods [UnigoldTM (Trinity Biotech, USA) and DetermineTM (Abbott 
Laboratories, USA)], and positive serological results were confirmed by proviral DNA PCR as 
described previously (Otieno et al. 2006).  All parents/guardians of the study participants 
received pre- and post-test HIV/AIDS counseling.  None of the study participants were receiving 
antiretroviral drugs at the time of enrollment.  Sickle-cell status was determined by alkaline 
cellulose acetate electrophoresis on Titan III plates (Helena BioSciences, UK) according to the 
manufacturers’ recommendations. 
5.1.4.4 Determination of plasma MIF.   
Before administration of antimalarials and/or any other treatment interventions, venous blood 
(<3 mL: a volume determined to be safe based on size, weight, and anemia status) was obtained 
from each study participant as described previously (Ong'echa et al. 2006).  Concentrations of 
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 MIF in plasma and culture supernatants were determined using an enzyme-linked 
immunosorbent assay (ELISA) with a matched anti-MIF antibody pair (R&D systems, USA).  
All samples were assayed at 1:5 and 1:10 dilutions in duplicate, and assays were performed 
according to manufacturer’s recommendations with the limit of detection >62.5 pg/mL.   
5.1.4.5 Genotyping.   
Blood spots were collected on FTA Classic® cards (Whatman Inc., USA) and stored at ambient 
temperature until DNA isolation.  DNA was extracted using the Gentra System (Gentra System 
Inc., USA).  The MIF-173 G/C SNP was genotyped using a Taqman® 5’ allelic discrimination 
Assay-By-Design method (rs755622, Applied Biosystems, USA).  The primer sequences were 
5’-CGATTTCTAGCCGCCAAGTG-3’ (forward) and 5’- AGCAACCGCCGCTAAGC-3’ 
(reverse) while the Taqman "minor groove binder" (MGB) probe sequences were (VIC)5’-
AGAACAGGTTGGAGCG-3’ and (FAM)5’- AGAACAGCTTGGAGCG-3’.  PCR was 
performed in a total volume of 5 µL with the following amplification protocol: 95°C for 10 
minutes, (95°C for 15 seconds, 60°C for 1 minute) × 40 cycles.  Following PCR, the genotype of 
each individual was assigned by measuring allelic specific fluorescence on the ABI Prism® 
7900HT sequence detection system using the SDS 2.1® software for allelic discrimination 
(Applied Biosystems, USA).  To validate results obtained with the Taqman® real-time 
genotyping assays, ~10% of the samples were randomly selected and genotyped using restriction 
fragment length polymorphism (RFLP) PCR as described previously (Donn et al. 2001).  There 
was 100% concordance between the two methods for the samples tested using both methods. 
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 5.1.4.6 PBMC cultures.   
PBMC were isolated from venous blood obtained from healthy, U.S donors using Ficoll-
Hypaque as described previously (Weinberg et al. 1981).   To ensure complete removal of RBCs, 
PBMC were treated with RBC lysis buffer (BioWhittaker, USA) for 5 mins and then washed 
prior to culture.  pfHz was isolated from P. falciparum (PfD6) parasites cultivated on type O+ 
RBCs as described in our previous report (Keller et al. 2004b).   The pfHz preparation was tested 
for the presence of endotoxin using Limulus amebocyte lysate test (LAL, BioWhittaker, USA), 
and endotoxin levels were found to be <0.125 U/mL (i.e., <0.025 ng/mL).  PBMC were plated at 
1 × 106 cells/mL in Dulbecco’s modified Eagles medium (DMEM) containing HEPES buffer 
(25mM), penicillin (100 U/mL)/streptomycin (100 μg/mL) and 10% heat inactivated human 
serum from a non-malarious region, and stimulated with media alone (unstimulated control) or a 
physiological concentration of pfHz (10 μg/mL) as described previously (Keller et al. 2004b).  
5.1.4.7 Statistical analyses.   
Kruskal-Wallis tests were used to compare variables across three or more groups, and where 
significant differences were observed, Mann-Whitney U tests were conducted for pairwise 
comparisons.  To determine associations between MIF -173 genotypes and disease severity, 
multivariate logistic regression analyses were conducted for each clinical definition (i.e., 
presence of parasitemia, HDP, and SMA) using a model that controlled for age, sex, HIV-1 
status [which included both HIV-1 exposed and HIV-1 PCR(+) results], and sickle-cell trait.  
Statistical significance for all analyses was determined using a critical alpha value of 0.05. 
  142
 5.1.5 Results 
5.1.5.1 Clinical and parasitological characteristics of study participants.   
Previous studies in Zambian children illustrate that variability at MIF -794 is associated with 
parasitemic outcomes in children with acute malaria (Zhong et al. 2005).  To investigate the role 
of variability at MIF -173 in influencing susceptibility and outcomes of parasitemia, children 
(n=477; age, 3-36 mos) presenting at a rural hospital with acute malaria or for routine 
immunizations were stratified according to parasite density: aparasitemic controls (AC, n=114), 
low-density parasitemia (LDP, <10 000 parasites/μL; n=127), and high-density parasitemia 
(HDP, ≥10 000 parasites/μL; n=236).  The clinical and parasitological characteristics of the 
study participants upon admission are summarized in Table 6.  There were no significant 
differences in gender distribution among the groups (P=0.687).  Age was significantly different 
across the groups (P<0.05), largely because children in the AC group were significantly younger 
than those with HDP (P<0.01); the differences in age between the LDP and AC (P=0.144) or 
HDP (P=0.236) groups were not significant.  Axillary temperature differed across the groups 
(P<0.0001), with children in the HDP group having significantly higher temperatures than those 
with LDP (P<0.005).  In addition, Hb concentrations were significantly different across the three 
groups (P<0.001).  Children with LDP had lower Hb levels than the HDP group, however, these 
differences did not reach statistical significance (P=0.061).  Despite the large disparity in 
parasite densities between LDP and HDP groups, the proportions of children with SMA (Hb<6.0 
g/dL) in these two groups were not significantly different (P=0.669).  These results illustrate that 
concomitant peripheral parasite density and SMA are largely independent in children presenting 
at hospital in this holoendemic area of P. falciparum transmission.       
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 5.1.5.2 Distribution of MIF -173 genotypes.   
The genotypic distribution of the MIF -173 G/C polymorphism in aparasitemic controls (n=114) 
and children with acute malaria (n=363) is shown in Table 7.  In the 477 children examined, 19% 
were GG, 43% were GC, and 38% were CC, representing a significant departure from Hardy 
Weinberg equilibrium (HWE; χ2=6.01, P<0.01).  Proportions of children with malaria from each 
genotypic group were 80% GG, 78% GC, and 72% CC.  The genotypic distribution in 
aparasitemic controls was 16%, 38%, and 46% for the GG, GC, and CC, respectively.  
Frequencies of the G and C alleles were 0.35 and 0.65 in aparasitemic controls with no departure 
from HWE (χ2=2.70, P=0.10).  Among children with acute malaria, there were 20% GG, 44% 
GC, and 36% CC yielding G and C allele frequencies of 0.42 and 0.58, respectively.  There was 
no significant evidence of departure from HWE (χ2=3.29, P=0.075).  Chi-squared analysis 
revealed that there was also no significant difference in the frequency distribution of the MIF -
173G/C polymorphism in cases compared to controls (χ2=2.10, P=0.349).                
5.1.5.3 Association of MIF -173 genotypic variants with malaria disease outcomes.   
The association between variation at MIF -173 and malaria disease severity was determined by 
multivariate logistic regression analyses.  Parasitemia (P. falciparum-positive blood smear), 
HDP, and SMA were the primary disease outcomes, controlling for age, gender, and sickle-cell 
status.  Since our recent studies also demonstrate that both HIV-1 exposure and HIV-1 virus 
increase the risk of developing SMA in the current study cohort (Otieno et al. 2006), HIV-1 
status was also controlled for in the analyses.  Relative to homozygous G alleles, the GC and CC 
genotypes were 10% (P=0.861) and 30% (P=0.257) less likely to have parasitemia, respectively 
(Table 8).  However, among parasitemic children, the GC and CC genotypes were associated 
with a 70% (P=0.065) and 90% (P=0.039) increased risk of developing HDP, respectively, 
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 relative to the GG group (Figure 19 and Table 8).  Analyses of the relationship between the MIF 
-173 polymorphism and SMA (Hb<6.0 g/dL) revealed that children in the GC group had a 30% 
(P=0.307) reduced risk of developing SMA compared to those with the GG genotype, while 
homozygous C alleles had no impact on the development of SMA in parasitemic children 
(P=0.960; Figure 19 and Table 8).  Additional analyses conducted using the WHO definition of 
SMA (i.e., Hb<5.0 g/dL) (WHO 2000) also failed to yield any significant associations between 
MIF -173G/C polymorphism and SMA (GC vs. GG, P=0.707 and CC vs. GG, P=0.967).  Taken 
together, these findings illustrate that the MIF -173 G/C polymorphism is associated with 
increased susceptibility to HDP, but not SMA, consistent with data presented above (Table 6) 
demonstrating that parasite density and anemia severity are not significantly associated in this 
holoendemic P. falciparum transmission area.   
5.1.5.4 Functional relationship between MIF -173 G/C polymorphism and circulating MIF 
levels.   
To examine the functional relationship between the polymorphism and plasma MIF 
concentrations, aparasitemic controls (n=114) and children with acute malaria (n=363) were 
analyzed separately since the presence of parasitemia can alter circulating MIF levels (Awandare 
et al. 2006b; Awandare et al. 2007b).  Among aparasitemic controls, plasma MIF levels were 
significantly different across the genotypic groups (P<0.05, Figure 20).  Relative to homozygous 
G alleles [median (interquartile range), 2179 (1452 – 9341) pg/mL], median circulating MIF 
concentration was 1.9 times higher in the GC group [4145 (2822 – 6288) pg/mL, P<0.05] and 
1.7 times elevated in the CC group [3701 (2142 – 5747) pg/mL, P=0.322; Figure 20).  However, 
peripheral blood MIF concentrations in children with acute malaria were not significantly 
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 different across the genotypic categories [GG, 4347 (2421 – 7199) pg/mL; GC, 3915 (2045 – 
5930) pg/mL; CC, 4085 (2704 – 5936) pg/mL; P=0.291, Figure 20].  
5.1.5.5 Influence of MIF -173 G/C polymorphism on MIF production in pfHz-stimulated 
PBMC.   
Several studies from our laboratory and others have demonstrated that phagocytosis of pfHz is 
associated with cytokine, chemokine and effector molecule dysregulation in vivo (Luty et al. 
2000; Chaisavaneeyakorn et al. 2002; Perkins et al. 2003; Awandare et al. 2007b), and 
stimulation of macrophages or PBMC with pfHz in vitro elicits a cytokine/chemokine/effector 
molecule production profile similar to that observed during malaria infection (Pichyangkul et al. 
1994; Sherry et al. 1995; Arese and Schwarzer 1997; Keller et al. 2004a; Keller et al. 2004b; 
Ochiel et al. 2005; Keller et al. 2006a; McDevitt et al. 2006).  Therefore, to further examine the 
functional significance of variation at MIF -173, PBMC were cultured from healthy malaria-
naïve U.S. individuals with differing genotypes and stimulated with pfHz.  As shown in Figure 
21, stimulation with physiological concentrations of pfHz (Keller et al. 2004b) significantly 
increased MIF production in individuals with homozygous G alleles (P<0.05), while treatment 
with pfHz significantly decreased MIF production in heterozygous individuals (P<0.05, Figure 
21).  Individuals with homozygous C alleles were not available for these analyses.  Taken 
together, these results demonstrate that variation at MIF -173 is associated with differential MIF 
production in response to malaria parasite products.   
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 5.1.6 Discussion 
This study presents the first report on the association between the MIF -173 G/C polymorphism 
and susceptibility to severe malaria.  Distribution of the MIF -173 polymorphism in the Kenyan 
cohort examined here parallels studies in Zambian children showing a higher frequency of the C 
allele (Zhong et al. 2005).  Distribution of the C and G alleles, therefore, differs substantially 
between sub-Saharan African ethnic groups and Caucasian populations in which the G allele is 
most prevalent (Donn et al. 2001; Donn et al. 2002).  Differences in allelic frequencies across 
populations may be due to selective pressure from infectious diseases, such as malaria, that have 
historically occurred in certain climates and not in others.  Consistent with a role of MIF in 
conditioning outcomes to infectious diseases (Bacher et al. 1996; Juttner et al. 1998; Bozza et al. 
1999; Calandra et al. 2000; Koebernick et al. 2002; Calandra and Roger 2003), multivariate 
modeling revealed that the CC genotype was significantly associated with an increased risk of 
HDP, while heterozygosity was associated with a moderately higher risk of developing HDP.  
However, there was no association between MIF -173 genotypes and SMA, supporting the 
observation that malarial anemia and parasite burden are not significantly related in this cohort of 
children.  Results presented here showing that parasitemia and the severity of malarial anemia 
are largely unrelated upon presentation at hospital are consistent with previous studies showing 
that parasite density during the preceding three months, rather than concomitant parasitemia, 
predicts the risk of developing childhood SMA in western Kenya (McElroy et al. 2000).   The G 
to C transition at MIF -173 creates a potential transcription factor binding site for activator 
protein (AP)-4, suggesting that polymorphic variability at -173 could functionally alter MIF 
production (Donn et al. 2002).  Cloning of a portion of the MIF gene (-775 to +84; excluding the 
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 CATT repeat at -794) into a luciferase reporter vector demonstrated that the -173C promoter was 
more active in CEM C7A (lung epithelial) cells, while the -173G promoter had the highest 
activity in A549 (T lymphoblast) cells (Donn et al. 2002).  These results illustrate the complex 
relationship between MIF promoter variants and regulation of MIF production.  Examination of 
the functional association between variability at MIF -173 and circulating MIF levels revealed 
that the C allele was correlated with increased peripheral blood MIF concentrations in 
aparasitemic controls.  These results parallel previous studies in individuals with chronic 
inflammatory diseases in which the C allele was associated with increased serum MIF 
concentrations (Donn et al. 2002; Donn et al. 2004).  Circulating MIF levels, however, were not 
significantly different across the genotypic groups with acute malaria.  Of interest, when MIF 
levels were compared between aparasitemic controls and acute malaria cases (Figure 2), 
homozygous G alleles were associated with a nearly two-fold increase in MIF levels in 
parasitemic children, whereas the GC and CC genotypes had similar MIF concentrations in cases 
and controls.  We hypothesize that despite lower baseline MIF production in the GG group, their 
ability to mount a potent MIF response may aid in controlling parasitemia.  This hypothesis is 
supported by the finding that homozygous G alleles were associated with a decreased risk of 
developing HDP.  
We have previously shown that stimulation of PBMC with pfHz or synthetic hemozoin 
(sHz) (Awandare et al. 2007b) suppresses MIF production, while others have demonstrated that 
sHz increases PBMC MIF production with specific variants of the MIF -794 polymorphism (5-
CATT/5-CATT, 6-CATT/6-CATT and 6-CATT/7-CATT) (McDevitt et al. 2006).  However, the 
influence of variation in the MIF gene on MIF production was not determined in our previous 
studies.  Data presented here demonstrate a dichotomous pattern of MIF responses in PBMC 
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 stimulated with pfHz; GG individuals had increased MIF production, while GC individuals had 
decreased MIF production, suggesting that the pattern of MIF production during malaria is 
largely influenced by variation at MIF -173.  Identical results were obtained using sHz (data not 
shown), suggesting that the core ferriprotoporphorin IX structure of hemozoin is responsible for 
altering MIF production, rather than adherent host or parasite-derived proteins, lipids, or nucleic 
acids.  It remains to be determined how individuals with homozygous C alleles at MIF -173 
respond to challenge with malarial pigment since these individuals were not available for 
analyses, largely because of the low frequency of this genotype in Caucasian populations (Donn 
et al. 2001; Donn et al. 2002).  
Several studies have demonstrated linkage disequilibrium between the MIF -173 SNP 
and the upstream MIF -794 CATT repeat polymorphism, with haplotypes of the two 
polymorphic sites being strongly associated with functional gene expression and susceptibility to 
inflammatory disease (Donn et al. 2002; Donn et al. 2004; Hizawa et al. 2004).  Therefore, 
although not examined in this study, it is possible that some of the relationships between the MIF 
-173 SNP and malaria disease severity, as well as MIF production may be influenced by the 
upstream CATT repeat polymorphism.  Previous results in reporter constructs, however, 
demonstrate that variation at -173 alters MIF production in the absence of the -794 CATT 
polymorphism (Donn et al. 2002), suggesting that effects of variation at the two sites may be, at 
least in part, independent.  
Taken together, results presented here illustrate that variation at MIF -173 is associated 
with functional differences in MIF production and susceptibility to severe malaria.  These data 
further illustrate that MIF -173 variants that confer protection against HDP are also associated 
with increased MIF production in response to stimulation by malaria parasite products (pfHz).  
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 Given the critical role of MIF in mediating protective immune responses to other infections, 
including Salmonella typhii (Koebernick et al. 2002) and Leishmania major (Juttner et al. 1998), 
a potent MIF response may be required for effective control of parasitemia during malaria.  Since 
recent studies illustrate that variation in the MIF -794 tetranucleotide repeat is associated with 
susceptibility to HDP in Zambian children (Zhong et al. 2005), we are currently examining the 
haplotypic distributions of MIF -173 and MIF -794 polymorphisms to obtain additional insight 
into the role of genetic variation in the MIF gene in conditioning malaria disease outcomes. 
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 Table 6: Demographic, parasitological, and hematological characteristics of study 
participants. 
 
Characteristic AC LDP HDP P 
Number (n) 114 127 236  
Gender (n, %)     
    Female 57 (50) 60 (47) 120 (51) 
    Male 57 (50) 67 (53) 116 (49) 
0.687a
Age (mos) 10.6 (0.8) 11.0 (0.5) 11.5 (0.4)b 0.033c
Axillary temperature (ºC) 37.1 (0.1) 37.3 (0.1) 37.8 (0.1) 0.0001c
Parasitemia (/μL) 0 3,584 (222) 56,652 (2 869) <0.0001d
Geomean parasitemia (/μL) 0 1,998 39,756 <0.0001e
Hemoglobin ( g/dL)  9.9 (0.2) 6.8 (0.2) 7.2 (0.1)b <0.001c
SMA (n, %)  NA 47 (37.4) 84 (35.5) 0.669a
 
 
Data are presented as mean (SEM) except otherwise indicated.  
aChi-Square test;  bnot significantly different from LDP group; cKruskal-Wallis test; dMann-
Whitney U test for HDP vs. LDP;  eStudent’s t test for HDP vs. LDP.  
AC, aparasitemic controls (P. falciparum-negative); LDP, low-density parasitemia (<10,000 
parasites/μL); HDP, high-density parasitemia (≥10,000 parasites/μL); and SMA, severe malarial 
anemia (Hb<6.0 g/dL); NA, not applicable. 
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 Table 7: Genotypic distribution of the MIF -173G/C polymorphism. 
 
 
MIF -173 
Genotype 
Aparasitemic controls   
n (%) 
Malaria cases    
n (%) 
Total        
n (%)          
GG 18 (16) 72 (20) 90 (19) 
GC 44 (38) 160 (44) 204 (43) 
CC 52 (46) 131 (36) 183 (38) 
 n = 114 n = 363 n=477 
 P(G) = 0.35 P(G) = 0.42 P(G)=0.40 
 
 
P(G) = frequency of G allele. 
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 Table 8:  Association of MIF -173G/C polymorphism with disease susceptibility and severity. 
 
Parasitemia  
(P. falciparum +) 
HDP  
(≥10,000 parasites/μL) 
SMA  
(Hb<6.0 g/dL) MIF -173 
Genotype 
OR 95% CI p OR 95% CI p OR 95% CI p 
GG 1.0   1.0   1.0   
GC 0.9 0.5-1.8 0.861 1.7 1.0-3.1 0.065 0.7 0.4-1.3 0.307 
CC 0.7 0.4-1.3 0.257 1.9 1.1-3.5 0.039 1.0 0.6-1.9 0.960 
 
 
Data presented are results of multivariate logistic regression analyses controlling for age, gender, 
HIV-1 status, and sickle-cell status.  OR, odds ratio; CI, confidence interval. 
Association between MIF -173 genotypes and susceptibility to malaria infection (P. falciparum-
positive blood smear) was examined in 477 children consisting of 114 aparasitemic controls and 
363 malaria cases.  Analyses of relationships between MIF -173 genotypes and high-density 
parasitemia (HDP, ≥10 000 parasites/μL), and severe malarial anemia (SMA, Hb<6.0 g/dL) were 
performed in parasitemic children only (n=363).  The GG genotype was used as reference for 
these analyses since this genotype was considered wild type in previous studies (Donn et al. 
2001; Donn et al. 2002).   
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Figure 19: Proportion of high-density parasitemia and severe malarial anemia stratified 
according to MIF -173 G/C genotype.  
Proportion of malaria cases with high-density parasitemia, HDP (≥10 000 parasites/μL) and severe malarial anemia, 
SMA (Hb<6.0 g/dL) are presented for each MIF -173 genotypic category (GG, n=72; GC, n=160; CC, n=130). 
*Significantly higher compared to the GG group (P<0.05), Chi-square test.  
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Figure 20: Circulating MIF levels in the MIF -173 G/C genotypic categories. 
Plasma levels of MIF in aparasitemic controls (GG, n=14; GC, n=32; CC, n=35) and malaria cases (GG, n=50; GC, 
n=124; CC, n=102) were measured by ELISA and are presented according to MIF -173 genotype.  Boxes represent 
the interquartile range, the line through the box represents the median, whiskers illustrate the 10th and 90th 
percentiles, and symbols represent outliers.    *Differences between groups were statistically significant by Mann-
Whitney U test (P<0.05).   
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Figure 21: MIF production in pfHz-stimulated PBMC in the MIF -173 G/C genotypic 
categories. 
PBMC obtained from healthy, U.S donors with the GG (n=3) and GC (n=3) genotypes at MIF -173 were stimulated 
with media alone (Con) or a physiological concentration of pfHz (10 μg/mL).  MIF concentrations were determined 
by ELISA in culture supernatants after 48 hours of incubation and are expressed as percent of Con.  Data are 
presented as mean (SEM) for n=3 donors per genotypic group. *P<0.05 compared to Con, Student’s t test. 
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 5.2 HYPOTHESES 1 AND 2, PRESENTATION OF MANUSCRIPT ENTITLED:  
MACROPHAGE MIGRATION INHIBITORY FACTOR PROMOTER HAPLOTYPES ARE 
ASSOCIATED WITH SUSCEPTIBILITY TO SEVERE MALARIAL ANEMIA IN 
CHILDREN. 
Hypothesis 1: MIF -173 and -794 variants that are associated with decreased MIF production 
also condition increased susceptibility to SMA.   
Hypothesis 2: Haplotypes of the MIF -173 and -794 polymorphisms are stronger predictors of 
SMA susceptibility and MIF production levels than either polymorphism alone.  
 
To address the second part of hypothesis 1, the MIF -794 CATT repeat polymorphism was also 
examined in the cohort of Kenyan children for whom the MIF -173 SNP had been analyzed.  The 
role of variation at MIF -794 alone in conditioning susceptibility to HDP and SMA and in 
influencing peripheral blood MIF production was investigated. In addition, hypothesis 2 was 
addressed by constructing haplotypes of the MIF -794 and -173 polymorphisms using genotypic 
data from the loci.  The relationships between MIF promoter haplotypes, susceptibility to SMA 
and HDP, and MIF production were then determined.  The results of these investigations are 
presented in the following unpublished manuscript. 
  
Gordon Awandare1, 3, 4, Jeremy Martinson1, Collins Ouma3, Greg Davenport1, John Michael 
On’gecha3, Robert Ferrell2, Richard Bucala5, and Douglas Perkins1, 3 
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 5.2.1 Abstract 
Severe malarial anemia (SMA), caused by Plasmodium falciparum infections, is one of the 
leading causes of childhood mortality in sub-Saharan Africa.  Recent studies demonstrate that 
SMA in associated with dysregulated production of the innate immune mediator macrophage 
migration inhibitory factor (MIF).  In addition, we have shown that a functional single nucleotide 
polymorphism (SNP) at -173 (G/C) of the MIF promoter is associated with increased 
susceptibility to high density parasitemia (HDP). However, the role of a second functional MIF 
promoter polymorphism, a CATT5-8 repeat polymorphism at -794, in malarial pathogenesis is 
largely unknown.  To further investigate the influence of MIF genetic variation on susceptibility 
to SMA, haplotypes of -173 (G/C) and -794 (CATT5-8) polymorphisms were examined in a 
cohort of Kenyan children (aged 3-31 mos; n=560) residing in a P. falciparum holoendemic 
transmission area. Multivariate regression analyses, controlling for age, gender, HIV-1 status and 
sickle cell trait revealed that individuals with the MIF -794CATT6/-173G (6G) haplotype were 
significantly protected from SMA, while carriers of the 7C or 8C haplotypes had a significantly 
increased risk of developing SMA. Functional analyses demonstrated that carriers of the 7C or 
8C haplotypes had significantly lower basal circulating MIF and decreased peripheral blood 
mononuclear cell (PBMC) MIF production during malaria infection.  Taken together, our 
findings demonstrate that genetic variation in the MIF promoter functionally influences 
peripheral MIF production and susceptibility to SMA in children.   
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 5.2.3 Introduction 
Plasmodium falciparum malaria accounts for 1-2 million deaths annually (WHO 2005).  Over 
75% of P. falciparum-related mortality occurs in sub-Saharan Africa, where malaria accounts for 
18% of all deaths in children less than 5 years of age (WHO 2005).  Life-threatening 
complications in children with falciparum malaria include: cerebral malaria (CM), high-density 
parasitemia (HDP), respiratory distress, and severe malarial anemia (SMA) (Marsh et al. 1995; 
Mockenhaupt et al. 2004; Awandare et al. 2006a). Clinical presentations of pediatric severe 
malaria vary markedly across regions with differing transmission intensities, with CM primarily 
occurring in lower transmission regions and SMA being most prevalent in holoendemic areas 
(Snow et al. 1997).  However, differences in disease severity among children of similar ages, 
residing in a given transmission area are likely due to variation in the host immune response that 
is conditioned by genetic factors. 
Our previous studies, as well as those of others, demonstrate that the nature and 
magnitude of innate immune mediator production (Perkins et al. 2000; Keller et al. 2004b; 
McDevitt et al. 2004; Awandare et al. 2006a),  and genetic variation in host immune response 
genes (Kwiatkowski 2005) are important determinants of the development and outcomes of 
severe malaria.   Since macrophage migration inhibitory factor (MIF) is a central regulator of 
innate immune responses to bacterial and parasitic infections (Juttner et al. 1998; Bozza et al. 
1999; Calandra et al. 2000; Koebernick et al. 2002; Calandra and Roger 2003; Reyes et al. 
2006), investigations in our laboratory have focused on the role of MIF in malarial pathogenesis. 
Although studies in murine models of malaria suggest that increased MIF production causes 
suppression of erythropoiesis and development of SMA (Martiney et al. 2000; McDevitt et al. 
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 2006), we have recently shown that circulating MIF concentrations progressively decline with 
increasing anemia severity in Kenyan children with falciparum malaria (Awandare et al. 2007b).  
These results are consistent with our previous findings in Gabon  (Awandare et al. 2006b) and 
results by Thuma et. al., (Thuma 2006) showing that peripheral blood MIF levels are 
significantly lower in children with acute malaria relative to healthy controls. 
    Of potential importance for influencing patterns of MIF expression and disease 
severity in children with malaria is genetic variation in the MIF promoter.  A tetranucleotide 
short tandem repeat polymorphism (STRP), MIF-794 CATT5-8, and a single nucleotide 
polymorphism (SNP), MIF-173G/C, functionally influence susceptibility and severity to 
inflammatory diseases, including arthritis, atopy, lung disease, and scleroderma (Donn et al. 
2001; Baugh et al. 2002; Donn et al. 2002; Barton et al. 2003; Donn et al. 2004; Renner et al. 
2005).  In general, longer CATT repeats (>5) at -794 and the -173 C allele are associated with 
elevated MIF production and increased susceptibility to inflammatory diseases (Donn et al. 
2001; Baugh et al. 2002; Donn et al. 2002; Barton et al. 2003; Donn et al. 2004; Radstake et al. 
2005), however, other investigations have observed an opposite pattern of MIF production and 
disease susceptibility (Donn and Ray 2004; Miterski et al. 2004). A previous study in Zambian 
children revealed that carriers of >5 CATT repeat alleles at -794 had a higher risk of developing 
HDP relative to those with the 5-repeat allele (Zhong et al. 2005). In addition, our recent 
investigation in a large cohort of Kenyan children demonstrated that a CC genotype at -173 were 
associated with an increased susceptibility to HDP (Awandare et al. 2006c).  Although several 
studies have demonstrated linkage disequilibrium between the polymorphisms at MIF -794 and -
173, with haplotypes of the two loci being stronger predictors of disease risk than either one 
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 alone (Donn et al. 2002; Barton et al. 2003; Donn et al. 2004; Hizawa et al. 2004), the role of 
MIF promoter haplotypes in SMA pathogenesis has not been reported. 
To comprehensively investigate the relationship between MIF promoter polymorphisms 
and SMA pathogenesis, we examined the MIF -794 STRP in the cohort of children in whom we 
recently analyzed the MIF -173 SNP (Awandare et al. 2006c), and constructed haplotypes for the 
two loci.  Data presented here show the relationship between malaria disease severity and the -
794 STRP, independent of the -173 SNP.  In addition, we demonstrate for the first time, an 
association between MIF -794 and -173 haplotypes, susceptibility to SMA, and peripheral blood 
MIF production.  
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 5.2.4 Study participants and methods 
5.2.4.1 Study site.   
This study was conducted as part of an ongoing study at the Siaya District Hospital (SDH), 
Nyanza Province, western Kenya, examining the genetic and immunological basis of pediatric 
SMA (Ong'echa et al. 2006).  Siaya district is an equatorial community with holoendemic P. 
falciparum transmission area where residents receive up to 300 infective mosquito bites per 
annum (Bloland et al. 1999; Ong'echa et al. 2006).  The prevalence of falciparum infection is 
83% in children 1 to 4 years of age in this region, with SMA and HDP being the primary clinical 
manifestations of severe childhood malaria  (Bloland et al. 1999; Ong'echa et al. 2006).  A more 
detailed demographic and clinical description of pediatric malarial anemia in this area is 
presented in our recent publication (Bloland et al. 1999; Ong'echa et al. 2006).   
5.2.4.2 Study participants.   
Children under three years of age (n=540) presenting at the SDH with acute malaria or for 
routine immunizations were recruited into the study.  All of the study participants were from the 
Luo ethnic group (Ong'echa et al. 2006), thus providing a homogenous population for the genetic 
studies.  After obtaining written informed consent from the parents/guardians, finger-prick blood 
was collected from study participants for determination of parasitemia and hemoglobin (Hb) 
levels.  Febrile children with detectable P. falciparum parasitemia (acute malaria, n=406) were 
categorized into two groups according to their anemia status: non-SMA (Hb≥6.0 g/dL, n=271), 
and SMA (Hb<6.0 g/dL, n=135).  The definition of SMA was based on the distribution of 
anemia determined by >10,000 longitudinal Hb measurements in age- and sex-matched children 
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 from the same geographic location (McElroy et al. 2000).  In addition, the definition of HDP 
(≥10,000 parasites/μL) was based on the distribution of parasitemia in the population determined 
in previous studies (Aidoo et al. 2002; Ong'echa et al. 2006).  Healthy children [aparasitemic 
controls (AC, n=134)] were defined as P. falciparum-negative blood smears and free from fever 
or other symptoms of malaria in the preceding two weeks prior to enrollment.  Exclusion criteria 
included those children co-infected with other species of Plasmodium, prior hospitalization or 
transfusion for any cause, and CM. 
5.2.4.3 Sample collection and laboratory evaluation.   
Prior to administration of anti-malarial therapy and supportive care, venous blood (<3 mL: a 
volume determined to be safe based on age, size, and anemia status) was collected into tubes 
containing anti-coagulant.  Peripheral blood smears prepared from venous blood were stained 
with Giemsa reagents and examined for Plasmodial parasites under oil immersion.  The number 
of parasites per 300 white blood cells (WBC) was determined, and parasitemia per/μL of blood 
was calculated using the total WBC count obtained from an automated hematology analyzer 
(Coulter® AcT diff2™, Beckman Coulter Corp.).    Venous blood was also used for a complete 
blood count, plasma preparation, HIV-1 testing, and where possible, isolation of peripheral blood 
mononuclear cells (PBMC).  Sickle-cell status was determined by alkaline cellulose acetate 
electrophoresis on Titan III plates (Helena BioSciences, UK) according to the manufacturers’ 
recommendations.  HIV-1 status was determined using two serological methods followed by 
proviral DNA PCR as described previously (Otieno et al. 2006).  All parents/guardians of the 
study participants received pre- and post-test HIV/AIDS counseling.   
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 5.2.4.4 Genetic analyses.   
Blood spots were collected on FTA Classic® cards (Whatman Inc., USA) and DNA was 
extracted using the Gentra System (Gentra System Inc., USA).  Genomic DNA was amplified 
using the GenomiPhi® system (GE Healthcare, Piscataway, NJ) to obtain sufficient quantities for 
genetic analysis.  Samples were genotyped for the MIF -794 STRP by amplifying a region of the 
MIF promoter containing the polymorphic site using a pair of flanking primers, one of which 
was pre-labeled with FAM fluorescent dye.  DNA (50 ng) was amplified in a total reaction 
volume of 25 μL containing 5 pmoles of each primer (forward: 5’-
TGCAGGAACCAATACCCATAGG-3’, reverse: FAM-5’-AATGGTAAACTCGGGGAC-3’) 
using the Supermix PCR system (Invitrogen, Carlsbad, CA) in a 96-well format on a PTC-100 
Peltier thermal cycler (BioRad, Hercules, CA).  Forty PCR cycles were carried out, each with 
denaturation for 30 sec at 95 oC, primer annealing for 30 sec at 54 oC, and extension for 60 sec at 
72 oC, followed by a final extension at 72 oC for 10 min. The PCR products (estimated size:  340-
352 bp) were diluted 1:10 with H2O and resolved by capillary electrophoresis.  Data were 
analyzed with Genemapper software.  Genotyping for the MIF -173 SNP was performed by 
Taqman® 5’ allelic discrimination (Applied Biosystems, USA) and restriction fragment length 
polymorphism PCR methods according to our previous methods (Awandare et al. 2006c).   
5.2.4.5 PBMC cultures.   
PBMC were isolated from venous blood using Ficoll-hypaque gradient as described previously 
(Weinberg et al. 1981).  Cells were cultured at a concentration of 1 x 106 cell/mL (2 x 105 
cells/well) in Dulbecco’s modified Eagles medium (DMEM) containing HEPES buffer (25mM), 
penicillin (100 U/mL)/streptomycin (100 μg/mL), and 10% heat inactivated human serum from 
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 malaria-naïve donors (Sigma, St Louis, MO).  Cultures were incubated in a humidified 
atmosphere with 5% CO2 and 5% O2.  Supernatants were harvested after 48 hrs of incubation 
and stored at -80 oC until use. 
5.2.4.6 Determination of MIF concentrations.   
MIF concentrations in plasma samples and culture supernatants were determined using an 
enzyme-linked immunosorbent assay (ELISA) with a matched anti-MIF antibody pair (R&D 
systems, Minneapolis, MN, USA) according to manufacturer’s recommendations. The limit of 
detection was >31.25 pg/mL.  
5.2.4.7 Statistical analyses.   
Comparison of variables across the three clinical groups (AC, non-SMA and SMA) were 
conducted using the Kruskal-Wallis test, and where significant differences were obtained, Mann-
Whitney U tests were used for pairwise comparisons. Differences in proportions of children 
within sub-groups, as well as frequencies of genotypes and haplotypes across clinical groups 
were compared using Chi-square analysis.  Circulating and culture supernatant MIF levels 
between groups were compared using Mann-Whitney U tests.  MIF promoter haplotypes were 
constructed from the -173 G/C and -794 CATTn genotype data by use of Bayesian Markov Chain 
Monte Carlo methods, as implemented in the PHASE software program (Stephens and Donnelly 
2003). Agreement with Hardy-Weinberg equilibrium was tested using the procedure of Guo and 
Thompson (Guo and Thompson 1992) as implemented in the software program Arlequin 
(Excoffier 2005). This program was also used to measure linkage disequilibrium between the -
173 and -794 loci, using a likelihood ratio test.  For analysis of association between disease and 
genetic variants, three primary outcomes were defined: presence of parasitemia, HDP, and SMA.  
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 Logistic regression analyses were conducted for each of these outcomes using 
genotype/haplotype, age, gender, sickle-cell trait, and HIV-1 status as independent predictors. 
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 5.2.5 Results 
5.2.5.1 Characteristics of study participants.   
Children (age: 3-32 mos) were categorized into three clinical groups: AC (n=134), non-SMA 
(n=271), and SMA (n=135).  The demographic, clinical, and parasitological characteristics of the 
children are shown in Table 9.  Differences in gender distribution across the groups were not 
statistically significant (P=0.610).  However, age differed significantly across the groups 
(P<0.001), with children in the non-SMA group being significantly older than those in the other 
two groups (P<0.001 for both comparisons).  Axillary temperature differed across the groups 
(P<0.001) and was significantly elevated in the acute malaria groups relative to the AC group 
(P<0.001 for both comparisons).  Hemoglobin, which was used in the categorization criteria, 
differed across the groups (P<0.001) as expected.  However, parasitemia, as well as percentage 
of children with HDP, did not significantly differ between the non-SMA and SMA groups 
(P=0.171, and P=0.262, respectively). 
5.2.5.2 Distribution of MIF -794 genotypes and alleles.   
Several studies have demonstrated significant associations of the MIF -794 STRP with various 
inflammatory diseases in Caucasian and Asian populations (Baugh et al. 2002; Barton et al. 
2003; Hizawa et al. 2004).  However, the role of this polymorphism in conditioning 
susceptibility to diseases in African populations remains largely unknown.  To investigate the 
association between variation in the MIF -794 CATT repeat and malarial pathogenesis, 
frequency distributions of the MIF -794 genotypes and alleles were determined in three groups of 
children: AC, non-SMA, and SMA.  The 5,5 genotype was the most frequent in all three groups 
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 (~ 26-34%), while the 5,8 and 8,8 were the rarest genotypes (<1%, Table 10).  The 5,6 genotype 
differed significantly across the groups (P=0.031) and was highest in the non-SMA group.  The 
most prevalent -794 allele in the clinical groups was the 5-repeat (~ 48-53%), while the 8-repeat 
had the lowest frequencies (0-2%, Table 10).  Frequencies of the 6-repeat allele differed 
significantly across the groups (P=0.044), with the non-SMA group having the highest frequency 
(Table 10), suggesting that this allele may be related to susceptibility to SMA.  
5.2.5.3 Distribution of MIF -794 genotypes and alleles.   
Several studies have demonstrated significant associations of the MIF -794 STRP with various 
inflammatory diseases in Caucasian and Asian populations (Baugh et al. 2002; Barton et al. 
2003; Hizawa et al. 2004).  However, the role of this polymorphism in conditioning 
susceptibility to diseases in African populations remains largely unknown.  To investigate the 
association between variation in the MIF -794 CATT repeat and malarial pathogenesis, 
frequency distributions of the MIF -794 genotypes and alleles were determined in three groups of 
children: AC, non-SMA, and SMA.  The overall distribution of -794 genotypes in the cohort 
showed significant departure from Hardy Weinberg equilibrium (HWE, P<0.01).  A similar 
departure from HWE was seen by us previously in these samples for the MIF -173 SNP 
(Awandare et al. 2006c), but not for SNPs in the IL-10, TNF-α, and IL-1β promoters (Perkins, 
unpublished data), suggesting that any departure from HWE in the MIF gene reflects gene-
specific events, and not a broader demographic feature of this population that would affect all 
loci.  The 5,5 genotype was the most frequent in all three groups (~ 26-34%), while the 5,8 and 
8,8 were the rarest genotypes (<1%, Table 10).  The 5,6 genotype differed significantly across 
the groups (P=0.031) and was highest in the non-SMA group (Table 10).  The most prevalent -
794 allele in the clinical groups was the 5-repeat (~ 48-53%), while the 8-repeat had the lowest 
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 frequencies (0-2%, Table 10).  Frequencies of the 6-repeat allele differed significantly across the 
groups (P=0.044), with the non-SMA group having the highest frequency (Table 10), suggesting 
that this allele may be related to susceptibility to SMA.  
5.2.5.4 Association of MIF -794 genotypes with disease.   
Based on the frequency distribution of the -794 repeat in our cohort (see Table 10), and previous 
studies demonstrating that an increasing number of CATT repeats are associated with enhanced 
susceptibility to inflammatory diseases (Baugh et al. 2002; Barton et al. 2003; Zhong et al. 
2005), children were divided into three genotypic groups: 5,5, 5,X, and X,X (where X represents 
alleles with >5 repeats).  To investigate the association of the CATT repeat with malaria disease 
outcomes, multivariate regression analyses were performed with outcome variables as 
parasitemia, HDP, and SMA, controlling for age, gender, sickle cell trait and HIV-1 status as co-
variates.  These analyses revealed that relative to individuals with the 5,5 genotype, there was a  
57% and 43% increase in the risk of parasitemia in children with 5,X and X,X genotypes 
(P=0.071 and P=0.179, respectively, Table 11).  The model further illustrated that there was no 
evidence of an association between genotypic groups and the risk of either HDP or SMA (Table 
11).  Taken together, these results suggest that an increasing number of CATT repeats at MIF -
794 may not be independently associated with malaria disease severity in children residing in a 
holoendemic transmission area. 
5.2.5.5 MIF promoter haplotypes.    
In addition to the MIF -794 genotypic analyses presented here, we recently demonstrated that 
variation at MIF -173 was associated with increased susceptibility to HDP in the current cohort 
of Kenyan children (Awandare et al. 2006c). Therefore, to investigate the impact of interactions 
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 between the -794 and -173 loci on susceptibility to severe malaria, haplotypes of the two 
polymorphic sites were constructed using the PHASE software.  In contrast to previous studies 
from other regions in which the 5C haplotype (i.e., -794 CATT5/-173 C) was rare (Barton et al. 
2003; Donn and Ray 2004; Hizawa et al. 2004), the most common haplotype in the cohort was 
5C, while the 8G haplotype had the lowest frequency (Table 12).  The distribution of haplotypes 
showed significant departure from HWE (P<0.001).   In addition, there was significant evidence 
of linkage disequilibrium between the -794 and -173 polymorphic sites (likelihood ratio χ2=42.4, 
P<0.001).  Of particular interest, the proportion of 5G to 5C and 6G to 6C differed ~2-fold, 
while there was a disproportionately higher prevalence of 7C and 8C relative to 7G and 8G (i.e., 
9-fold and 7-fold difference respectively, Table 12), suggesting potential interactions between 
the two polymorphic sites.  
5.2.5.6 Association of MIF promoter haplotypes with disease.   
To determine if MIF haplotypes were associated with susceptibility to malaria, PHASE software 
was used to analyze the relationship between haplotypes and primary disease outcome variables 
(i.e., parasitemia, HDP, and SMA).  These analyses revealed that MIF haplotypes were 
significantly associated with SMA (P=0.02), but not parasitemia status (P=0.22), or HDP 
(P=0.83).  Therefore, the association of MIF haplotypes with SMA was further examined by 
comparing the frequencies of individual haplotypes in the non-SMA vs. SMA groups to identify 
likely disease-associated haplotypes (Figure 22).  The frequency of the 6G haplotype was 
significantly under-represented (P=0.031), while 7C and 8C haplotypes were over-represented in 
the SMA group relative to children with non-SMA malaria (Figure 22), suggesting possible 
associations with susceptibility to SMA.  Additional analyses using a logistic regression model 
that controlled for the confounding effects of age, gender, sickle cell trait, and HIV-1 exposure, 
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 demonstrated that children with the 6G haplotype were 51% less susceptible to SMA relative to 
individuals without the haplotype (P=0.001, Table 13). Conversely, children with the 7C 
haplotype had a 48% increased risk of SMA relative to those without 7C although this difference 
did not reach statistical significance (P=0.132, Table 13).  However, when children with 7C or 
8C haplotypes were combined, they had a statistically significant 70% increased risk of SMA 
relative to children without 7C and 8C (P=0.035, Table 13).   Finally, since children with 
homozygous C at MIF -173 have a significantly increased susceptibility to HDP (Awandare et 
al. 2006c), it was of interest to know if the risk of SMA was further exacerbated in the subset of 
children with the -173 CC genotype who carried a 7C or 8C haplotype.  Indeed, risk of SMA was 
nearly 3-fold higher in this subset relative to all other children [odds ratio (95% confidence 
interval) = 2.90 (1.51-5.57), P=0.001], representing a further increase over the risk observed in 
the 7C/8C haplotype group as a whole.  Thus, genetic variation within the MIF promoter can 
both confer protection from SMA, or condition increased susceptibility to SMA in children 
infected with P. falciparum. 
5.2.5.7 Functional relationship between MIF haplotypes and MIF production.    
To investigate the functional significance of MIF promoter variation in influencing MIF 
production, the relationship between disease-associated MIF promoter haplotypes and peripheral 
blood MIF production was examined.  Since P. falciparum infection dysregulates MIF 
production (Martiney et al. 2000; Awandare et al. 2006b; McDevitt et al. 2006; Awandare et al. 
2007b), circulating MIF levels and PBMC MIF production in aparasitemic children and children 
with acute malaria were examined separately.  Circulating levels of MIF were not significantly 
different between children with and without the 6G haplotype in both the aparasitemic and acute 
malaria categories (P=0.473, and P=0.276 respectively, Figure 23A).  However, among 
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 aparasitemic children, the 7C/8C haplotype group had significantly decreased MIF levels relative 
to non-7C/8C children (P=0.049, Figure 23B).  Possession of the 7C or 8C haplotype did not 
significantly affect MIF levels in children with acute malaria (P=420, Figure 23B). 
 MIF production in cultured PBMC was also not significantly different in the 6G vs. non-
6G haplotype groups in both aparasitemic and acute malaria categories (P=0.773, and P=0.499 
respectively, Figure 24A). On the other hand, while there was no statistically significant 
difference in PBMC MIF production between children with and without 7C/8C in the 
aparasitemic category (P=0.910, Figure 24B), the 7C/8C haplotype was associated with 
significantly decreased MIF production in children with acute malaria (P=0.018, Figure 24B).  
Taken together, these data suggest that MIF promoter haplotypes associated with susceptibility 
to SMA appear to be functionally related to peripheral blood MIF production.  
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 5.2.6 Discussion 
We recently demonstrated that variation at MIF -173 was associated with susceptibility to HDP, 
but not SMA, in the cohort of Kenyan children examined here (Awandare et al. 2006c).  In the 
current study, a more comprehensive examination of the role of genetic variation in the MIF 
promoter on conditioning susceptibility to severe childhood malaria was conducted by analyzing 
the MIF -794 STRP, and by examining haplotypes of MIF -794 and -173.  Consistent with 
previous observations in Zambian children (Zhong et al. 2005), the 5-repeat was the most 
prevalent MIF -794 allele in the Kenyan cohort.  This distribution of -794 alleles differs from the 
patterns reported in Caucasian (Baugh et al. 2002) and Asian (Hizawa et al. 2004) populations, 
where the 6-repeat was predominant.  Thus, there appears to be significant regional variation in 
the distribution of the MIF -794 STRP as has been documented for the MIF -173 SNP  (Renner 
et al. 2005; Zhong et al. 2005; Awandare et al. 2006c).   
In holoendemic transmission areas, such as our current study site in western Kenya, 
nearly all of the children experience multiple clinical episodes of malaria during the first five 
years of life (Snow et al. 1997).  While a majority of these infected children present with only 
mild forms of malaria, others experience severe life-threatening complications that 
predominantly manifest as SMA (Ong'echa et al. 2006).  Therefore, identifying gene variants 
associated with susceptibility to severe disease is best accomplished by comparing the genetic 
backgrounds of P. falciparum-infected children who do not develop SMA versus those that 
present with SMA.  The impact of MIF promoter polymorphisms on susceptibility to SMA was 
investigated by examining MIF gene variants in three clinically distinct groups: healthy, 
aparasitemic controls; P. falciparum-infected children with non-SMA; and children with SMA.  
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 Results presented here demonstrate significant differences in frequencies of the 5,6 genotype, 
and the 6-repeat allele at MIF -794 across the clinical groups.  These differences primarily 
resulted from an increased representation of the 5,6 genotype and 6-repeat allele in the non-SMA 
group relative to the SMA group, suggesting that these variants may be associated with a 
decreased likelihood of developing SMA.  However, although a similar pattern was observed for 
the 6,6 genotype, the differences were not statistically significant, suggesting that the 
relationship of the 6-repeat allele with susceptibility to SMA should be interpreted with caution. 
To account for the confounding effects of other factors that influence the pathogenesis of 
SMA, additional multivariate regression analysis were conducted to control for age, gender, 
sickle-cell trait, and HIV-1 status.  For these analyses, the 5,5 genotype was used as a reference 
group since this genotype was the most frequent in the cohort, and because previous studies 
suggest that differences in disease susceptibility are related to carriage of the 5-repeat (Renner et 
al. 2005). Since data presented here, as well as our previous analyses (Awandare et al. 2006c; 
Ong'echa et al. 2006; Ouma et al. 2006; Awandare et al. 2007b), demonstrate that SMA is not 
significantly associated with parasite density, HDP and SMA were examined as separate 
outcome variables. These regression analyses failed to identify a relationship between the 
presence of >5-repeat alleles and susceptibility to either HDP or SMA.  However, there was a 
trend toward an increased likelihood of being parasitemic (any density) in children with >5-
repeat variants, suggesting that children with the 5,5 genotype may be less susceptible to P. 
falciparum infections.  Since the parasitemic status of children in areas of high transmission 
intensity is dynamic, longitudinal studies are required to definitively show an association 
between MIF genetic variants and susceptibility to infection over extended periods of exposure.    
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 Although the MIF -794 STRP and -173 SNP are independently associated with various 
diseases (Renner et al. 2005), haplotypes of the two polymorphic sites are more strongly 
associated with functional gene expression and susceptibility to inflammatory disease (Barton et 
al. 2003; Donn et al. 2004; Hizawa et al. 2004).  Therefore, using the genetic data for the two 
polymorphisms, MIF promoter haplotypes were constructed, and the association of haplotypes 
with malaria disease severity was investigated.  Despite the lack of an independent association 
between either the MIF -794 STRP or -173 SNP and SMA, haplotypic analyses revealed that the 
6G haplotype was protective against SMA, while individuals with either 7C or 8C were at an 
elevated risk of developing SMA.  The haplotypic distribution in the SMA and non-SMA groups 
showed similar patterns for the 7C and 8C haplotypes, thereby, allowing us to combine the two 
haplotypes for increased statistical power. Although the 7C haplotype is associated with several 
inflammatory diseases, including scleroderma (Wu et al. 2006), atopy (Hizawa et al. 2004) and 
arthritis (Barton et al. 2003), to our knowledge, this is the first report of an association between 
the 6G haplotype and protection from any disease.  Moreover, the role of the 8C haplotype has 
not previously been examined due to the extremely low frequency of this haplotype in most 
populations (Donn and Ray 2004; Renner et al. 2005).  Additional analyses revealed that risk of 
SMA was further increased in children who had the SMA-susceptible haplotype (i.e., 7C or 8C) 
in combination with the HDP-susceptible CC genotype at -173 (Awandare et al. 2006c), 
suggesting that the impact of these disease susceptibility traits may be synergistic.  
The mechanism(s) by which MIF promoter variants influence susceptibility to SMA was 
further investigated by examining peripheral blood MIF production in aparasitemic and 
parasitemic children separately, allowing us to distinguish the impact of genetic variation on 
basal MIF production from changes that result from host-parasite interactions.  While the 6G 
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 haplotype showed no significant relationship with MIF production, carriage of the 7C or 8C 
haplotypes was associated with decreased MIF production.  These observations are in contrast to 
previous in vitro studies in various cell types demonstrating that increased MIF production is 
associated with an increasing number of CATT repeats (Baugh et al. 2002; Donn et al. 2004), 
and in individuals with the 7C haplotype relative to those with non-7C haplotypes (Wu et al. 
2006).  However, results presented here are consistent with other investigations demonstrating 
that MIF expression is significantly suppressed in 7C promoter constructs compared to 5G and 
6G promoters (Hizawa et al. 2004), illustrating the complexity of MIF transcriptional regulation.  
None the less, results presented here showing that the 7C and 8C haplotypes are associated with 
increased susceptibility to SMA and reduced MIF expression are in agreement with our previous 
investigations demonstrating decreased MIF production in Kenyan children with SMA 
(Awandare et al. 2007b).  These data also support our recent study illustrating that healthy 
children with a history of severe malaria have lower basal circulating MIF levels relative to those 
with a history of mild malaria (Awandare 2007a), suggesting that adequate MIF production may 
be important in the mediating protective immune responses to P. falciparum infection.   
Taken together, this study represents the most comprehensive investigation to date on the 
role of MIF promoter polymorphisms in conditioning susceptibility to severe malaria.  While the 
mechanisms by which MIF gene variants mediate protection and pathogenesis of SMA are not 
fully elucidated, these investigations definitively demonstrate important roles for the 6G, 7C, and 
8C haplotypes in the development of SMA.  Longitudinal studies are currently ongoing in our 
laboratories to further examine the mechanisms by which MIF genetic variants influence MIF 
production and susceptibility to SMA following repeated episodes of malaria.      
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 Table 9: Demographical, clinical, and parasitological characteristics of study participants 
 
 
  Acute malaria  
Characteristic AC Non-SMA SMA P 
Number (n) 134 271 135  
Gender (n, %)     
    Female 70 (52) 132 (49) 61 (45) 
    Male 64 (48) 139 (51) 74 (55) 
0.610 
Age (mos) 8.0 (5.0-14.0) 11.0 (6.7-16.0) 8.0 (5.0-12.0) <0.001 
Axillary temperature (ºC) 36.9 (36.4-37.7) 37.6 (36.8-38.7) 37.5 (36.8-38.3) <0.001 
Parasitemia (/μL) 0 27062 (7246-68458) 
37012 (10448-
69425) 0.171 
HDP (n, %) - 190 (70) 104 (77) 0.262 
Hemoglobin ( g/dL) 10.3 (8.8-11.3) 8.3 (6.9-9.8) 5.0 (4.3-5.6) <0.001 
 
 
Data are presented as median (interquartile range) or n (%), and P-values were obtained from 
Kruskal-Wallis or Chi-square tests respectively, for differences across groups.  
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 Table 10: MIF -794 genotype and allele frequencies according to clinical categories 
 
 Frequencies, n (%)  
MIF -794 
genotypes AC Non-SMA SMA Total P* 
5,5 45 (33.6) 70 (25.8) 42 ( 31.1) 157 (29.1) 0.226 
5,6 38 (28.3) 102 (37.6) 35 (25.9) 175 (32.4) 0.031 
5,7 13 (9.7) 15 (5.5) 15 (11.1) 43 (8.0) 0.102 
5,8 0 (0) 1 (0.4) 0 (0) 1 (0.2) NT 
6,6 21 (15.7) 43 (15.9) 16 (11.9) 80 (14.8) 0.534 
6,7 8 (6.0) 20 (7.4) 10 (7.4) 38 (7.0) 0.856 
6,8 0 (0) 0 (0) 4 (3.0) 4 (0.7) NT 
7,7 9 (6.7) 19 (7.0) 12 (8.9) 40 (7.4) 0.746 
8,8 0 (0) 1 (0.4) 1 (0.7) 2 (0.4) NT 
total 134 (100) 271 (100) 135 (100) 540 (100)  
MIF -794 
alleles      
5 141 (52.6) 258 (47.6) 134 (49.6) 533 (49.4) 0.404 
6 88 (32.8) 208 (38.4) 81 (30.0) 377 (34.9) 0.044 
7 39 (14.6) 73 (13.5) 49 (18.2) 161 (14.9) 0.207 
8 0 (0) 3 (0.5) 6 (2.2) 9 (0.8) NT 
total 268 (100) 542 (100) 270 (100) 1080 (100)  
 
*Chi-square test for frequency distribution across the three clinical groups. 
NT, not tested due to small sample (<5) in one or more groups.  
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 Table 11: Association of MIF -794 genotypic categories with malaria disease. 
 
 
Risk relative to 5/5 genotype 
Disease category 5/X  X/X  
 
Parasitemic 
Odds ratio 1.57 1.43 
95% CI 0.96 – 2.58 0.85 – 2.42 
P 0.071 0.179 
High-density parasitemia 
Odds ratio 1.16 1.07 
95% CI 0.70 – 1.93 0.62 – 1.84 
P 0.562 0.818 
Severe Malarial Anemia 
Odds ratio 0.74 0.92 
95% CI 0.43 – 1.25 0.52 – 1.63 
P 0.260 0.773 
 
 
Children were categorized based on the presence of >5-CATT repeat alleles (X), and odds of 
disease relative to individuals with the 5,5 genotype was determined by multivariate logistic 
regression, controlling for age, gender, HIV-1 status, and sickle cell trait.  
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 Table 12: MIF -794/-173 haplotype frequencies in Kenyan children. 
 
 
MIF -794/ -173 
haplotypes Haplotype frequencies, n (%) 
5G 176 (16.3) 
5C 357 (33.1) 
6G 261 (24.2) 
6C 116 (10.7) 
7G 16 (1.5) 
7C 145 (13.4) 
8G 1 (0.1) 
8C 8 (0.7) 
total 1080 (100) 
 
MIF promoter haplotypes were constructed from -794 and -173 genotypic data using PHASE 
software. 
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 Table 13: Association of MIF -794/-173 haplotype carriage and susceptibility to severe 
malarial anemia (SMA). 
 
 Risk of SMA according to MIF -794/-173 haplotype carriage 
 6G haplotype 7C haplotype 7C or 8C haplotypes 
Odds ratio 0.49 1.48 1.71 
95% CI 0.31 – 0.77 0.88 – 2.48 1.04 – 2.82 
P 0.002 0.132 0.035 
 
Association with SMA was determined as the odds of SMA in carriers of given haplotypes 
compared to non-carriers, using multivariate logistic regression controlling for age, gender, HIV-
1 status, and sickle cell trait. 
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Figure 22: Association of MIF promoter haplotypes with susceptibility to SMA.   
Haplotypes were constructed from the MIF -794 CATT5-8 and -173 G/C genotypic data using PHASE software, and 
the frequencies of each haplotype in children with severe malarial anemia (SMA) or malaria without severe anemia 
SMA (non-SMA) are expressed as percentages. Differences in haplotype frequencies between the two groups were 
compared using Fisher’s test.  *P<0.05, #P<0.10, compared to the non-SMA group. 
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Figure 23: Functional relationship of SMA-associated haplotypes with circulating MIF levels.   
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 Figure 23: Functional relationship of SMA-associated haplotypes with circulating MIF levels.  
Plasma levels of MIF were determined in children with acute malaria (Mal) and aparasitemic controls (AC) using 
ELISA.  A) MIF levels in the AC (non-6G, n=53; 6G, n=25) and Mal (non-6G, n=147; 6G, n=95) groups presented 
according to carriage of the MIF -794/-173 6G haplotype.  B) MIF levels in the AC (non-7C, 8C, n=59; 7C, 8C, 
n=19) and Mal (non-7C, 8C n=195; 7C, 8C, n=47) groups presented according to carriage of the MIF -794/-173 7C 
or 8C haplotypes.  Boxes represent the interquartile range, the line through the box represents the median, whiskers 
illustrate the 10th and 90th percentiles, and symbols represent outliers.    *Differences between groups were 
statistically significant by Mann-Whitney U test (P<0.05). 
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Figure 24: Functional relationship of SMA-associated haplotypes with peripheral blood 
mononuclear cell (PBMC) MIF production. 
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 Figure 24: Functional relationship of SMA-associated haplotypes with peripheral blood 
mononuclear cell (PBMC) MIF production.   
Peripheral blood mononuclear cells (PBMC) were isolated from venous blood of children with acute malaria (Mal) 
and aparasitemic controls (AC) and cultured for 48 hours.  Due to limited samples volumes, these experiments were 
conducted for only children from whom sufficient blood was collected.  MIF concentrations in culture supernatants 
were determined using ELISA. A) PBMC MIF production in the AC (non-6G, n=9; 6G, n=8), and Mal (non-6G, 
n=26; 6G, n=20) categories presented according to carriage of the MIF -794/-173 6G haplotype.  B) PBMC MIF 
production in the AC (non-7C, 8C, n=13; 7C, 8C, n=4), and Mal (non-7C, 8C n=38; 7C, 8C, n=8) groups presented 
according to carriage of the MIF -794/-173 7C or 8C haplotypes.  Boxes represent the interquartile range, the line 
through the box represents the median, whiskers illustrate the 10th and 90th percentiles, and symbols represent 
outliers.    *Differences between groups were statistically significant by Mann-Whitney U test (P<0.05). 
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 CHAPTER SIX: DISCUSSION 
Although P. falciparum infections cause a wide range of clinical disease syndromes including 
cerebral malaria, hypoglycemia, and metabolic acidosis, the majority of malaria-related 
morbidity and mortality in children is caused by anemia (Breman et al. 2001).  The mechanisms 
involved in the pathogenesis of malarial anemia are only partially defined, but appears to be 
related to the production of inflammatory mediators generated in response to Plasmodial 
infections (Clark and Chaudhri 1988; Perkins et al. 2000; Angulo and Fresno 2002; Clark and 
Cowden 2003; McDevitt et al. 2004; Keller et al. 2006b).  Pro-inflammatory cytokines play a 
dual role in influencing malaria disease outcomes, such that protective immune responses require 
induction of IL-12, IFN-γ, TNF-α and NO (Gyan et al. 1994; Luty et al. 1999; Luty et al. 2000; 
Perkins et al. 2000; John et al. 2004; Stevenson and Riley 2004; Moormann et al. 2006), while 
over-production of TNF-α, NO, and other potential inflammatory mediators enhance disease 
pathogenesis (Keller et al. 2004b; Awandare et al. 2006a; Keller et al. 2006a; Grau et al. 1989; 
Kwiatkowski et al. 1990; Kurtzhals et al. 1998; Akanmori et al. 2000; Clark and Chaudhri 
1988).  For example, while TNF-α and NO have anti-plasmodial activities and are involved in 
the control of parasitemia (Gyan et al. 1994; Kwiatkowski and Perlman 1999), high levels of 
these inflammatory mediators may also cause anemia by inducing RBC hemolysis and 
suppressing erythropoiesis (Clark and Chaudhri 1988; Angulo and Fresno 2002; Clark and 
Cowden 2003; McDevitt et al. 2004).  Therefore, it appears that a fine balance between 
protective and pathogenic responses obtained through careful regulation of the sequence and 
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 magnitude at which these inflammatory mediators are produced is required for favorable malaria 
disease outcomes.   Since MIF has been shown to induce both protective and pathogenic immune 
responses in various diseases primarily by regulating the production of inflammatory mediators 
including IL-12, IFN-γ, TNF-α and NO (Calandra et al. 1994; Calandra and Bucala 1995; Juttner 
et al. 1998; Koebernick et al. 2002), we hypothesized that MIF may play a central role in 
influencing malaria disease outcomes.  In support of this hypothesis, studies in murine models of 
malaria provided strong evidence implicating MIF in the pathogenesis of SMA via suppression 
of erythropoiesis (Martiney et al. 2000; McDevitt et al. 2006).  Additional evidence for a 
pathogenic role for MIF in malaria was provided by studies in patients with placental and 
cerebral malaria demonstrating increased local production of MIF in intervillous blood and chest 
blood vessel walls respectively (Chaisavaneeyakorn et al. 2002; Clark et al. 2003; Chaiyaroj et 
al. 2004).  However, although children carry the greatest burden of malaria morbidity and 
mortality (WHO 2005), the role of MIF in the pathogenesis of childhood malarial anemia has 
remained unknown.  In addition, since clinical disease is caused by the blood-stage of the 
malarial parasite (Kwiatkowski and Perlman 1999), and MIF production during malaria appears 
to be both tissue- and compartment-specific (Chaisavaneeyakorn et al. 2002; Clark et al. 2003; 
Chaisavaneeyakorn et al. 2005), systemic regulation of MIF, in addition to local tissue 
production, may provide important insight into the role of MIF in malarial pathogenesis.   
 To investigate the role of MIF in regulating cytokine production during childhood 
malaria, peripheral blood production of MIF, as well as a comprehensive panel of pro- and anti-
inflammatory mediators was examined in a cohort of Gabonese children with acute malaria and 
in healthy aparasitemic controls.  These investigations revealed that both plasma MIF and PBMC 
MIF transcript levels were decreased in children with acute malaria relative to aparasitemic 
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 controls, suggesting that parasitic antigens/products or parasite-induced mediators may be 
suppressing peripheral blood MIF production.  In addition, multivariate regression analyses 
showed a significant correlation between circulating levels of MIF and IL-12, with IFN-γ 
emerging as the best predictor of MIF production.  These findings are consistent with the fact 
that IFN-γ induces MIF, and MIF promotes IL-12 production (Calandra et al. 1994; Koebernick 
et al. 2002).  Interestingly, although MIF can also induce production of TNF-α and NO (Juttner 
et al. 1998), regression analyses presented here found no significant relationship between MIF 
levels and either TNF-α or NO, suggesting that MIF may not be responsible for the over-
production of these mediators in children with acute malaria.    
The Gabonese cohort was drawn from an area with hyperendemic malaria transmission; 
therefore, clinical manifestations of acute malaria included mild malaria, hyperparasitemia and 
SMA.  However, due to the limited sample size of the cohort, a valid analysis of the relationship 
between MIF production and malaria disease severity could not be conducted.  Despite this 
limitation, the strong correlation between MIF and IL-12 levels in children with acute malaria 
suggested that peripheral blood MIF production could have implications in regulating disease 
severity since it is well-established that IL-12 protects against the development of severe malaria 
(Crutcher et al. 1995; Stevenson et al. 1995; Luty et al. 2000; Perkins et al. 2000).  As such, we 
hypothesized that increased MIF production during malaria will protect against the development 
of childhood SMA. 
  To comprehensively investigate the role of MIF in the pathogenesis of SMA in children, 
we examined peripheral blood MIF production in a large cohort of Kenyan children residing in a 
holoendemic P. falciparum transmission area where SMA is the predominant clinical 
manifestation of severe malaria (McElroy et al. 2000; Ong'echa et al. 2006).  This Kenyan 
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 cohort represents, to our knowledge, the most clinically well-characterized group to-date of 
children residing in a holoendemic transmission area.  This provided the unprecedented 
advantage of defining clinically distinct categories of children with varying malarial anemia 
severity, and excluding co-morbidities such as bacteremia and HIV-1, which are common in 
malaria-endemic areas.  In support of a protective role for MIF, these investigations revealed that 
while children with uncomplicated malaria increased MIF production in response to infection, 
circulating MIF and PBMC MIF levels progressively declined in children with increasing 
malarial anemia severity.  Furthermore, multivariate regression analyses, controlling for the 
confounding effects of age and parasite density, showed that circulating MIF concentration was a 
strong positive predictor of Hb levels, indicating a role for increased MIF in protection against 
severe anemia.  These observations are in contrast to the pathogenic role of MIF that was 
described in a P. chabaudi model of murine malaria in which MIF levels directly correlated with 
anemia severity (Martiney et al. 2000; McDevitt et al. 2006).  A potentially important difference 
between MIF regulation in murine versus human systems is that the pituitary gland appears to be 
the major source of circulating MIF in mice, but not in humans (Calandra et al. 1995; Isidori et 
al. 2002).  Consistent with this fact, data presented here demonstrate a robust correlation 
between PBMC MIF gene expression and plasma MIF levels in children, suggesting that PBMC 
may be the major source of circulating MIF in these children.  In addition, the fact that ex vivo 
PBMC MIF production in children with varying anemia severity paralleled the pattern observed 
with plasma MIF levels demonstrates that P. falciparum-derived MIF (Augustijn et al. 2007; 
Cordery et al. 2007) did not significantly contribute to circulating MIF in these children.  
Another significant difference between murine models and childhood malaria is that anemia 
severity in mice is strongly reflected by parasite density (Martiney et al. 2000; McDevitt et al. 
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 2006), whereas data presented here showed no significant relationship between SMA and 
peripheral parasitemia. These differences are likely due to the fact that SMA in mice is 
associated with rapid increases in parasitemia, accompanied by extensive RBC hemolysis 
(Martiney et al. 2000; McDevitt et al. 2006), which is not the case for children examined in the 
current study who are exposed to holoendemic P. falciparum transmission.   
 In addition to the lack of an association between concomitant parasitemia and SMA, 
multivariate regression models also revealed that parasite density was not a significant 
independent predictor of MIF levels, suggesting that parasite burden alone could not be 
responsible for suppression of MIF in children with SMA.  Based on previous studies 
demonstrating that acquisition of Hz by monocytes and neutrophils plays a role in cytokine 
dysregulation and disease pathogenesis during acute malaria (Nguyen et al. 1995; Luty et al. 
2000; Lyke et al. 2003; Perkins et al. 2003; Casals-Pascual et al. 2006; Keller et al. 2006b), we 
hypothesized that accumulation of Hz in children with SMA caused suppression of MIF 
production in circulating phagocytes.   Examination of peripheral blood smears revealed a higher 
abundance of PCM relative to PCN in children with malarial anemia, which is indicative of 
chronicity of infection since PCN are cleared from circulation within 3-4 days while PCM can 
persist for more than 10 days (Day et al. 1996).  More importantly, PCM and PCN levels 
increased progressively with anemia severity, and PCM emerged as the best predictor of Hb and 
MIF levels in multivariate regression models than included age and parasite density as co-
factors.    The robust inverse correlation between MIF and PCM levels was supported by in vitro 
experiments showing that Hz suppressed MIF production from malaria-naïve mononuclear cells, 
demonstrating that monocyte-acquisition of Hz is, at least in part, responsible for decreased MIF 
production in children with SMA. 
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  In previous studies implicating MIF in murine SMA pathogenesis, Martiney et al. 
(Martiney et al. 2000) proposed that MIF promoted the development of SMA by suppressing 
erythropoiesis.  However, regression analyses presented here found no significant relationship 
between circulating MIF levels and reticulocyte production in children with acute malaria.  
Therefore, it was of interest to directly examine the role of MIF in regulating erythropoiesis.  
Given the difficulties in obtaining bone marrow samples from infants and young children with 
malarial anemia, a novel in vitro model of erythropoiesis was developed using peripheral blood-
mobilized CD34+ stem cells to investigate the effects of MIF on erythroid cell development.  
Analysis of supernatants from erythroid cell cultures demonstrated the novel observation that 
these cells produced high levels of MIF during erythropoiesis, which is consistent with previous 
studies showing that erythrocytes store substantial quantities of pre-formed MIF (Mizue et al. 
2000).  Since it is unlikely that erythroid cells will produce and store high levels of a molecule 
that is detrimental to their survival, we hypothesized that endogenous MIF production may be 
required for efficient erythropoiesis.  However, results presented here show that neutralization of 
endogenous MIF using blocking antibodies does not have any noticeable adverse effects on 
erythroid cell proliferation, survival, and maturation, suggesting that endogenous MIF may not 
be required for efficient erythropoiesis.  In addition, although treatment with exogenous MIF 
slightly augmented proliferation of early erythroid progenitors and marginally suppressed 
proliferation of more mature erythroid cells, these effects were only minor compared to those 
observed when cells were cultured in the presence of TNF-α and NO.  Furthermore, no 
significant effects on survival and maturation were observed when erythroid progenitors were 
cultured in the presence of exogenous MIF, while NO caused increased apoptosis and inhibited 
maturation of erythroid progenitors.  Since data presented here, as well as previous studies, show 
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 over-production of TNF-α and NO in children with acute malaria (Keller et al. 2004b; Awandare 
et al. 2006a; Keller et al. 2006a; Grau et al. 1989; Kwiatkowski et al. 1990; Kurtzhals et al. 
1998; Akanmori et al. 2000; Clark and Chaudhri 1988), our findings suggest that TNF-α and 
NO, rather than MIF, are the major inflammatory mediators involved in suppression of 
erythropoiesis during malarial infection.  
A unique strength of the Gabonese cohort was that extensive longitudinal data were 
available for the enrollees, including their previous malaria disease history.  Using this 
information, healthy children were selected based on either a history of consistently experiencing 
mild malaria episodes or a history of exclusively severe malarial episodes.  A comparison of MIF 
production in these two groups revealed an interesting pattern whereby children with prior 
episodes of severe malaria produced lower levels of MIF.  Since these children were 
aparasitemic and healthy at the time of sampling, we postulated that the observed differences in 
MIF production levels were likely based on genetic factors.  Previous analyses of the MIF 
promoter sequence identified several putative transcription factor binding sites within the 
vicinity of two polymorphic loci at -173 (G/C) and -794 (CATT5-8) (Paralkar and Wistow 1994; 
Donn et al. 2002; Calandra and Roger 2003), indicating that genetic variation at these loci could 
functionally alter MIF production.  Consistent with such functional variation, the -173 SNP and -
794 STRP have been shown to influence MIF production and susceptibility to several 
inflammatory diseases (Donn et al. 2001; Baugh et al. 2002; Donn et al. 2002; Barton et al. 
2003; Donn et al. 2004; Renner et al. 2005).  Therefore, we hypothesized that MIF gene 
polymorphisms conditioned MIF production and SMA susceptibility in children exposed to 
intense P. falciparum transmission.  Since factors such as age, sickle cell trait, and HIV-1 status 
impact on severe malarial pathogenesis, multivariate regression analyses were conducted to 
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 control for the confounding effects of these variables.  Independent analysis of the -173 SNP 
demonstrated that the -173 C allele was dose-dependently associated with susceptibility to HDP, 
with CC genotypes having a ~2-fold higher risk of HDP compared to the GG genotypes.  
However, variation at MIF -173 alone was not significantly associated with susceptibility to 
SMA.  Additional investigations demonstrated that PBMC from carriers of the C allele at -173 
have decreased MIF production, while GG carriers have increased MIF production in response to 
Hz stimulation in vitro, suggesting that susceptibility to HDP may be related to the magnitude of 
the MIF response to P. falciparum infection.  Independent analysis of the MIF -794 STRP 
revealed no significant relationship between the number of CATT repeats and HDP, SMA or 
MIF production.  Since haplotypes of the MIF -794 and -173 polymorphisms are often stronger 
predictors of disease susceptibility and MIF production than either locus alone (Barton et al. 
2003; Donn et al. 2004; Hizawa et al. 2004), additional investigations examined the relationship 
of MIF promoter haplotypes with HDP, SMA, and MIF production.  Interestingly, despite the 
lack of independent associations between either the -173 SNP or -794 STRP with SMA, 
multivariate regression analyses identified carriers of the 6G haplotype to be protected from 
SMA, while the 7C or 8C haplotypes were associated with a ~2-fold higher risk of developing 
SMA.  In addition, consistent with previous studies showing that 7C promoter constructs 
produced decreased levels of MIF (Hizawa et al. 2004) compared to 5G and 6G haplotypes, data 
presented here show that carriage of the 7C or 8C haplotypes was associated with lower basal 
circulating MIF in aparasitemic controls and decreased PBMC MIF production during acute 
malaria.   Taken together, these genetic investigations show a pattern in which decreased MIF 
production appears to predispose children to severe malaria, suggesting that adequate MIF 
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 production may be an integral part of the protective immune response to P. falciparum infection 
in children exposed to intense transmission. 
This study represents the most comprehensive investigation into the role of MIF in 
childhood malarial pathogenesis. While previous studies in other forms of malaria, such as 
placental malaria and murine SMA implicated MIF as a promoter of disease pathogenesis 
(Martiney et al. 2000; Chaisavaneeyakorn et al. 2002; McDevitt et al. 2006), investigations 
conducted here in a clinically well-characterized cohort of children from a holoendemic 
transmission area demonstrate that MIF may play a pivotal role in mediating protection against 
SMA in children.  Although the precise mechanism(s) through which MIF mediates protection 
against SMA remain to be elucidated, data presented here are consistent with a role for MIF in 
regulating the inflammatory response to P. falciparum infection thereby ensuring efficient 
control of parasitemia while minimizing disease pathogenesis.   Based on knowledge gained 
from all of the investigations conducted in Specific Aims 1-3, a proposed model for the role MIF 
in the pathogenesis of SMA in a holoendemic setting is described in Figure 25.  In children with 
high MIF-producing promoter variants, P. falciparum infection induces a robust type 1 immune 
response characterized by increased production of MIF, IL-12, IFN-γ, and TNF-α.  This strong 
systemic inflammatory response elicits the classical symptoms of acute malaria, including fever, 
which leads to presentation at hospital with mild forms of malaria. As a result of an early 
hospital visit, disease resolution is rapid due to the combination of appropriate treatment and a 
potent anti-parasitic immune response.  In the extreme scenario, P. falciparum infection elicits 
only a sub-optimal inflammatory response in low MIF producers which may initially be 
clinically asymptomatic, or result in non-specific symptoms such as mild fever.  In the resource-
poor settings in endemic areas, children who do not appear seriously ill are usually administered 
  199
 anti-pyretic drugs, such as aspirin and acetaminophen, at home and are not immediately taken to 
the hospital.  In such cases, parasitemia persists for a few days leading to accumulation of Hz, 
which when taken up by monocytes and neutrophils contributes to suppression of MIF 
production, inhibition of erythropoiesis, and development of anemia.  Manisfestation of 
symptoms associated with severe disease eventually lead to presentation at hospital with a 
chronic infection, characterized by Hb<6.0 g/dL and/or respiratory distress, accompanied by 
high levels of PCM and decreased MIF production.  If given appropriate supportive care, 
including blood transfusion and administration of oxygen, children with SMA can often achieve 
full recovery.  Prolonged MIF suppression may also contribute to the immuno-suppression 
associated with malaria (Greenwood et al. 1972; Berkley et al. 1999) which favors increased 
parasite replication and susceptibility to co-infections such as bacteremia.  The role of MIF in the 
pathogenesis of SMA proposed here is currently being investigated as part of our longitudinal 
studies in the Kenyan cohort examining the genetic basis of severe disease susceptibility 
following repeated episodes of acute malaria. 
The results of investigations conducted here have vast public health implications.  For 
example, MIF blocking agents have been proposed as potential treatment for SMA in children 
based on previous experiments in murine models of malaria demonstrating an association 
between increased MIF and SMA (Martiney et al. 2000; McDevitt et al. 2006).  However, data 
presented here represent the first direct investigation of the role of MIF in childhood malaria and 
demonstrate that the use MIF blocking agents will likely be detrimental in children with SMA.  
In addition, the search for an effective malaria vaccine has been hampered by the lack of 
adequate understanding of protective immune responses.  Therefore, data presented here 
significantly increases our understanding of protective inflammatory responses to P. falciparum 
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 infection and strongly suggests that induction of a potent MIF response should be an important 
consideration in the formulation of an effective vaccine against childhood severe malaria.  
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Figure 25: Proposed model for the role of MIF in the development of SMA in children. 
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